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Summary 
Background: Tuberculosis (TB) caused by Mycobacterium tuberculosis complex is a global 
public health concern, causing significant morbidity and mortality. The resource limited settings 
are the worst hit, especially where there is also high burden of co-infections which increase 
the risk of developing TB and negatively affect TB treatment outcomes. HIV, helminth and 
respiratory pathogens are prevalent in Tanzania, a country that is in among the top 30 high 
burden countries as categorized by World Health Organization (WHO). There is 
epidemiological evidence of increased risk of developing TB with HIV, and little evidence on 
the association of TB and helminth infection and respiratory pathogens. It is therefore important 
to understand the epidemiology of TB and co-infections, so that we can design interventions 
that will address the burden of TB and relevant co-infections.  
 
The objectives: The main objective of this PhD thesis was to determine the burden and the 
association of HIV, helminth and respiratory pathogens (viruses and bacteria) co-infections 
and TB at Temeke district, Dar es Salaam, Tanzania. The specific objectives were: i) to 
determine the treatment outcome of TB and HIV co-infected patients routinely diagnosed at 
Temeke district treated under home- and facility-based direct observed therapy (DOT), ii) to 
determine the prevalence of helminth infection and respiratory pathogens among smear 
positive TB cases and household contact controls without TB, iii) to investigate the risk factors 
for helminth infection and respiratory pathogens among smear-positive TB cases and 
household contact controls without TB, and iv) to determine the clinical effects of helminth 
infection and respiratory pathogens on clinical phenotypes and clinical outcomes among 
smear-positive TB patients. 
 
Methods: This PhD is nested within a large TB cohort in Dar es Salaam region (TB-DAR): a 
prospective collection of clinical data and biological specimens to study the epidemiology of 
tuberculosis, including molecular epidemiology and the evaluation of new diagnostics and 
biomarkers). There are two distinctive methodological parts as described below:  
Objective 1: We obtained anonymized electronic data from the TB district register of all adult 
TB patients (aged ≥15 years) who were notified between 2010 and 2013 in a single 
geographical area of two TB sub-districts (Wailes I and Wailes II) in the Temeke district, Dar 
es Salaam, Tanzania.  
 
Objective 2-4: We consecutively enrolled ≥18 years TB patients and household contact 
controls between November 2013 until October 2015 to reach the required sample size. Any 
individual living in the same household as the index TB patients enrolled in the study is referred 
to as a household contact control. Controls at recruitment were free of symptoms and signs 
suggestive of TB, healthy on physical examination, and had a negative Xpert MTB/RIF result 
(Cepheid; California, USA). We collected sputum, nasopharyngeal swabs, stool and urine 
samples from TB patients and household controls at recruitment. Löwenstein-Jensen 
mycobacterial culture was used to confirm TB. Kato-katz and Bearman methods for detection 
of soil transmitted helminths infections from stool. Urine filtration and Circulating Cathodic 
Antigen (CCA) assay for detection of Schistosomiasis. Nasopharyngeal swabs samples were 
analyzed using Allplex™ Respiratory full panel assay and PCR Anyplex™II RV16 for detection 
of respiratory bacterial and viral pathogens respectively. 
 
xv 
 
 
Principle findings: In a study to determine the treatment outcome of TB and HIV co-infected 
patients routinely diagnosed at Temeke district treated under home- and facility-based DOT: 
data of 4,835 adult TB patients were analyzed, with a median age of 35 years, 2,943 (60.9%) 
were men and TB/HIV co-infection prevalence of 39.9%. A total of 3,593 (74.3%) patients were 
treated under home-based DOT. Patients on home-based DOT were more likely to die 
compared to patients on facility-based DOT (RR 2.04, 95% Confidence Interval [95% CI]: 1.52-
2.73), and more likely to complete TB treatment (RR 1.14, 95% CI: 1.06-1.23), but less likely 
to have a successful treatment outcome (RR 0.94, 95% CI: 0.92-0.97). Home-based DOT was 
preferred by women (adjusted Odds Ratio [aOR] 1.55, 95% CI: 1.34-1.80, p<0.001), older 
people (aOR 1.01 for each year increase, 95% CI: 1.00-1.02, p=0.001) and patients with extra-
pulmonary TB (aOR 1.45, 95% CI: 1.16-1.81, p=0.001), but less frequently by patients on a 
retreatment regimen (aOR 0.12, 95% CI: 0.08-0.19, p<0.001). 
 
In a study to assess the association of TB and helminth infection: a total of 597 TB patients 
and 375 household contact controls were included. The median age was 33 years and 60.2% 
(585/972) were men. The prevalence of any helminth infection among TB patients was 31.8% 
(190/597) and 25.9% (97/375) among controls. Strongyloides stercoralis was the predominant 
helminth species (16.6%, 161), followed by hookworm (9.0%, 87) and Schistosoma mansoni 
(5.7%, 55). An infection with any helminth was not associated with TB (aOR 1.26, 95% CI: 
0.88-1.80, p=0.22), but S. mansoni infection was (aOR 2.15, 95% CI: 1.03-4.45, p=0.040). 
Moreover, S. mansoni infection was associated with lower sputum bacterial load (aOR 2.63, 
95% CI: 1.38-5.26, p=0.004) and tended to have fewer lung cavitations (aOR 0.41, 95% CI: 
0.12-1.16, p=0.088). 
 
When assessing the interaction between TB and respiratory pathogens: we analyzed 794 
study participants, of which 489 (61.6%) were TB patients and 305 (38.4%) were household 
contact controls. The median age of the study participants was 33 years; 61% (484/794) were 
men, and 21% (168/ 794) were HIV-positive. TB patients had a higher prevalence of HIV 
(28.6%; 140/489) than controls (9.2%; 28/305). Overall prevalence of respiratory viral 
pathogens was 20.4% (160/794; 95%CI 17.7-23.3%) and of bacterial pathogens 38.2% 
(303/794; 95%CI 34.9-41.6%). TB patients and controls did not differ in the prevalence of 
respiratory viruses (Odds Ratio [OR] 1.00, 95%CI 0.71-1.44), but respiratory bacteria were 
less frequently detected in TB patients (OR 0.70, 95%CI 0.53-0.94). TB patients with both 
respiratory viruses and respiratory bacteria were likely to have more severe disease (adjusted 
OR [aOR] 1.6, 95%CI 1.1-2.4; p=0.011). TB patients with respiratory viruses tended to have 
more frequent lung cavitations (aOR 1.6, 95%CI 0.93-2.7; p=0.089).  
 
Conclusion: TB patients under home-based DOT had more risk factors for death such as 
older age, HIV infection and sputum smear-negative TB, and had higher TB mortality 
compared to patients under facility-based DOT. Assessment of TB mortality risk factors and 
offering additional clinical care could be beneficial in reducing TB mortality. Further operational 
research is warranted to monitor implementation of DOT and discern other risk factors for 
deaths. S. mansoni infection was an independent risk factor for active TB and altered the 
clinical presentation in TB patients. S. mansoni infection may play a role in TB pathogenesis 
in humans. Bidirectional screening of TB and helminth including treatment for both diseases 
should be considered in a clinical management of patients. Respiratory viruses are common 
xvi 
 
for both TB patients and household controls. TB patients may present with more severe TB 
disease, particularly when they are co- infected with both bacteria and viruses.  
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1. Introduction 
Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis 
complex (MTBC) (WHO, 2016). The MTBC comprises of closely related bacterial species and 
sub-species, including M. tuberculosis M. bovis and M. africanum which are adapted to 
humans (Coscolla and Gagneux, 2014). M. tuberculosis is the commonest cause of TB in 
humans. TB presents as pulmonary (PTB) and extrapulmonary TB (EPTB). Transmission of 
TB occurs when an individual inhales infectious droplets containing M. tuberculosis produced 
by an infectious TB patients during coughing, talking, sneezing or singing (Pai et al., 2016; 
Rieder, 1999). Individuals with M. tuberculosis infection (tuberculosis infection) do not show 
any symptoms. Whereas PTB manifest with symptoms such as cough, prolonged low grade 
fevers, excessive night sweats, unintentional weight loss and hemoptysis (WHO, 2016). 
 
The risk of infection to M. tuberculosis is determined by the number of infectious TB patients 
in the community, duration infectiousness of those TB patients in the community, and close 
contact between a TB patient and susceptible contact per unit of time of infectiousness (Rieder, 
1999). It is estimated around 2-3 billion people have tuberculous infection (WHO, 2016). 
However, only 5-10% of individuals with tuberculosis infection will end up developing TB in 
their lifetime (Rieder, 1999; WHO, 2016). Diseases and conditions like human 
immunodeficiency virus (HIV) infections, malnutrition, smoking, diabetes mellitus, helminth 
infections are known to increase the risk of developing TB from tuberculous infection (Marais 
et al., 2013). However, HIV is by far the most significant risk factor for developing TB especially 
in sub-Saharan Africa where HIV and TB are most prevalent (WHO, 2016). Furthermore, 
helminths and respiratory bacterial and viruses could also potentially play a pathogenic role in 
TB development. TB clinical course and treatment outcome can also be negatively affected by 
comorbidities such as HIV and diabetes mellitus (Marais et al., 2013; Waitt and Squire, 2011). 
 
It is worth to mention, the emergence of drug resistance TB across the globe which is both 
alarming and threatens to halt and even reverse the achievements so far gained in TB control. 
M. tuberculosis strains become resistant to either first line or second lines anti-TB drugs and 
are known as multi-drug resistance TB (MDR-TB) or extensively drug resistance TB 
respectively (XDR-TB). MDR-TB are resistant to at least isoniazid, rifampicin which are the 
first line TB drugs. Meanwhile XDR-TB is a type of multidrug-resistant tuberculosis (MDR TB) 
that is also resistant to any fluoroquinolone and at least one of three injectable second-line 
drugs (i.e., amikacin, kanamycin, or capreomycin)  (WHO, 2016).  
 
This PhD focuses on HIV, helminth infections and respiratory pathogens co-infections. 
Noteworthy, the distribution HIV and helminth are disproportionately high in high TB burden 
settings like Tanzania. The geographical overlap of TB and these risk factors warrant further 
understanding of their epidemiology. The subsequent sections describe the epidemiology of 
TB and co-infections and the immunological interplay.  
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1.1. Tuberculosis  
1.1.1. Global tuberculosis epidemiology  
MTBC accounted for an estimated 10.4 million new (incident) TB cases worldwide and 1.4 
million TB related deaths in the year 2015 (WHO, 2016). TB disproportionately affects more 
men than women (5.9 million vs. 3.5 million) (WHO, 2016). Over 60% of the TB cases notified 
in 2015, came from six countries namely India, Indonesia, China, Nigeria, Pakistan and South 
Africa. The World Health Organization (WHO) has reclassified the countries with high TB 
burden to 30 from the previous 22. These 30 high TB burden countries accounted for 87% of 
all estimated incident TB cases in the world in 2015 (WHO, 2016). Figure 1 shows the 
estimated number of new TB cases (all forms) per 100,000 populations per year in 2015. It is 
evident from Figure 1, that the burden of TB is high in the sub-Saharan Africa, and most 
countries are having incidence rates of above 200 TB patients per 100,000 population per 
year.  
 
 
(Source: Global tuberculosis report 2016) 
Figure 1. Estimated TB incidence rates, 2015 
1.1.1. Tuberculosis in Tanzania  
Tanzania is among the 30 high TB burden countries as categorized by WHO in the sub-
categories of high TB and TB/HIV burden as shown in Figure 2 (WHO, 2016). The prevalence 
survey that was done in 2013, estimates the prevalence of TB to be around 295 per 100,000 
population (NTLP, 2013). The total notification of all forms of TB cases in 2014 was 63,151 
(NTLP, MoHSW, 2015). About 25% of these 63,151 notified TB patients came from Dar es 
Salaam, a densely-populated city. Tanzania is one of the many countries in sub-Saharan Africa 
that has seen a six-fold increase in number of TB patients since early 1980’s (Egwaga, 2003). 
The remarkable rise and sustained TB burden in Tanzania is attributed to the concurrent HIV 
epidemic (Chum et al., 1996; Egwaga, 2003).  
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(Source: Global tuberculosis report 2016) 
Figure 2. List of countries with high TB burden that will be used by WHO during the 
period 2016–2020, and their areas of overlap.  
1.1.2. TB spectrum from tuberculous infection to TB disease 
Approximately 2-3 billion people in the world are estimated to be infected with M. tuberculosis 
(WHO, 2016). Tuberculous infection can either be eliminated from the host by the host innate 
or persists to attain latency lifelong or later on develop TB (Pai et al., 2016; Yates et al., 2016). 
In response to infection, the host immunity forms a granuloma that limits the mycobacterial 
growth in the lungs. TB develops when an individual acquires or develops a TB related risk 
factors such as HIV, helminth infection and diabetes mellitus (Marais et al., 2013; Pai et al., 
2016). These co-infections impair TB specific immunity rendering the body unable to contain 
the bacteria within the granuloma, and thus causing TB disease (Pai et al., 2016). Figure 3 
illustrates the spectrum of TB from tuberculous infection to TB (Pai et al., 2016).  
 
 
(Source: Tuberculosis, Pai et al., 2016) 
Figure 3. The spectrum of TB – from M. tuberculosis infection to active (pulmonary) TB 
diseases.  
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1.1.3. Diagnosis and management of tuberculosis  
Early identification of infectious TB patients and appropriate treatment are the mainstay of TB 
control. Smear microscopy, which has low sensitivity, is the most common TB diagnostic tool 
at a primary health care level in resource limited settings (Pai et al., 2012). Gene Xpert 
MTB/RIF, a molecular TB diagnostic tool which is more sensitive than smear microscopy, has 
improved TB diagnosis and detection of rifampicin resistant TB especially in high HIV burden 
setting (Steingart et al., 2014).  
 
Directly Observed Treatment Short course (DOTS) strategy recommended by the World 
Health Organization in 1994 (De Cock and Chaisson, 1999; Van Deun and Rieder, 2012; 
WHO, 2006), has proved to be one of the most effective public health interventions (Van Deun 
and Rieder, 2012). TB treatment using Directly Observed Therapy (DOT) TB is the mainstay 
of TB treatment which is based on the standardized regimen by WHO. Tanzania has adopted 
these guidelines and treats susceptible new TB patients for six months and eight months for 
the retreatment patients (NTLP, MoHSW, 2013).  
 
1.2. Tuberculosis and human immunodeficiency virus  
1.2.1. Global epidemiology of TB and human Immunodeficiency virus 
HIV remains the most important known risk factor for developing TB from tuberculous infection 
(Lönnroth et al., 2009; Pai et al., 2016; WHO, 2016). HIV/AIDS infected individuals have 5-
15% increased risk of developing TB in a year as compared to 5-15% in lifetime risk in 
immunocompetent individuals (Antonucci et al., 1995). The hallmark of HIV infection is the 
depletion of CD4+ T cells which are essential for control of M. tuberculosis infection in the 
human body (Pawlowski et al., 2012). Globally in the year 2015, TB/HIV co-infection is 
estimated to be around 11%, translating to about 1.2 million new TB patients (WHO, 2016). 
WHO Africa region had 31% of the total burden of TB/HIV co-infection. The majority of the 
countries in the sub-Saharan Africa have TB/HIV co-infection prevalence of ≥20% as shown 
in Figure 4 (WHO, 2016).  
 
 
(Source: Global tuberculosis report 2016)  
Figure 4: Estimated HIV prevalence in new TB cases in 2015.  
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1.2.2. TB and HIV in Tanzania 
Tanzania is among the 30 high TB burden countries for the sub-categories of TB and TB/HIV 
(WHO, 2016). The rising and sustained TB epidemic since early 1980s is due to the concurrent 
HIV epidemic (Chum et al., 1996; Egwaga, 2003). TB caused a fourfold increase in mortality 
among HIV-positive patients (Kabali et al., 2013). HIV patients with low body mass index (BMI) 
are at increased risk of dying from TB (Maro et al., 2010).  
 
Tanzania implements the collaborative TB/HIV services which addresses the burden of TB and 
HIV for patients affected by both diseases (NTLP, MoHSW, 2013). The burden of TB and HIV 
co-infection is slightly above the WHO Afro region TB/HIV co-infection rate. For instance, from 
the annual TB report of 2014, 63,151 TB cases were notified, of which 55,686 (88%) were 
counseled and tested for HIV status, and 19,890 (36%) were co-infected with HIV (NTLP, 
MoHSW, 2015). Thus, still yet HIV drives the TB epidemic in Tanzania.  
1.2.3. The clinical effects of HIV on TB patients  
HIV has significantly changed the clinical phenotypes and negatively influences the TB 
treatment outcomes favouring poor treatment outcomes (Fenner et al., 2012; Mhimbira et al., 
2016; Sharma et al., 2004).  In both HIV-negative and early HIV infection, TB predominantly 
presents with productive cough with upper lobe involvement, cavitation and smear-positive 
AFB results from smear microscopy (Sharma et al., 2004). On the other hand for severely 
immunosuppressed TB and HIV co-infected patients, they present with non-severe cough, 
extrapulmonary TB, atypical radiological presentation with lobar infiltration and severe disease 
(Sharma et al., 2004).  
 
High TB mortality is observed in many TB patients who are also co-infected with HIV (Waitt 
and Squire, 2011). In 2015, there were a total of 0.4 million deaths resulting from TB diseases 
among people living with HIV (WHO, 2016). Severely immunosuppressed HIV-positive 
patients are likely to have life threatening infections (Pawlowski et al., 2012) such as 
Pneumocystis jirovecii pneumonia (PCP) (Field et al., 2014), develop Immune Reconstitution 
Inflammatory Syndrome (IRIS), which is a consequence of the immune recovery after initiation 
of ART among TB patients, that can result to death (Cohen and Meintjes, 2010; Lawn et al., 
2005; Leone et al., 2010; Naidoo et al., 2012). 
 
1.3. Helminth infection 
1.3.1. Global epidemiology of helminth  
Helminth infections are neglected tropical diseases (NTD) affecting both pediatric and adults 
in developing countries (McCarty et al., 2014). Helminth infections by soil-transmitted 
helminths, schistosomiasis, filariasis and/or food-borne trematode are common and affect over 
one billion people (Knopp et al., 2012; Pullan et al., 2014; Utzinger et al., 2012). Globally, the 
most prevalent helminth species are Ascaris lumbricoides followed by Trichuris trichiura, 
Necator americanus and Strongyloides stercoralis (Bethony et al., 2006; McCarty et al., 2014). 
Soil transmitted helminth (STH) (A. lumbricoides, T. trichiura and hookworms) are known to 
cause significant physical and intellectual growth retardation especially in children, but are 
largely neglected in resources to control them (Bethony et al., 2006). An estimated 819 million 
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people in the world are infected by A. lumbricoides, 465 million by T. trichiura, 439 million by 
hookworm and 252 million by Schistosoma mansoni (Babu and Nutman, 2016).  
 
Poor hygiene and sanitation practices sustain the high transmission of helminth in high burden 
settings (Bethony et al., 2006). For instance, the life cycle of Schistosoma species shown in 
Figure 5, shows source of infection is from contaminated water by feaces and urine from an 
infected person.  
 
 
(Source:  https://www.cdc.gov/parasites/schistosomiasis.html): accessed 04.01.2017) 
Figure 5. life cycle of S. haematobium, S. japonicum, and S. mansoni species 
Eggs are eliminated with feces or urine . Under optimal conditions the eggs hatch and release miracidia , 
which swim and penetrate specific snail intermediate hosts . The stages in the snail include 2 generations of 
sporocysts and the production of cercariae . Upon release from the snail, the infective cercariae swim, 
penetrate the skin of the human host , and shed their forked tail, becoming schistosomulae . The 
schistosomulae migrate through several tissues and stages to their residence in the veins ( , ). Adult worms in 
humans reside in the mesenteric venules in various locations, which at times seem to be specific for each species 
. For instance, S. japonicum is more frequently found in the superior mesenteric veins draining the small intestine 
, and S. mansoni occurs more often in the superior mesenteric veins draining the large intestine . However, 
both species can occupy either location, and they are capable of moving between sites, so it is not possible to state 
unequivocally that one species only occurs in one location. S. haematobium most often occurs in the venous plexus 
of bladder , but it can also be found in the rectal venules. The females (size 7 to 20 mm; males slightly smaller) 
deposit eggs in the small venules of the portal and perivesical systems. The eggs are moved progressively toward 
the lumen of the intestine (S. mansoni and S. japonicum) and of the bladder and ureters (S. haematobium), and are 
eliminated with feces or urine, respectively . 
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1.3.2. Epidemiology of helminth infection in Tanzania  
Tanzania is a high NTD burden setting. The prevalence of STH is estimated to be between 57-
85% (Bundy et al., 2000). The burden of helminth infection depends on the area and the 
species (Brooker et al., 2000). For instance, prevalence of S. mansoni was 54% among women 
of reproductive age near Lake Victoria. Figure 6 shows prevalence variation of STH in 
Tanzania in the survey areas. 
 
(Source: http://www.thiswormyworld.org/maps/distribution-of-soil-transmitted-helminth-survey-data-in-tanzania, accessed on 
04.01.2017) 
Figure 6. distribution of soil transmitted helminth survey data and average district-level 
prevalence.  
1.3.3. The helminth-induced immune regulation on M. tuberculosis  
The burden of TB and helminth infection overlap geographically. The burden of TB and 
helminth is high in developing countries affecting the communities with poor socio-economic 
status (Simon, 2016; WHO, 2015a). The distribution of TB and helminth co-infection globally 
is shown Figure 7. To note, Africa has overall higher prevalence of co-infections of TB, HIV, 
malaria and helminth as compared to the rest of the world (Salgame et al., 2013).  
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(Source: Salgame et al, 2013) 
Figure 7. World map showing the geographic distribution of coinfection together with 
tuberculosis, malaria and/or HIV infection of adults.  
Evidence from experimental mice models shows that immune dysregulations caused by 
helminth infections can negatively affect the prognosis of HIV, TB and malaria (Salgame et al., 
2013; Simon, 2016). In TB, the immune response to helminth infections is characterized by the 
induction of CD4+ T-helper 2 (Th2) that down-regulates CD4+ T-helper 1 (Th1) cells (Babu and 
Nutman, 2016; Mishra et al., 2014; Monin et al., 2015; Salgame et al., 2013). Figure 8 
summarizes the immunological pathways induced by helminth that immunomodulate the 
responses to TB (Babu and Nutman, 2016).  
 
The clinical significance of helminth infection immunomodulation include increasing the human 
body susceptibility to infection, developing TB and possibly causing a protracted clinical course 
of the TB disease (Borkow and Bentwich, 2000; Resende Co et al., 2006). Helminth infection 
also reduces the protective effect of TB vaccines such as Bacillus Calmette–Guérin (BCG) 
(Elias et al., 2005). Therefore, where TB and helminthiases co-exist, helminth infections could 
potentially be a risk factor that sustain the TB epidemic. 
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(Source: Babu * Nutman 2016) 
Figure 8. Modulation of immune response to TB infection by helminths based on murine 
models.  
 
1.3.4. Control of intestinal helminth infection   
The global health policies have been produced to address the challenges of NTD control. One 
of the global health policies is the 2012 London declaration on NTD which has several 
commitments which includes: i) to expand and extend programmes that ensures supply of 
drugs, ii) advance research,  and iii) development, strengthen national and international 
collaborations and adequate funding (“The London Declaration | Uniting to Combat NTDs,” 
n.d.). Chemotherapy through mass drug administration (MDA) is cost effective and is 
recommended in endemic area to reduce morbidity associated with helminth infection 
(Bethony et al., 2006; McCarty et al., 2014). The frequency of administration of MDA is 
dependent on the burden of helminth infection (McCarty et al., 2014). In addition, improving 
supply of clean and safe water, and strengthening sanitation and hygiene practices, can help 
to reduce the burden of helminth infection in high burden settings (Dangour et al., 2013).  
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1.4. Respiratory viral pathogens  
1.4.1. Global epidemiology and impact of respiratory viral pathogens   
Respiratory viral pathogens are of increasing public health importance especially the human 
influenza viruses. Respiratory virus pathogens cause varying degrees of morbidity and 
mortality in different settings depending on the level of co-infections. In the pediatric population 
from the multicounty study involving 17 centers in southern hemisphere, showed the most 
prevalent viruses to be Rhinovirus (RSV)/enterovirus (41.5%), followed by influenza (15.8%), 
adenovirus (9.8%), parainfluenza and respiratory syncytial virus (RSV) (both 9.7%), 
coronavirus (5.6%), human metapneumovirus (5.5%) and human bocavirus (HBov) (2.0%) 
(Taylor et al., 2017). In sub-Saharan Africa, influenza virus is responsible in causing 1-25% of 
outpatient acute respiratory illness (Gessner et al., 2011). In East Africa, RSV was detected 
from 12.5% nasopharyngeal swabs from children and adults from rural sites and 11.7% form 
urban site (Bigogo et al., 2013). The population survey reported detecting influenza virus 
10.4% of the specimens, and showed seasonality between September to November and 
March to June (Wabwire-Mangen et al., 2016). 
 
Evidence from industrialized countries show, viral respiratory pathogens may cause acute 
exacerbation of Chronic Obstructive Pulmonary Diseases (COPD) leading to hospitalization 
(O’Brien et al., 2000; Rohde et al., 2003). Also, respiratory viral infections are important 
preceding infection prior to bacterial pneumonia among adults and children and especially 
those with chronic underlying conditions (Glezen et al., 2000). The most notable effect of 
respiratory viruses in humans is, the influenza virus in particular, tend to selectively cause 
higher mortality among TB patients (Noymer, 2009; Walaza et al., 2015; Zürcher et al., 2016). 
1.4.2. The immunological interaction between respiratory viral 
pathogens and TB 
The immunological pathways which respiratory viruses, especially influenza A virus, affect the 
human host and increase TB progression from tuberculous infection is still unclear. However, 
two immunological mechanism have been proposed. First, experimental mouse models 
suggest that prior infection with Influenza A virus, enhance type I Interferon (IFN) signaling 
pathway which in turn enhances mycobacterial growth (Redford et al., 2013). Second, 
Influenza A virus decrease the Major Histocompatibility Complex II (MHC II) expression on 
dendritic cells, resulting to reduced activation of BCG-specific CD4 and CD8 cells, and 
impaired clearance of mycobacteria (Flórido et al., 2013). These two mechanisms both 
increase mycobacterial growth, suggesting TB patients co-infected with respiratory viral 
pathogens may have different clinical phenotypes compared to TB only patients.  
 
1.4.3. Tuberculosis and respiratory bacteria pathogens   
The burden and relationship between TB and respiratory bacteria are still not known. However, 
TB patients and controls with no TB, appear to have differences in composition and diversity 
of sputum microbiota (Cheung et al., 2013). Also new, recurrent and treatment failure TB 
patient categories seem to have different lung microbiota (Wu et al., 2013). The findings from 
these two studies may suggest the pathogenic role of respiratory bacteria on TB pathogenesis. 
However, the actual immunological mechanism underpinning that assumption and clinical 
significance of respiratory pathogens on TB are still unknown.  
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1.5. Global TB control strategy 
The End TB Strategy set the global strategy and targets for TB prevention, care and control 
after 2015 (WHO, 2015b) The End TB Strategy has put up ambitious targets to reduce TB 
incidence by 90% (<10 TB cases per 100,000 population) and TB deaths by 95% by the year 
2035. The pillars and components of the strategy are: i) integrated, patient-centred care and 
prevention, ii) bold policies and supportive systems and iii) intensified research and innovation 
(WHO, 2015b).  
 
The targets of End TB Strategy can only be attained if the annual decline of TB incidence is 
accelerated from 2% per year in 2015 to 10% per year in 2015 (WHO, 2015b). To achieve 
such a decline; low cost sensitive screening test, efficient vaccines and more effective 
preventive therapy are needed to eradicate TB, coupled with investment in public health to 
control and reduce the drivers TB such as HIV, diabetes mellitus, smoking and undernutrition 
(Dheda et al., 2016). 
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2. Rationale and research questions 
TB remains a disease of public health concern in the world. TB affects communities that have 
low socio-economic status, with underfunded health systems and have high burden of risk 
factors for developing TB. Tanzania is among the 30 high burden countries with a significant 
overlap of high burden of HIV and helminth infections. HIV has increased and sustained the 
TB burden in Tanzania since early 1980s. TB mortality is also high among TB patients co-
infected with HIV. The high burden of helminth and possible association as a risk factor for TB, 
warrants understanding of the co-infection epidemiology and the clinical significance of 
helminth infection. The burden or respiratory pathogen is unknown and what clinically 
significant effects do they have on the TB epidemiology.  
 
The epidemiological evidence of the association between TB and helminth and respiratory 
pathogens will pave the way to designing interventions to address the burden of TB and co-
infections. The opportunities of programme integration and resource mobilization to fight the 
burden of TB and NTD are justifiable once we understand their interaction. The knowledge 
gained may influence policy change and clinical practice in the clinical care of TB patients and 
those with helminth infection. 
 
This PhD thesis contributes to the knowledge on ways to achieve End TB Strategy targets. 
First, identifying possible risk factors for TB may help to halt and reverse the TB incidence. 
Controlling risk factors for TB, will help to attaining the target of reducing TB incidence by 90% 
by the year 2015. Second, we need to identify the factors associated with mortality in a 
programmatic setting to design interventions that will help to reduce TB mortality and attain the 
End TB Strategy of decrease the number of TB deaths by 90% by the year 2035.  
 
The following were the research questions:  
i. What are the TB treatment outcomes in high TB and HIV settings who are treated under 
home- or facility-based DOT?  
ii. Are there differences in the burden of helminth infections and respiratory pathogens 
among TB patients and household contact controls with no TB?  
iii. Are there differences in clinical phenotypes among TB patients co-infected with 
helminth infection or respiratory pathogens?  
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3. Objectives and aims  
3.1. General objective 
To determine the burden and the association of HIV, helminth and respiratory pathogens co-
infections and TB at Temeke district, Dar es Salaam, Tanzania.   
 
3.2. Specific objectives 
1. To determine the treatment outcome of TB and HIV co-infected patients routinely 
diagnosed at Temeke district treated under home- and facility-based DOT.  
2. To determine the prevalence of helminth infection and respiratory pathogens among 
smear positive TB cases and household contact controls without TB.  
3. To investigate the risk factors associated for helminth infection and respiratory 
pathogens among smear-positive TB cases and household contact controls without 
TB.  
4. To determine the clinical effects on helminth infection and respiratory pathogens on 
clinical phenotypes and clinical outcomes among smear-positive TB patients.  
3.3. Specific aims  
i. To collect clinico-epidemiological data of smear positive TB patients and describe their 
relationship with HIV, respiratory viral and intestinal helminth co-infection. 
ii. To analyze routinely collected data from TB program and assess the TB and HIV co-
infection and treatment outcome.  
iii. To evaluate the effects of respiratory viral and intestinal helminth co-infection on the 
clinical phenotypes and TB treatment outcome of smear positive TB patients.  
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4. Methods 
4.1. Study setting  
The study was conducted at Temeke district, Dar es Salaam region in Tanzania. Temeke is 
the largest district of the three districts of Dar es Salaam region, occupying 48.3% of the total 
surface area, (Figure 9). Temeke has a total population of 1,368,881 (National Bureau of 
Statistics. Ministry of Finance, Dar es Salaam, 2013; PMORALG, 2014). Temeke district 
notified 4,373 TB patients in 2014 (NTLP, MoHSW, 2015) and has HIV prevalence of 5.2% in 
the general adult population (PMORALG, 2014). We further selected the two sub-districts of 
Wailes I and Wailes II, as categorized by National TB and Leprosy Programme, which are 
densely populated areas surrounding the Temeke district hospital. Temeke district hospital has 
the largest TB clinic serving the two sub-districts of Wailes I and II.  
 
This PhD project is nested within a larger TB cohort study entitled; Tuberculosis Cohort Study 
in the Dar es Salaam region (TB-DAR): a prospective collection of clinical data and biological 
specimens to study the epidemiology of tuberculosis, including molecular epidemiology and 
the evaluation of new diagnostics and biomarkers). TB-DAR study is done within the IHI 
research platform in collaboration with Swiss TPH of Switzerland.  
 
    
 
(Source: National Tuberculosis and Leprosy Programme Annual Report 2012) 
Figure 9. Map of Tanzania with TB notification rate per 100,000 population notified in 
2011.  
4.2. Study population  
Objective 1: We obtained anonymized electronic data from the TB district register of all adult 
TB patients (aged ≥15 years) who were notified between 2010 and 2013 in a single 
geographical area of two TB sub-districts (Wailes I and Wailes II) in the Temeke district, Dar 
es Salaam, Tanzania.  
 
Objective 2-4: We consecutively enrolled study participants starting in November 2013 until 
October 2015 to reach the required sample size. Over this period, we included adult TB 
patients (≥18 years of age and sputum-smear positive) and household contact controls. Any 
individual living in the same household as the index TB patients enrolled in the study is referred 
Dar es Salaam Region
Temeke 
District 
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to as a household contact control. Controls at recruitment were free of symptoms and signs 
suggestive of TB, healthy on physical examination, and had a negative GeneXpert MTB/RIF 
result (Cepheid; California, USA). Table 1 summarizes the inclusion and exclusion criteria of 
the study population for objective 3-4.  
 
Table 1. Inclusion and exclusion criteria 
Study group Inclusion criteria Exclusion criteria  
Pulmonary TB 
cases  
Smear-positive TB patient by AFB 
smear microscopy and confirmed 
by LJ or Gene Xpert MTB/RIF 
positive patient  
Age above 18 years 
 
Inability to give consent.  
Less than 18 years of age.  
 
Contact controls  Age above 18 years.  
No symptoms and signs of TB at 
recruitment.  
Age and sex matched to an index 
case.  
TB confirmed by Xpert MTB Rif 
positive. 
Age less than 18 years of age. 
History of TB in the last two years. 
 
 
4.3. Study design 
Objective 1: A retrospective cohort study of routinely collected data by NTLP and National 
AIDS Control Programme (NACP) at Temeke hospital TB/HIV co-infection and treatment 
outcomes.  
Objective 2-4: Mixed study design was used whereby case-control design was used to assess 
the association between TB and co-infections. A prospective cohort study was used to assess 
the clinical effects of helminth and respiratory viruses on clinical outcome of TB patients 
followed for 6 months of TB treatment.  
 
4.4. Sample size 
Case control study: The sample size was calculated based on the assumptions from previous 
publications of TB helminth co-infection rate (Elias et al., 2006). The estimated sample size 
using the “sampsi” command in Stata (significance level of test 0.05, two-sided, and a power 
of 80% to detect relevant differences) 332 for pulmonary TB cases and 332 household contact 
controls.  
 
Longitudinal study: Assuming the co-infection rate of HIV, intestinal helminth infection and 
respiratory viral pathogens of 50% among TB patients and assuming treatment failure of 
patient with co-infection of 20% and 10% for TB only; the calculated sample size using the 
alpha=0.05 to detect 80% power, then the sample size needed was 424. Considering the 20% 
loss to follow-up, the sample size needed was 500 TB patients.  
4.5. Laboratory samples and procedures:  
Study participants’ samples were analyzed at Bagamoyo and Research Training Center 
(BRTC) laboratory of IHI. BRTC has TB biosafety laboratory level 2 & 3, hematology and 
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helminth laboratory. Table 2 below summarizes the specimens collected from the study 
participants and the analysis done. The detailed laboratory procedures are covered in the 
respective chapters of this thesis.  
Table 2: Specimen type and tests 
Sample Laboratory tests 
Sputum Confirmation of M. tuberculosis on the Löwenstein-Jensen 
medium 
Gene Xpert MTB/RIF (Controls) 
Nasopharyngeal swabs  Allplex™ Respiratory Full Panel assay (respiratory bacterial 
pathogens) and PCR Anyplex™II RV161 Detection (respiratory 
viral pathogens).  
Stool Kato-katz and Baermann methods for detection of helminth 
infections.  
Urine Circulating Cathodic Antigen for detection of S. mansoni. 
Urine filtration for detection of S. haematobium.  
 
4.6. Statistical analysis 
Objective 1: Descriptive statistics were used for patient characteristics, and groups were 
compared using Chi-Square and Wilcox rank-sum test as appropriate. We estimated treatment 
outcomes risk ratios (RR) comparing patients under home-based with patients under health 
facility-based DOT. We used logistic regression models to assess the association of home-
based DOT on mortality and treatment success.  
 
Objective 2-4: We used descriptive statistics to compare study participants’ characteristics. 
The prevalence of helminth infections and respiratory pathogens were determined using 
generalized estimations equation adjusting for clustering at the household level. Multilevel 
mixed-effects logistic regression with random intercepts at the level of household models were 
used to assess the risk factors for helminth infection and respiratory pathogens. Logistic 
regression models were used to determine the association between TB and helminth infection 
or respiratory pathogens. All analyses were performed using Stata version 14.0 (Stata Corp; 
Texas, USA). For TB and helminth co-infection we produced maps describing the prevalence 
of helminth by wards (administrative units) using software package ArcGIS Desktop version 
10.2 (Esri; California, USA).  
 
 
 
                                               
 
1 http://www.seegene.com/en/any/RV16_010.php 
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5.1. Abstract  
Introduction: Decentralization of Directly Observed Treatment (DOT) for tuberculosis (TB) to 
the community (home-based DOT) has improved the coverage of TB treatment and reduced 
the burden to the health care facilities (facility-based DOT). We aimed to compare TB treatment 
outcomes in home-based and facility-based DOT under programmatic conditions in an urban 
setting with a high TB burden. 
 
Methodology: A retrospective analysis of a cohort of adult TB patients (≥15 years) routinely 
notified between 2010 and 2013 in two representative TB sub-districts in the Temeke district, 
Dar es Salaam, Tanzania. We assessed differences in treatment outcomes by calculating Risk 
Ratios (RRs). We used logistic regression to assess the association between DOT and 
treatment outcomes.  
 
Results: Data of 4,835 adult TB patients were analyzed, with a median age of 35 years, 2,943 
(60.9%) were men and TB/HIV co-infection prevalence of 39.9%. A total of 3,593 (74.3%) 
patients were treated under home-based DOT. Patients on home-based DOT were more likely 
to die compared to patients on facility-based DOT (RR 2.04, 95% Confidence Interval [95% 
CI]: 1.52-2.73), and more likely to complete TB treatment (RR 1.14, 95% CI: 1.06-1.23), but 
less likely to have a successful treatment outcome (RR 0.94, 95% CI: 0.92-0.97). Home-based 
DOT was preferred by women (adjusted Odds Ratio [aOR] 1.55, 95% CI: 1.34-1.80, p<0.001), 
older people (aOR 1.01 for each year increase, 95% CI: 1.00-1.02, p=0.001) and patients with 
extra-pulmonary TB (aOR 1.45, 95% CI: 1.16-1.81, p=0.001), but less frequently by patients 
on a retreatment regimen (aOR 0.12, 95% CI: 0.08-0.19, p<0.001). 
Conclusions/significance: TB patients under home-based DOT had more frequently risk 
factors of death such as older age, HIV infection and sputum smear-negative TB, and had 
higher mortality compared to patients under facility-based DOT. Further operational research 
is needed to monitor the implementation of DOT under programmatic conditions. 
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5.2. Introduction 
In 2014 globally, almost 1.5 million people died from tuberculosis (TB) from an estimated 9.6 
million who developed TB (WHO, 2015a). TB is now the leading cause of death from an 
infectious disease worldwide, surpassing those caused by Human Immunodefiency Virus 
(WHO, 2015b). Globally, TB mortality trends are on the decline, but remain high despite 
effective short-course treatment regimens (WHO, 2015a). In Africa, however, the decline did 
not meet the 2015 Stop TB Partnership goal of a 50% decline from 1990 to 2015 (WHO, 
2015a).  
 
Early diagnosis and effective treatment of TB are critical to reduce TB mortality and control the 
spread of TB [1]. The Directly Observed Treatment Short course (DOTS) strategy 
recommended by the World Health Organization in 1994 (De Cock and Chaisson, 1999; Van 
Deun and Rieder, 2012; WHO, 2006), has proved to be one of the most effective public health 
interventions (Van Deun and Rieder, 2012). The DOTS strategy provides a comprehensive 
package to control TB which consists of six components, and one of them addresses the use 
of standardized treatment with supervision and patients supporters (directly observed therapy, 
DOT) (WHO, 2006). DOT was pioneered in Tanzania in the 1980s, and resulted in improved 
cure rates from 60% to 80% (Van Deun and Rieder, 2012). TB treatment under DOT can be 
given at the health facility (facility-based DOT) or in the community (home-based DOT). The 
facility-based DOT approach requires that patients visit daily the health facility for supervised 
drug intake by health workers, with continuous assessment of adherence to TB medication 
(NTLP, MoHSW, 2013). However, this delivery system places a burden on the health care 
system and the patient (Maher, 2003; Wandwalo et al., 2006). This made it necessary to 
decentralize TB treatment to the community (home-based DOT) (Lwilla et al., 2003; Maher, 
2003). 
 
Although systematic reviews showed that patients under home-based DOT can achieve similar 
or better treatment outcomes compared to facility-based DOT (Volmink and Garner, 2003; 
Wright et al., 2015), the implementation of treatment under home-based DOT has also raised 
concerns (Frieden and Sbarbaro, 2007). Health care workers have expressed concerns about 
treatment adherence, storage of drugs and lack of supervision under home-based DOT which 
may contribute to unfavorable TB treatment outcomes (Egwaga et al., 2008). We therefore 
aimed to assess TB treatment outcomes in home-based and facility-based DOT under 
programmatic conditions in the high TB incidence country Tanzania. 
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5.3. Methods  
5.3.1. Ethics statement 
We used anonymized population-level data of notified TB patients. Hence, ethical approval 
and informed consent were not required for this analysis. The permission to use the data was 
authorized by the Program Manager of the National TB and Leprosy Programme (NTLP) in the 
Ministry of Health, Community Development, Gender, Elderly and Children (MoHCDGEC). All 
TB patients received the standardized TB treatment regimen in line with national TB treatment 
guideline (NTLP, MoHSW, 2013). HIV-positive TB patients were managed in accordance to 
the National Guidelines for the Management of HIV in Tanzania (NACP, 2015). 
5.3.2. Study setting  
Temeke is one of the three districts in Dar es Salaam region in Tanzania. Temeke is the largest 
district that occupies 48.3% of the total surface area of Dar es Salaam and has a total 
population of 1,368,881 (National Bureau of Statistics. Ministry of Finance, Dar es Salaam, 
2013; PMORALG, 2014). Temeke district notified 4,373 TB patients in 2014 (NTLP, MoHSW, 
2015) and has HIV prevalence of 5.2% in the general adult population (PMORALG, 2014). We 
selected Temeke district because it represents an urban setting with a high TB notification rate, 
and because it was one of the few districts in Tanzania where the acceptability study of home-
based and facility-based DOT was done in 2006 (Wandwalo et al., 2006). The two sub-districts 
of Wailes I and Wailes II, as categorized by National TB and Leprosy Programme, are densely 
populated areas surrounding the Temeke district hospital which has the largest TB clinic 
serving these two sub-districts.  
5.3.3. Study population and study definitions 
We obtained anonymized electronic data from the TB district register of all adult TB patients 
(aged ≥15 years) who were notified between 2010 and 2013 in a single geographical area of 
two TB sub-districts (Wailes I and Wailes II) in the Temeke district, Dar es Salaam, Tanzania. 
The patient selection is presented in Figure 10. We excluded 31 patients with unknown DOT 
preference and 363 patients with treatment outcome “not evaluated” (“unknown” or “transferred 
out”). The included and excluded (patients with unknown DOT and “not evaluated” outcome) 
patients did not differ in baseline characteristics (Supplementary Table 1).  
We used the study definitions according to the WHO updated guidelines (World Health 
Organization (WHO), 2013). A “new” patient was defined as never had treatment for TB, or 
has taken anti-TB drugs for less than one month; a “retreatment” patient was defined as 
previously treated patient who has received one month or more of anti-TB drugs in the past; 
TB death as any death that occurred during TB treatment. “Treatment success” combines 
cured and treatment completed outcomes (World Health Organization (WHO), 2013). 
“Unsuccessful” treatment combines failed treatment, loss to follow-up and died outcomes. Not 
evaluated combines the transferred-out and unknown treatment outcomes.  
5.3.4. Facility-based and home-based DOT  
According to the national guidelines, facility-based DOT requires health care workers to 
supervise daily intake of anti-TB medication during the intensive and continuation phases 
(NTLP, MoHSW, 2013). While at the clinic, TB patients will also receive health education and 
clinical evaluation by the clinicians and nurses. Under home-based DOT, a patient takes 
medication at home and is supervised by a treatment supporter who is chosen by the TB 
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patient (NTLP, MoHSW, 2013). The treatment supporter, who can be either a family member 
or a neighbor, supervises anti-TB medication intake at home on daily basis during the entire 
TB treatment phase (Egwaga et al., 2008; NTLP, MoHSW, 2013). Treatment supporters would 
also accompany the TB patients to the health facility for anti-TB medication refill weekly during 
the intensive phase and fortnightly during the intensive phase. TB patients with their treatment 
supporters while at the health facility will receive health education from health care workers; 
and TB patients will undergo a clinical evaluation (NTLP, MoHSW, 2013). Under the current 
Patient-Centered Treatment (PCT) approach, the patient can indicate the choice of DOT at the 
time of TB diagnosis (hereafter referred as “preference of DOT”). 
5.3.5. Laboratory investigations 
TB diagnosis was made either by microbiological confirmation of acid fast bacilli (AFB) in the 
sputum smear examination by Ziehl-Nielsen method or based on clinical grounds or 
radiological findings as determined by the attending clinician at the TB clinic. The quality control 
of smear microscopy was done by the Central Tuberculosis Reference Laboratory (CTRL) in 
Dar es Salaam. AFB smear positive results was as per World Health Organization/International 
Union Against Tuberculosis and Lung Disease grading: “scanty” with of 1–9 AFB per 100 oil 
immersion fields; 1+” with 10–99 AFB per 100 immersion fields; “2+” with 1–10 AFB per 1 
immersion field and “3+” with >10 AFB per immersion field (NTLP, MoHSW, 2013; WHO, 
2013).Tanzania also implements collaborative TB/HIV services, and all TB patients were 
offered rapid HIV testing as per National guidelines for the management of HIV and AIDS of 
Tanzania (NACP, 2015).  
 
5.3.6. Statistical analyses 
Descriptive statistics were used for patient characteristics, and groups were compared using 
Chi-Square and Wilcox rank-sum test as appropriate. We estimated treatment outcomes risk 
ratios (RR) comparing patients under home-based with patients under health facility-based 
DOT. We used logistic regression models to estimate the effect of home-based DOT on 
mortality and treatment success. The results are presented as crude and adjusted odds ratio 
(OR) after adjusting for age, sex, HIV status, site of disease, AFB sputum smear results at 
diagnosis, and patient category (new or retreatment patient). Point estimates are presented 
with their corresponding 95% Confidence Intervals (95% CIs). We also performed a complete 
case analysis excluding all patients with any missing value. All analyses were performed using 
Stata version 14.0 (Stata Corp, College Station, TX, USA). 
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5.4. Results  
5.4.1. Patient characteristics  
We analyzed 4,835 adult TB patients from the Temeke District, Dar es Salaam, notified 
between 2010 and 2013. The median age was 35 years (Interquartile Range [IQR]: 27-44 
years); 2,943 (60.9%) were men. The HIV prevalence was 39.9 % (95% Confidence Interval 
[95% CI]: 38.5-41.3%). Home-based DOT was the most preferred (3,593 patients, 74.3%) 
compared to facility-based DOT. Patients on home-based DOT were more likely to be HIV-
positive, women, with EPTB, smear-negative at diagnosis and older (Table 3). TB/HIV co-
infected patients were more frequently men, of older age, and patients with EPTB and smear-
negative TB, and opted more often for home-based DOT (Supplementary Table 2). 
 
Figure 10. Selection of patients included in the study. 
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Table 3: Baseline characteristics of TB patients at Temeke district by choice of DOT.  
Characteristics All Home-based Facility-
based 
p-value 
 (n=4,835) (n=3,593) (n=1,242)  
 n (%) n (%) n (%)  
Proportion of diagnosis, n 
(%) 
4,835 (100) 3,593 (100) 1,242 (100)  
Sex    <0.001 
Male 2,943 (60.9) 2,082 (57.9) 861 (69.3)  
Female 1,892 (39.1) 1,511 (42.1) 381 (30.7)  
Age in years, median (IQR) 35 (27-44) 35 (29-45) 34 (28-41) 0.007a 
Age groups (years)    <0.001 
15-19 285 (5.9) 238 (6.6) 47 (3.8)  
20-24 544 (11.3) 390 (10.9) 154 (12.4)  
25-29 724 (15.0) 521 (14.5) 203 (16.3)  
30-34 820 (17.0) 577 (16.1) 243 (19.6)  
35-39 706 (14.6) 521 (14.5) 185 (14.9)  
40-44 570 (11.8) 405 (11.3) 165 (13.3)  
45-49 428 (8.9) 319 (8.9) 109 (8.8)  
50-54 279 (5.8) 218 (6.1) 61 (4.9)  
≥55  479 (9.9) 404 (11.2) 75 (6.0)  
HIV status    0.002 
Positive 1,927 (39.9) 1,485 (41.3) 442 (35.6)  
Negative  2,582 (53.4) 1,874 (52.2) 708 (57.0)  
Unknown status  326 (6.7) 234 (6.5) 92 (7.4)  
Site of disease     <0.001 
PTB 3,977 (82.3) 2,884 (80.3) 1,093 (88.0)  
EPTB  858 (17.7) 709 (19.7) 149 (12.0)  
Category    <0.001 
New 4,706 (97.3) 3,557 (99.0) 1,149 (92.5)  
Retreatment  129 (2.7) 36 (1.0) 93 (7.5)  
AFB smear result at 
diagnosis 
   <0.001 
Smear-positive 2,438 (50.4) 1,706 (47.5) 732 (58.9)  
Smear-negative 2,352 (48.6) 1,845 (51.3) 507 (40.8)  
Unknown 47 (0.9) 42 (1.2) 3 (0.2)  
aWilcox-ranksum test; n (%), absolute number and column percentage 
Patients with unknown DOT preference were excluded (n=31, 0.6%). 
AFB, acid-fast bacilli; IQR, Interquartile Range; HIV, Human Immunodeficieny Virus; TB, Tuberculosis; PTB, Pulmonary 
tuberculosis; EPTB, Extrapulmonary tuberculosis; DOT, Directly Observed Treatment 
 
5.4.2. TB treatment outcomes by DOT preference 
Overall, treatment success which combines cured and treatment completed outcomes, was 
reported in 4,006 (82.8%) patients and 345 (7.1%) patients died during TB treatment. Patients 
on home-based compared to facility-based DOT were less likely to have treatment success 
(RR 0.94, 95% CI: 0.92-0.97). We observed no significant difference in loss to follow-up and 
“not evaluated” treatment outcomes. Treatment failure was only reported in the home-based 
DOT (24 patients, 0.7%). When restricting the analysis to smear-positive TB patients, patients 
on home-based DOT were less likely to be cured compared to facility-based DOT (RR, 0.93 
95 CI: 0.88-0.98), and were more likely to die but the results were not significant (RR 1.35, 
95% CI: 0.88-2.06). We found no statistically significant differences in all other treatment 
outcomes (Table 4).  Of 31 TB patients with unknown DOT preference, 2 patients died during 
the TB treatment.  
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Table 4: Differences in TB treatment outcomes among TB patients under home-based 
DOT compared to facility-based DOT. 
Treatment outcome All 
 
Home-based 
DOT 
Facility-
based DOT 
RR (95% CI) p-value 
 n (%) n (%) n (%)   
All patients  4,835 3,593 (100) 1,242 (100)  <0.001 
Treatment success 4,006 (82.8) 2,932 (81.6) 1,073 (86.4) 0.94 (0.92-0.97)  
Cured 1,738 (35.9) 1,192 (33.2) 546 (44.0) 0.75 (0.70-0.82)  
Treatment completed 2,268 (46.9) 1,741 (48.5) 527 (42.4) 1.14 (1.06-1.23)  
Died 345 (7.1) 295 (8.2) 50 (4.0) 2.04 (1.52-2.73)  
Loss to follow-up  97 (2.0) 68 (1.9) 29 (2.3) 0.81 (0.53-1.25)  
Treatment failed 24 (0.5) 24 (0.7) 0 (0) ND  
Not evaluated  363 (7.5) 273 (7.6) 90 (7.2) 1.05 (0.83-1.32)  
      
Smear-positive  2,438 (100)  1,706 (100) 732 (100)  0.024 
Treatment success 2060 (84.5) 1431 (83.9) 629 (85.9) 0.98 (0.94-1.01)  
Cured 1,738 (71.3) 1,192 (69.9) 546 (74.6) 0.93 (0.88-0.99)  
Treatment completed 322 (13.2) 239 (14.0) 83 (11.3) 1.23 (0.98-1.56)  
Died 109 (4.5) 83 (4.9) 26 (3.6) 1.35 (0.88-2.06)  
Loss to follow-up  52 (2.1) 34 (2.0) 18 (2.5) 0.83 (0.48-1.46)  
Treatment failed 14 (0.6) 14 (0.8) 0 (0) ND  
Not evaluated  203 (8.3) 144 (8.4) 59 (8.1) 1.04(0.78-1.40)  
Patients with unknown DOT preference were excluded (n=31, 0.6%; n (%)=absolute number and column 
percentage 
DOT, Directly Observed Treatment; RR, Risk ratio; 95% CI: 95% Confidence Interval; ND, Not Defined; Not 
evaluated; Transferred out and unknown TB treatment outcome 
 
5.4.3. TB mortality and associated patient factors 
TB mortality was strongly associated with home-based compared to facility-based DOT 
(adjusted OR [aOR] 2.28, 95% CI: 1.64-3.18, p<0.001). Other patient factors associated with 
mortality included older age (e.g ≥45 years, aOR 2.05, 95% CI: 1.36-3.08, p<0.002), HIV-
positive (aOR 1.68, 95% CI: 1.31-2.15, p<0.001), retreatment category (aOR 3.99, 95% CI: 
2.33-6.84, p<0.001) and smear-positive TB (aOR 0.49, 95% CI: 0.38-0.64, p<0.001) (Table 5). 
A complete case analysis (excluding any missing values) produced similar results. 
Supplementary Table 3 shows the patient characteristics separately for home-based and 
facility-based DOT for TB patients who were reported as dead or alive. 
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Table 5: Risk factors for mortality among TB patients. 
 Characteristic Crude OR  Adjusted OR 
 OR (95% CI) p-value  OR (95% CI) p-value 
Place of DOT  <0.001   <0.001 
Facility 1 (Ref)   1(Ref)  
Home 2.15 (1.58-2.92)   2.28 (1.64-3.18)  
Sex  0.2   0.8 
Male  1 (Ref)   1 (Ref)  
Female 1.14 (0.92-1.43)   0.97 (0.77-1.23)  
Age groups (years)  <0.001   0.002 
<25  1 (Ref)   1 (Ref)  
25-34 1.47 (0.97-2.22)   1.37 (0.90-2.08)  
35-44 2.15 (1.44-3.22)   1.69 (1.11-2.57)  
≥45 2.64 (1.78-3.93)   2.05 (1.36-3.08)  
HIV status  <0.001   <0.001 
Negative 1 (Ref)   1 (Ref)  
Positive 2.07 (1.65-2.61)   1.68 (1.31-2.15)  
Unknown HIV status  1.11 (0.68-1.82)   0.98 (0.59-1.63)  
Site of disease   0.006   0.8 
PTB  1 (Ref)   1 (Ref)  
EPTB 1.46 (1.12-1.89)   0.93 (0.59-1.63)  
AFB smear result at 
diagnosis 
 <0.001   <0.001 
Smear-negative 1 (Ref)   1 (Ref)  
Smear-positive 0.44 (0.35-0.56)   0.49 (0.38-0.64)  
Unknown 1.82 (0.80-4.17)   1.39 (0.60-3.25)  
Category of TB patient  0.001   <0.001 
New 1 (Ref)   1 (Ref)  
Retreatment 2.61 (1.59-4.29)   3.99 (2.33-6.84)  
OR, Odds Ratio; 95% CI=95% Confidence Interval; DOT, Directly Observed Treatment; Ref, Reference Group; 
HIV, Human Immunodeficiency Virus; TB, Tuberculosis; PTB, Pulmonary tuberculosis; EPTB, Extra-pulmonary 
tuberculosis:  
All variables were included in the adjusted model  
Excluded from the analysis: Not evaluated=Transferred-out and TB patients with unknown TB treatment outcomes, 
n= 363, 7.5% 
 
5.4.4. Successful treatment outcome and associated patient factors  
Treatment success was less likely to be associated with home-based compared to facility-
based DOT (aOR 0.53, 95% CI: 0.41-0.70, p<0.001). Treatment success was less likely with 
increasing age, among HIV-positive and patients on retreatment category and smear-negative 
TB patients (Table 6).  
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Table 6: Factors associated with treatment success among adult TB patients. 
Characteristic Crude OR  Adjusted OR 
 OR (95% CI) p-value  OR (95% CI) p-value 
Place of DOT  <0.001   <0.001 
Facility-based 1 (Ref)   1 (Ref)  
Home-based 0.56 (0 .43-0.72)   0.53 (0.41-0.70)  
Sex  0.9   0.2 
Male  1 (Ref)   1 (Ref)  
Female 1.0 (0.82-1.22)   1.15 (0.94-1.41)  
Age groups (years)  <0.001   0.03 
<25  1 (Ref)   1 (Ref)  
25-34 0.79 (0.57-1.09)   0.84 (0.60-1.17)  
35-44 0.60 (0.43-0.83)   0.73 (0.52-1.03)  
≥45 years 0.51 (0.37-0.70)   0.63 (0.45-0.88)  
HIV status  <0.001   <0.001 
Negative  1 (Ref)   1 (Ref)  
Positive 0.55 (0.45-0.67)   0.62 (0.50-0.77)  
Unknown HIV status 0.76 (0.51-1.12)   0.81 (0.54-1.20)  
Site of disease  0.046    0.7 
PTB  1 (Ref)   1 (Ref)  
EPTB 0.79 (0.62-0.99)   1.09 (0.84-1.41)  
AFB smear results at 
diagnosis 
 <0.001   <0.001 
Smear-negative 1 (Ref)   1 (Ref)  
Smear-positive  1.74 (1.43-2.12)   1.61 (1.29-2.01)  
Unknown 0.59 (0.27-1.29)   0.74 (0.33-1.64)  
Category of TB patient  0.02    <0.001 
New 1 (Ref)   1 (Ref)  
Retreatment 0.45 (0.28-0.72)   0.34 (0.21-0.56)  
OR, Odds Ratio; 95% CI=95% Confidence Interval; DOT, Directly Observed Treatment; Ref, Reference Group; 
HIV, Human Immunodeficiency Virus; TB, Tuberculosis; PTB, Pulmonary tuberculosis; EPTB, Extra-pulmonary 
tuberculosis:  
All variables were included in the adjusted model  
Excluded: Not evaluated=Transferred-out and TB patients with unknown TB treatment outcomes, n= 363, 7.5% 
 
5.4.5. Patient factors associated with preference of home-based DOT 
Patients opting for home-based DOT were more likely to be women (aOR 1.55, 95% CI: 1.34-
1.80, p<0.001), older (aOR 1.01, 95% CI: 1.00-1.02, p=0.001; for each year increase in age), 
more likely to have EPTB (aOR 1.45, 95% CI: 1.16-1.81, p<0.001), but less likely to have 
smear-positive TB (aOR 0.80, 95% CI: 0.68-0.93, p=0.002) and less likely to be on a 
retreatment category (aOR 0.12, 95% CI: 0.08-0.19, p<0.001). HIV-positive TB patients tended 
to prefer home-based compared to facility-based DOT (aOR 1.16, 95% CI: 0.99-1.36, p=0.052) 
(Table 7).  
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Table 7: Factors associated with preference to home-based DOT. 
Characteristic Crude OR  Adjusted OR 
 OR (95% CI) p-
value 
 OR (95% CI) p-value 
Sex  <0.001   <0.001 
Male  1 (Ref)   1 (Ref)  
Female  1.63 (1.41-1.88)   1.55 (1.34-1.80)  
Age groups (years)  <0.001   <0.001 
<25  1 (Ref)   1 (Ref)  
25-34 0.78 (0.63-0.95)   0.73 (0.59-0.90)  
35-44 0.83 (0.67-1.02)   0.77 (0.61-0.96)  
≥45 years 1.24 (0.99-1.54)   1.17 (0.93-1.48)  
HIV status  0.005   0.05 
Negative 1 (Ref)   1 (Ref)  
Positive 1.24 (1.08-1.43)   1.16 (0.99-1.36)  
Unknown HIV status  0.92 (0.71-1.19)   0.86 (0.66-1.13)  
Site of disease   <0.001   0.001 
PTB  1 (Ref)   1 (Ref)  
EPTB 1.81 (1.49-2.20)   1.43 (1.14-1.78)  
AFB smear results at 
diagnosis 
 <0.001   0.001 
Smear negative 1 (Ref)   1 (Ref)  
Smear positive  0.64 (0.56-0.74)   0.78 (0.69-0.92)  
Unknown smear result 3.41 (1.04-11.11)   3.38 (1.02-11.23)  
Category of TB patient  <0.001   <0.001 
New TB patient  1 (Ref)   1 (Ref)  
Retreatment  0.13 (0.08-0.19)   0.12 (0.08-0.19)  
OR, Odds Ratio; 95% CI=95% Confidence Interval; DOT, Directly Observed Treatment; Ref, Reference Group; 
HIV, Human Immunodeficiency Virus; TB, Tuberculosis; PTB, Pulmonary tuberculosis; EPTB, Extra-pulmonary 
tuberculosis. 
All variables were included in the adjusted model  
n=4,472; Excluded: Not evaluated=Transferred-out and TB patients with unknown TB treatment outcomes, n= 363, 
7.5% 
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5.5. Discussion  
We showed that TB patients who opted for home-based DOT had more frequently risk factors 
for mortality and a higher mortality compared to the facility-based DOT group. The risk factors 
for mortality were older age (>35 years), HIV infection, smear-negative TB, and being on a TB 
retreatment regimen. 
 
Our main finding demonstrated that TB mortality was strikingly higher in the home-based 
compared to the facility-based DOT group under programmatic conditions. This is in contrast 
to three previous studies from Tanzania (Egwaga et al., 2009; Lwilla et al., 2003; van den 
Boogaard et al., 2009) which showed that mortality rates were lower or equal in the home-
based compared to the  facility-based DOT. A cluster randomized trial conducted in a rural 
district in Tanzania done in 2003, reported mortality to be lower in the home-based compared 
to facility-based DOT patient group (Lwilla et al., 2003). However, the observed results may 
be due to the close supervision by community-based DOT observers and health care workers 
under trial conditions (Lwilla et al., 2003). In 2009, shortly after the introduction of home-based 
DOT in Tanzania, an observational study conducted in several urban and rural settings 
reported a lower mortality in the PCT cohort (home-based DOT) compared to a historic cohort 
(facility-based DOT) (Egwaga et al., 2009). As the authors argue, however, the difference could 
be explained by the more efficacious and shorter six-month regimen (rifampicin throughout 
regimen, a more potent anti-TB) during the PCT implementation compared to the eight months 
regimen in the historic cohort. Moreover, the availability of the treatment supporters in the PCT 
cohort was verified by the study team. Another observational study in the northern Tanzania 
reported no difference in TB mortality in home-based compared to facility-based DOT (van den 
Boogaard et al., 2009). The higher mortality in facility-based DOT could be attributed to TB 
patients who were admitted at the national TB hospital, who may have been severely sick 
patients referred from other districts.  
 
The higher mortality in the home-based DOT group could be explained by the fact that TB 
patients under home-based DOT had more frequently risk factors of death such as older age 
(>35 years), HIV infection and smear-negative TB. Similarly, a study from the Northern part of 
Tanzania showed that HIV-positive and smear-negative TB patients preferred home-based 
DOT (van den Boogaard et al., 2009). In line with other studies from Tanzania (van den 
Boogaard et al., 2009; Wandwalo et al., 2006), we found that the majority (more than 60%) of 
TB patients in Tanzania appear to prefer home-based compared to facility-based DOT. Home-
based DOT could have been the likely choice because of convenience (e.g., older people who 
are less mobile or severely sick TB patients) and because patient related treatment costs are 
considerably lower (Wandwalo et al., 2006, 2005). Furthermore, adequate treatment 
supervision and adherence under home-based DOT may not have been guaranteed and 
implemented throughout the treatment period as stipulated in the guidelines (Egwaga et al., 
2008; van den Boogaard et al., 2009; Wandwalo et al., 2006), which could have caused the 
higher mortality in the home-based DOT group. The overall mortality during TB treatment in 
our study (7%) is comparable to previous studies in Tanzania (9%) (van den Boogaard et al., 
2009), and also comparable to studies elsewhere in sub-Saharan Africa (5 %) (Pepper et al., 
2015). However, mortality was lower than in the neighboring country Malawi (22%) (Harries A. 
et al., 2001), and lower than the global average (16%) [1].  
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We found that patient characteristics such as older age, HIV infection, and smear-negative TB 
were risk factors for mortality. This is in line with previous reports from several countries in 
sub-Saharan Africa (Connolly et al., 1998; Kabali et al., 2013; Kang’ombe et al., 2004; Lawn 
and Churchyard, 2009; van den Broek et al., 1998) and a systematic review (Waitt and Squire, 
2011). Smear-negative TB is associated with a higher mortality possibly because smear-
negative TB is more common in HIV-positive patients with severe immunosuppression 
(Sharma et al., 2005). Therefore, HIV-positive patients with severe immunosuppression may 
have developed the Immune Reconstitution Inflammatory Syndrome (IRIS), which is a 
consequence of the immune recovery after initiation of ART, and can result in death (Cohen 
and Meintjes, 2010; Lawn et al., 2005; Leone et al., 2010; Naidoo et al., 2012). We further 
speculate that other life threatening opportunistic infections such as Pneumocystis jirovecii 
pneumonia (PCP) (Field et al., 2014) may have contributed to the higher mortality in patients 
opting for home-based DOT. Furthermore, older age was also associated with higher mortality, 
consistent with several previous studies (Harries A. et al., 2001; Kang’ombe et al., 2004; van 
den Broek et al., 1998; Zachariah et al., 2002). Older people often have additional 
comorbidities such as diabetes mellitus, hypertension and chronic obstructive pulmonary 
disease (COPD) which are independently associated with increased risk of mortality (Waitt and 
Squire, 2011). In addition, fatal hepatotoxicity due to anti-TB is more common among older 
patients (Hosford et al., 2015). Finally, we also found that TB retreatment was associated with 
increased mortality. Retreatment TB patients (treatment failures or treatment after loss to 
follow-up) may have undetected initial or acquired drug resistance while on TB treatment (Field 
et al., 2014; Vijay et al., 2011), which may contribute to a higher mortality (Field et al., 2014). 
Although the prevalence of multi-drug resistance is low in Tanzania (3.9% among retreatment 
category patients, 1.1% among new TB patients) (Chonde et al., 2010), its contribution to the 
increased mortality cannot be ruled out. 
 
Our study has several limitations. First, this was a retrospective analysis using routinely 
collected data. However, we analyzed a large dataset of TB patients notified to the National 
TB Programme over four years. Also, the patients without the outcome of interest were equally 
distributed between home-based and facility-based DOT, and therefore we expect no bias of 
results. Therefore, these findings may reflect the “real life” situation under the programmatic 
conditions. Second, DOT preference by the patient is as recorded in the TB registers and we 
could not verify if patient remained with that choice throughout the TB treatment. However, the 
proportion of patients under home-based DOT in our study is very comparable to others 
previous studies done in Tanzania (Egwaga et al., 2008; van den Boogaard et al., 2009; 
Wandwalo et al., 2006); indicating that the data used in our study reflects the practice of DOT 
implementation in programmatic conditions. Third, additional factors such as socio-economic 
factors, causes of death, use of cotrimoxazole prophylaxis and anti-retroviral therapy (ART) 
and treatment supporter characteristics were not available from the routine dataset. However, 
we can reasonably assume that most of the TB patients included in our study were supported 
by their family members (Egwaga et al., 2009, 2008; Wandwalo et al., 2005), and the use of 
CPT and ART initiation was given as per Tanzanian HIV and AIDS treatment guidelines 
(NACP, 2015). Finally, we analyzed only data from an urban setting, and thus our findings may 
only be generalizable to other urban areas in sub-Saharan Africa.  
 
In conclusion, our results demonstrated that patients opting for home-based DOT under 
programmatic conditions are more likely to have risk factors for mortality and have an 
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increased mortality compared to facility-based DOT. Our findings suggest that there is a need 
for a risk assessment of patients at the time of TB diagnosis and a need for a careful monitoring 
of the implementation of DOT under programmatic conditions. The counseling and support of 
TB patients during TB treatment by trained health care workers may need to be improved, 
particularly in high-risk groups such as older people and those with comorbidities and co-
infections.  
 
Future research should focus on developing simple risk assessment tools based on evidence 
from prospective cohort studies (Bigna et al., 2015; Waitt and Squire, 2011) to identify patient 
and treatment supporter factors which may potentially influence mortality during TB treatment. 
In addition, operational research is needed to monitor the quality of treatment supervision and 
performance of DOT. Due to the limitations of current DOT strategies to assure proper drug 
intake (Maher, 2003; Van Deun and Rieder, 2012), additional new innovative public health 
interventions such as medication monitors and mobile text message reminders (Liu et al., 
2015) should also be considered in the transition phase to the “post-DOT” era (Metcalfe et al., 
2015). Combined with shortened and simplified TB treatment regimens, this may further 
reduce mortality and improve clinical outcomes to ultimately meet the “End TB” WHO targets 
by 2035 (WHO, 2015b). 
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5.6. Supporting information  
Supplementary Table 1. Patient characteristics of TB patients included and excluded in 
the study. 
Characteristics 
n (%) 
All 
(n=4,866) 
n (%) 
Included 
(n=4,472) 
n (%) 
Excluded 
(n=394) 
n (%) 
p-
value 
Total, n (%) 4,866 (100) 4,472 (91.9) 394 (8.1)  
Sex    0.5 
Male 2,960 (60.8) 2,714 (60.7) 246 (62.4)  
Female 1,906 (39.2) 1,758 (39.3) 148 (37.6)  
Age in years, median (IQR) 35 (27-44) 35 (27-44) 34 (28-44) 0.9 
Age groups, years    0.9 
15-19 285 (5.9) 267 (6.0) 18 (4.6)  
20-24 546 (11.2) 495 (11.1) 51 (12.9)  
25-29 727 (14.9) 670 (15.0) 57 (14.5)  
30-34 825 (17.0) 753 (16.8) 72 (18.3)  
35-39 709 (14.6) 652 (14.6) 57 (14.5)  
40-44 573 (11.8) 531 (11.9) 42 (10.7)  
45-49 435 (8.9) 400 (8.9) 35 (8.9)  
50-54 283 (5.8) 260 (5.8) 23 (5.8)  
≥ 55  483 (9.9) 444 (9.9) 39 (9.9)  
HIV status    0.4 
Positive 1,936 (39.8) 1,786 (39.9) 150 (38.1)  
Negative  2,597 (53.4) 2,376 (53.1) 221 (56.1)  
Unknown 333 (6.8) 310 (6.9) 23 (5.8)  
Site of disease     0.054 
PTB 4,001 (82.2) 3,663 (81.9) 338 (85.8)  
EPTB  865 (17.8) 809 (18.1) 56 (14.2)  
Patient category    0.080 
New 4,735 (97.3) 4,357 (97.4) 378 (95.9)  
Retreatment  131 (2.7) 115 (2.6) 16 (4.1)  
AFB smear results at 
diagnosis 
   0.052 
Smear-positive 2,455 (50.5) 2,235 (50.0) 220 (55.8)  
Smear-negative 2,366 (48.2) 2,197 (49.1) 169 (42.9)  
Unknown smear results  45 (0.9) 40 (0.9) 5 (1.3)  
n (%), absolute number and column percentage; TB, Tuberculosis; PTB, Pulmonary Tuberculosis; EPTB, 
Extrapulmonary Tuberculosis; IQR, Inter Quartile Range. 
We excluded 31 patients with unknown DOT preference, and 363 patients with the outcome “not evaluated” 
(“unknown” outcome or “transferred out”). Of the 31 patients with unknown DOT preference, only 2 patients died.  
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Supplementary Table 2. Baseline characteristics of TB patients, stratified by HIV status. 
Characteristic  HIV-positive 
(n=1,936) 
HIV-
negative 
(n=2,597) 
p-
value 
HIV status 
unknown 
n =2597 
All 
Sex   <0.001   
Male 970 (50.1) 1,791 (69.0)  199 (59.8) 2,960 (60.8) 
Female 966 (49.9) 806 (31.0)  134 (40.2) 1,772 (39.1) 
Age in years, median 
(IQR) 
38 (31-45) 32 (25-42) <0.001  35 (27-44) 
Site of disease    0.022   
PTB 1,570 (81.1) 2,174 (83.7)  257 (77.2) 4,001 (82.2) 
EPTB  366 (18.9) 423 (16.3)  76 (22.8) 865 (17.8) 
Category   0.1   
New 1,877 (97.0) 2,536 (97.7)  322 (96.7) 4,735 (97.3) 
Retreatment  59 (3.0) 61 (2.3)  11 (3.3) 131 (2.7) 
TB treatment outcomes    <0.001   
Treatment success  1549 (80.0) 2198 (84.6)   3747 (82.6) 
Cured 577 (29.8) 1083 (41.7)  87 (26.1) 1,747 (35.0) 
Treatment completed 972 (50.2) 1115 (42.9)  196 (58.9) 2,283 (46.9) 
Died 195 (10.1) 133 (5.1)  19 (5.7) 347 (7.1) 
Loss to follow-up  43 (2.2) 44 (1.7)  11 (3.3) 87 (1.9) 
Treatment failed 7 (0.4) 15 (0.6)  2 (0.6) 24 (0.5) 
Not evaluated  142 (7.3) 207 (8.0)  18 (5.4) 363 (7.5) 
AFB smear results at TB 
diagnosis 
  <0.001   
Smear-positive 839 (43.3) 1,468 (56.5)  148 (44.4) 2,307 (50.9) 
Smear-negative 1,065 (55.0) 1,119 (43.1)  182 (54.7) 2,184 (48.2) 
Unknown smear results   32 (1.7) 10 (0.4)  3 (0.9) 42 (0.9) 
DOT preference    0.003   
Home-based 1,485 (76.7) 1,874 (72.2)  234 (70.3) 3,359 (74.1) 
Facility-based 442 (22.8) 708 (27.3)  92 (27.6) 1,150 (25.4) 
Unknown 9 (0.5) 15 (0.6)  7 (2.1) 24 (0.5) 
n (%), absolute number and column percentage; TB, Tuberculosis; PTB, Pulmonary Tuberculosis; EPTB, 
Extrapulmonary Tuberculosis; IQR, Inter Quartile Range; DOT, Directly Observed Treatment 
HIV-positive and HIV-negative patients were compared using the Chi-square test for categorical variables and the 
nonparametric Wilcrox-ranksum test for continuous variables   
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Supplementary Table 3. Patient characteristics of TB patients who died and were alive 
during TB treatment, stratified by the preference of DOT. 
 All patients 
(n=4,472) 
Home-based 
(n=3,320) 
 Facility-based 
(n=1,152) 
  Dead Alive p-value  Dead Alive p-value 
Sex    0.2    0.2 
   Male 2,714 (60.7) 160 (54.2) 1,759 (58.1)   39 (78.0) 756 (68.6)  
   Female 1,758 (39.3) 135 (45.8) 1,266 (41.9)   11 (22.0) 346 (31.4)  
Age in years, 
median (IQR) 
35 (27-44) 40 (32-49) 35 (27-45) <0.001 
 
35 (26-42) 34 (28-41) 0.8 
Age groups in years   <0.001    0.09 
   15-19 267 (6.0) 13 (4.4) 214 (7.1)   2 (2.0) 38 (3.4)  
   20-24 495 (11.1) 15 (5.1) 336 (11.1)   3 (6.0) 141 (12.8)  
   25-29 670 (15.0) 19 (6.4) 465 (15.4)   12 (24.0) 174 (15.8)  
   30-34 753 (16.8) 52 (17.6) 473 (15.6)   6 (12.0) 222 (20.1)  
   35-39 652 (14.6) 44 (14.9) 436 (14.4)   12 (24.0) 160 (14.5)  
   40-44 531 (11.9) 43 (14.6) 332 (11.0)   6 (12.0) 150 (13.6)  
   45-49 400 (8.9) 40 (13.6) 261 (8.6)   1 (2.0) 98 (8.9)  
   50-54 260 (5.8) 28 (9.5) 174 (5.8)   5 (10.0) 53 (4.8)  
   ≥ 55  444 (9.9) 41 (13.9) 334 (11.0)   3 (6.0) 66 (6.0)  
HIV status    <0.001    0.2 
   Positive 1,786 (39.9) 175 (59.3) 1,197 (39.6)   19 (38.0) 395 (35.8)  
   Negative  2,376 (53.1) 108 (36.6) 1,620 (53.6)   24 (48.0) 624 (56.6)  
   Unknown 310 (6.9) 12 (4.1) 208 (6.9)   7 (14.0) 83 (7.5)  
Site of disease     0.007    0.6 
   PTB 3,663 (81.9) 218 (73.9) 2,434 (80.5)   45 (90.0) 966 (87.7)  
   EPTB  809 (18.1) 77 (26.1) 591 (19.5)   5 (10.0) 136 (12.3)  
Patient category    <0.001    0.003 
   New 4,357 (97.4) 284 (96.3) 3,004 (99.3)   41 (82.0) 1,028 (93.3)  
   Retreatment  115 (2.6) 11 (3.7) 21 (0.7)   9 (18.0) 74 (6.7)  
AFB smear results at diagnosis   <0.001    0.6 
   Smear-positive 2,235 (50.0) 83 (28.1) 1,479 (48.9)   26 (52.0) 647 (58.7)  
   Smear-negative 2,197 (49.1) 205 (69.5) 1,516 (50.1)   24 (48.0) 452 (41.0)  
    Unknown  7 (2.0) 7 (2.4) 30 (1.0)   0 (0.0) 3 (0.3)  
HIV-positive and HIV-negative were compared using pearson chi-square test for categorical variables and 
nonparametric Mann-Whitney test for continuous variable  
*n (%), absolute number and column percentage; TB, Tuberculosis; PTB, Pulmonary Tuberculosis; EPTB, 
Extrapulmonary Tuberculosis; IQR, Inter Quartile Range; DOT, Directly Observed Therapy 
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6.1. Abstract 
Background 
Helminth infections can negatively affect the immunologic host control, which may increase 
the risk of progression from latent Mycobacterium tuberculosis infection to tuberculosis (TB) 
disease and alter the clinical presentation of TB. We assessed the prevalence and determined 
the clinical relevance of helminth co-infection among TB patients and household contact 
controls in urban Tanzania. 
 
Methodology 
Between November 2013 and October 2015, we enrolled adult (≥18 years) sputum smear-
positive TB patients and household contact controls without TB during an ongoing TB cohort 
study in Dar es Salaam, Tanzania. We used Baermann, FLOTAC, Kato-Katz, point-of-care 
circulating cathodic antigen, and urine filtration to diagnose helminth infections. Multivariable 
logistic regression models with and without random effects for households were used to assess 
for associations between helminth infection and TB. 
 
Principal findings 
A total of 597 TB patients and 375 household contact controls were included. The median age 
was 33 years and 60.2% (585/972) were men. The prevalence of any helminth infection among 
TB patients was 31.8% (190/597) and 25.9% (97/375) among controls. Strongyloides 
stercoralis was the predominant helminth species (16.6%, 161), followed by hookworm (9.0%, 
87) and Schistosoma mansoni (5.7%, 55). An infection with any helminth was not associated 
with TB (adjusted odds ratio (aOR) 1.26, 95% confidence interval (CI): 0.88-1.80, p=0.22), but 
S. mansoni infection was (aOR 2.15, 95% CI: 1.03-4.45, p=0.040). Moreover, S. mansoni 
infection was associated with lower sputum bacterial load (aOR 2.63, 95% CI: 1.38-5.26, 
p=0.004) and tended to have fewer lung cavitations (aOR 0.41, 95% CI: 0.12-1.16, p=0.088). 
 
Conclusions/Significance:  
S. mansoni infection was an independent risk factor for active TB and altered the clinical 
presentation in TB patients. These findings suggest a role for schistosomiasis in modulating 
the pathogenesis of human TB. Treatment of helminths should be considered in clinical 
management of TB and TB control programs. 
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6.2. Author summary 
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, and parasitic worm 
infections are typical diseases of poverty. They often overlap geographically, and can occur in 
the same individual. Parasitic worm infections contribute to the down-regulation of the essential 
immune response against TB, and therefore can increase progression from latent M. 
tuberculosis infection to active TB. We conducted a case-control study in Dar es Salaam, the 
economic capital of Tanzania, where TB and helminths constitute a considerable burden. We 
found that infection with the blood fluke Schistosoma mansoni was associated with active TB, 
while none of the other parasitic worms showed such an association. Interestingly, TB patients 
infected with S. mansoni had significantly lower sputum bacterial load at diagnosis and tended 
to have fewer lung cavitations compared with TB patients without any parasitic worm infection. 
Diagnosis and treatment of parasitic worm infections, particularly schistosomiasis, should be 
considered during the management of TB patients and in the context of TB control programs. 
This could help to reduce the TB burden in settings where TB and parasitic worms co-exist. 
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6.3. Introduction 
Tuberculosis (TB), caused by Mycobacterium tuberculosis remains a challenging disease to 
control. Indeed, over two billion people are estimated to be infected with M. tuberculosis 
worldwide (WHO, 2015a). Moreover one billion people are infected with soil-transmitted 
helminths, schistosomes, filarial worms, and food-borne trematodes (Knopp et al., 2012; Pullan 
et al., 2014; Utzinger et al., 2012). In 2014, an estimated 9.6 million new TB patients were 
notified and 1.5 million TB patients died from the disease (WHO, 2015a). TB is a leading cause 
of deaths from an infectious disease (WHO, 2015b). 
 
TB and helminthiases overlap geographically, particularly in areas where poverty persists, for 
example in countries of sub-Saharan Africa (Simon, 2016; WHO, 2015a). Where TB and 
helminth infections co-occur, they can affect the same individual and thus exacerbate the 
course of disease (Simon, 2016). Several conditions such as diabetes mellitus, malnutrition, 
and malignancies are known to increase the risk of progressing from latent M. tuberculosis 
infection to active TB (Lönnroth et al., 2009). Human immunodeficiency Virus (HIV)-induced 
immunodeficiency is by far the most important risk factor for developing TB (NTLP, MoHSW, 
2013; WHO, 2015a), but parasitic co-infections such as with helminths can also contribute to 
the development of TB (DiNardo et al., 2016; Potian et al., 2011; Rafi et al., 2012). Immune 
dysregulations caused by helminth infections are known to negatively affect the prognosis of 
HIV and malaria (Salgame et al., 2013; Simon, 2016). The immune response to helminth 
infections is characterized by the induction of CD4+ T-helper 2 (Th2) and down-regulation of 
CD4+ T-helper 1 (Th1) cells (Babu and Nutman, 2016; Mishra et al., 2014; Monin et al., 2015; 
Salgame et al., 2013). This immunological imbalance has been suggested to increase the risk 
of progression from latent M. tuberculosis infection to active TB and to worsen the clinical 
outcomes. 
 
We aimed to study the interaction between TB and helminth co-infections by comparing the 
prevalence of helminth infections, using a suite of diagnostic techniques, between TB patients 
and household contact controls without TB in an ongoing cohort study in Dar es Salaam, 
Tanzania, and to assess the effects of helminth infection on the clinical presentation and 
outcomes of TB disease. 
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6.4. Methods  
6.4.1. Ethics statement 
The study protocol was approved by the institutional review board of the Ifakara Health Institute 
(IHI; reference no. IHI/IRB/No 04-2015) and the Medical Research Coordinating Committee of 
the National Institute of Medical Research (NIMR; reference no. NIMR/HQ/R.8c/Vol.I/357) in 
Tanzania, and the ethics committee of north-west and central Switzerland (EKNZ; reference 
no.: UBE-15/42). Written informed consent was obtained from all study participants. TB 
patients were treated according to the National TB and Leprosy Programme (NTLP) treatment 
guideline (NTLP, MoHSW, 2013). Individuals with a Schistosoma spp. infection were treated 
with praziquantel (40 mg/kg). Other helminth infections were treated with albendazole (400 
mg) immediately after diagnosis, as recommended by the national treatment guidelines 
(MoHSW, 2013). HIV-positive patients were clinically managed according to the Tanzania 
National HIV and acquired immune deficiency syndrome (AIDS) treatment guideline (NACP, 
2015). 
6.4.2. Study setting 
The study was conducted in the densely populated urban setting of Temeke district in Dar es 
Salaam, which is the economic capital of Tanzania. The population of Temeke is estimated at 
1.4 million. In 2014, about one third of all TB patients from Dar es Salaam were notified in 
Temeke district (4,373; 32%) (NTLP, MoHSW, 2015). The overall HIV prevalence in the 
general adult population in Dar es Salaam is 5.2% (PMORALG, 2014). The study area includes 
two TB sub-districts, Wailes I and Wailes II, whose patients are clinically managed at the 
Temeke district hospital and the two associated TB diagnostic and treatment centers of 
Tambukareli and Pasada (Mhimbira et al., 2016). 
6.4.3. Study design 
The study was conducted within the frame of an ongoing prospective cohort study of TB 
patients and household contact controls in Dar es Salaam (TB-DAR). We assessed the 
association of TB and helminth infection in a case-control study design of TB patients (sputum 
smear-positives for acid-fast bacilli [AFB]) and household contact controls (Xpert MTB/RIF 
negative), who were matched by age (±5 years) and whenever possible by sex. We 
prospectively followed-up TB patients and assessed the clinical outcomes comparing TB 
patients with and without helminth infection at 6 and 12 months after recruitment. 
6.4.4. Study population and sample size 
We consecutively enrolled study participants starting in November 2013 until October 2015 to 
reach the required sample size. Over this period, we included adult TB patients (≥18 years of 
age and sputum-smear positive) and household contact controls. Any individual living in the 
same household as the index TB patients enrolled in the study is referred to as a household 
contact control. Controls at recruitment were free of symptoms and signs suggestive of TB, 
healthy on physical examination, and had a negative Xpert MTB/RIF result (Cepheid; 
California, United States of America). 
 
Assuming a helminth prevalence of 45% in TB patients and 26% in controls based on results 
from previous publications (Elias et al., 2006) and a power of 80%, the target sample size was 
109 study participants (for each group) to detect a prevalence difference of 19% between the 
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two groups with a significance level of test 0.05, two-tailed and calculated with Stata version 
14.0 (Stata Corp; Texas, United States of America). 
6.4.5. Study procedures 
TB patients and household contact controls were interviewed and underwent physical 
examination during recruitment at the study site (see under “Data Collection and Definitions”). 
We collected skinfold measurements from four body sites (biceps, triceps, subscapular, and 
suprailiac) using the Harpenden skinfold caliper (Baty International (BI), 2007). The percentage 
body fat was calculated as previously described (Durnin and Womersley, 1974). Household 
contacts with no symptoms or signs of TB submitted a sputum sample for Gene Xpert MTB/RIF 
to rule-out TB. We collected blood, stool, and urine samples from TB patients and controls for 
subsequent laboratory investigations. Chest X-rays for TB patients were done at the Temeke 
district hospital and were interpreted by an experienced board certified radiologist who was 
blinded to patients’ clinical data. Trained field workers collected geographic coordinates (global 
positioning system [GPS]) from the patients’ homes using Samsung Tab 4 android tablet 
(Samsung; Suwon, South Korea). 
6.4.6. Laboratory procedures 
Microbiological Investigations. A patient was considered as having TB when any of the two 
submitted sputum samples were positive for AFB by staining sputum smears using the Ziehl-
Nielsen (ZN) method, and a positive mycobacterial culture. Sputum smear microscopy was 
done at the Temeke district hospital under continuous quality control by the central tuberculosis 
reference laboratory (Dar es Salaam, Tanzania). AFB smear-positive results were graded 
according to World Health Organization/International Union Against Tuberculosis and Lung 
Disease (WHO/IUATLD) guidelines: “scanty” with 1-9 AFB per 100 oil immersion fields; “1+” 
with 10-99 AFB per 100 immersion fields; “2+” with 1-10 AFB per 1 immersion field, and “3+” 
with >10 AFB per immersion field (NTLP, MoHSW, 2013; WHO, 2013). To rule out TB among 
household controls, an additional sputum sample from TB patients and controls was sent to 
the TB laboratory at the Bagamoyo Research and Training Center (BRTC), IHI, for GeneXpert 
MTB/RIF (controls) and for culture on Löwenstein-Jensen media (TB patients and controls). 
 
Helminthological Investigations. For the diagnosis of helminth infections, single stool and 
urine samples were collected from each participant before the start of TB treatment (TB 
patients) and at the time of enrolment (controls). All stool and urine samples were transferred 
to the Helminth Unit at BRTC and examined for helminth infections using standardized, quality-
controlled procedures as described elsewhere (Knopp et al., 2014; Salim et al., 2015, 2014). 
The Kato-Katz (triplicate thick smears per stool sample) and the FLOTAC methods were used 
to diagnose Ascaris lumbricoides, hookworm, S. mansoni, and Trichuris trichiura infections. 
The Baermann method was used to identify Strongyloides stercoralis infections (WHO, 1994). 
In addition, a rapid point-of-care circulating cathodic antigen (POC-CCA) urine cassette test 
was employed for the diagnosis of S. mansoni (Colley et al., 2013). The urine filtration method 
was applied to detect S. haematobium infections (Salim et al., 2015). For quality control, 10% 
of Kato-Katz slides were randomly selected and re-examined by a second reader. 
 
Blood Testing. In line with national HIV testing algorithms, screening was done using the 
Alere Determine HIV rapid test (AlereTM, USA). The Uni-gold HIV (Trinity Biotech; Wicklow, 
Ireland) rapid test served as a confirmatory test in case of a positive screening test. The CD4+ 
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T-cells counts were determined using a FACSCount machine (Becton Dickinson Biosciences; 
California, United States of America). A full blood cell count was done with a MS4 Vet 
hematology analyzer (Diamond Diagnostics; Massachusetts, United States of America). All 
blood tests were performed at the Temeke district hospital laboratory, which is under 
supervision and quality control by the regional laboratory technician. 
6.4.7. Data collection and definitions 
We collected socio-demographic indicators including age, sex, ethnicity, education, and 
household income. Anthropometric data included weight, height, and skinfold measurements. 
Clinical data collected pertained to presenting symptoms of TB patients, TB treatment 
category, and treatment outcomes. Laboratory data included ZN sputum smear results and 
Gene Xpert MTB/RIF results, helminth species infections, HIV status, full blood cell count, and 
CD4+ cell count. All study participants were asked about their use of anthelmintic treatment in 
the last 12 months prior to the enrollment into the study. Study data were captured by electronic 
case report forms using the open-source data collection software ODK on Android PC tablets 
(Andreas Steiner et al., 2016). Data management was done using the eManagement tool 
“odk_planner”, as previously described (Andreas Steiner et al., 2016). Data were uploaded to 
a password protected secure server with regular back-ups. 
 
In order to grade the clinical severity of TB, we adopted a previously published clinical TB 
score (Wejse et al., 2008), with the following modification: 12 points TB score parameters 
instead of 13 points as tachycardia was not systematically measured. The following TB score 
parameters were used: (i) coughing; (ii) hemoptysis; (iii) chest pain; (iv) dyspnea; (v) night 
sweating; (vi) anemic conjunctivae; (vii) positive finding at auscultation; (viii) axillary 
temperature >37.0 °C; (ix) mid upper arm circumference (MUAC) <220 mm; (x) MUAC <200 
mm; (xi) body mass index (BMI) <18 kg/m2; and (xii) BMI <16 kg/m2. TB score was then 
categorized into mild (score of 1-5) and severe (score of ≥6). Low BMI was defined as BMI 
<18 kg/m2; high sputum bacterial load as AFB sputum smear result ≥2+ (quantitative scoring), 
which correlates with GeneXpert Ct values (Blakemore et al., 2011). To assess the clinical 
outcomes among TB patients, we defined poor gain as a change in absolute body weight (<7 
and ≥7 kg), BMI (<2.6 and ≥2.6 kg/m2) and body fat (<0 and ≥0%) from recruitment to month 
6 of follow-up.  
 
“Any helminth infection” was defined as infection with any of the following helminth species: 
A. lumbricoides, Enterobius vermicularis, hookworm, Hymenolepis diminuta, S. haematobium, 
S. mansoni, S. stercoralis and T. trichiura. High occupational risk for schistosomiasis was 
defined as working in rice fields, sand harvesting, washing cars, and fishing in freshwater. The 
intensity of helminth infection was defined according to WHO classification (WHO, 2011). The 
average egg counts from the triplicate Kato-Katz thick smears per stool sample and per 
individual were multiplied by a factor of 24 to obtain eggs per gram (EPG) of stool (Knopp et 
al., 2014). 
6.4.8. Statistical analysis 
We compared the characteristics of TB patients and household contact controls at the time of 
TB diagnosis or enrolment. The prevalence of helminth infection was calculated from the 
generalized estimations equation adjusting for clustering at the household level. We used 
multilevel mixed-effects logistic regression with random intercepts at the level of households 
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to assess risk factors for helminth infection. To assess risk factors for TB, we compared cases 
and controls using unconditional logistic regression because not all TB cases could be 
assigned a control. In addition, we also performed conditional logistic regression among 
matched pairs to confirm the results. Additional analyses assessed the association of TB and 
with specific helminth species separately. We also examined whether the association between 
the presence of a helminth infection and a recent history of deworming drugs depended on 
HIV infection status by including an interaction term in the logistic regression model. Among 
TB patients, logistic regression models were used to study associations between helminth 
infection and clinical presentation at the time of TB diagnosis (such as TB score, high sputum 
bacterial load, lung infiltration, and cavitation), and to study the association between helminth 
infection and clinical outcomes after 6 months of TB treatment (change in absolute weight, 
BMI, and percentage body fat). Associations were expressed as crude odds ratios (ORs) and 
adjusted ORs (aORs). All analyses were performed in Stata version 14.0 (Stata Corp; Texas, 
United States of America). 
 
We used the geographic coordinates of the TB patients’ homes to analyze the spatial 
distribution of TB and helminth co-infections. The prevalence of helminths and helminth 
species was analyzed at the ward level for optimal readability. The average area per ward in 
the Dar es Salaam region is 15.5 km2 (PMORALG, 2014). The maps were produced using the 
software package ArcGIS Desktop version 10.2 (ESRI; California, United States of America) 
and the shape files from the National Bureau of Statistics of Tanzania (“Tanzania: shapefiles 
for EAs, villages, districts and regions,” n.d.). 
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6.5. Results 
6.5.1. Characteristics of the study participants  
A total of 597 TB patients and 375 household contact controls were included. Table 8 
summarizes the socio-demographic and clinical characteristics of TB patients and controls. 
The study participants’ flow diagram is shown in Figure 11. Among all study participants, the 
median age was 33 years (interquartile range [IQR]: 26-41 years) and 60.2% (585/972) were 
men. HIV prevalence was 20.4% (95% confidence interval (CI): 17.9-23.0%). TB patients were 
more frequently male compared with controls (68.8% [411/597] vs. 46.4% [174/375]), HIV-
positive (27.3% [163] vs. 9.3% [35]), and smokers (18.1% [108] vs. 8.8% [33]). TB patients 
also had a lower median BMI (18.3 kg/m2, IQR: 16.5-20.4 kg/m2 vs. 23.9 kg/m2, IQR: 21.6-28.1 
kg/m2) and a lower median hemoglobin level (11.3 g/dl, IQR: 9.9-12.7 g/dl vs. 12.8 g/dl, IQR: 
11.5-14.1 g/dl). The patient characteristics, stratified by HIV status, are shown in 
Supplementary Table 4. 
 
Figure 11. Study participants flow diagram  
 
  
44 
 
Table 8. Socio demographic and clinical characteristics of tuberculosis (TB) patients 
and household contact controls without TB enrolled between November 2013 to 
October 2015 in Dar es Salaam, Tanzania 
Characteristics Total TB patient Controls 
 (n=972) (n=597) (n=375) 
Age in years, median (IQR) 33 (26-41) 33 (26-40) 33 (26-42) 
Age groups (years)    
18-24 194 (20.0) 107 (17.9) 87 (23.2) 
25-34 347 (35.7) 226 (37.9) 121 (32.3) 
35-44 266 (27.4) 169 (28.3) 97 (25.9) 
≥45 165 (17.0) 95 (15.9) 70 (18.7) 
Sex     
Female  387 (39.8) 186 (31.2) 201 (53.6) 
Male 585 (60.2) 411 (68.8) 174 (46.4) 
HIV status    
Negative  774 (79.6) 434 (72.7) 340 (90.7) 
Positive 198 (20.4) 163 (27.3) 35 (9.3) 
Education level     
No/Primary  806 (82.9) 500 (83.8) 306 (81.6) 
Secondary/University 166 (17.1) 97 (16.2) 69 (18.4) 
Occupation     
Unemployed 349 (35.9) 204 (34.2) 145 (38.7) 
Employed  623 (64.1) 393 (65.8) 230 (61.3) 
Smoking status    
No 831 (85.5) 489 (81.9) 342 (91.2) 
Yes 141 (14.5) 108 (18.1) 33 (8.8) 
People in the household    
≤3 731 (75.2) 442 (74.0) 289 (77.1) 
>3 241 (24.8) 155 (26.0) 86 (22.9) 
Household income per month (USD)    
≤100 763 (78.5) 473 (79.2) 290 (77.3) 
>100 209 (21.5) 124 (20.8) 85 (22.7) 
Body weight at diagnosis, [in kg], (IQR) 54 (48-61) 51 (46-57) 59 (53-67) 
BMI (kg/m2), median (IQR) 20.0 (17.6-23.4) 18.3 (16.6-20.4) 23.9 (21.6-28.1) 
BMI categories (kg/m2)    
Underweight <18.5 337 (34.7) 318 (53.3) 19 (5.1) 
Normal, 18.5-24.9 454 (46.7) 256 (42.9) 198 (52.8) 
Overweight 25.0-29.9 119 (12.2) 21 (3.5) 98 (26.1) 
Obese ≥30 62 (6.4) 2 (0.3) 60 (16.0) 
Body fat (%) 10.1 (7.7-14.7) 9.5 (6.8-13.7) 11.5 (8.5-17.0) 
MUAC (cm), median (IQR) 24.3 (22.7-26.2) 23.3 (22.0-25.3) 25.3 (23.7-28.0) 
Waist hip ratio, median (IQR) 0.89 (0.86-0.94)  0.89 (0.86-0.94) 0.89 (0.86-0.94) 
Occupational risk a     
No 521 (54.2) 322 (54.2) 199 (54.1) 
Yes 441 (45.8) 272 (45.8) 169 (45.9) 
Individual deworming (in 12 months)    
Yes 797 (82.0) 484 (81.1) 313 (83.5) 
No 175 (18.0) 113 (18.9) 62 (16.5) 
Hb level (g/dl), median (IQR) 12 (10.4-13.3) 11.3 (9.9-12.7) 12.8 (11.5-14.1) 
a Helminth infection occupation risk (working in rice fields, car wash and fishing); 
BMI, body mass index; HIV, human immunodefiency virus; Hb, hemoglobin level; IQR, inter-quartile range; MUAC, mid-upper arm 
circumference; USD, United States Dollars (1 USD=2,190 Tanzanian Shillings in March 2016) 
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6.5.2. Prevalence and risk factors for helminth infection 
Among all participants, the prevalence of any helminth infection was 29.5% (95% CI: 26.7-
32.6%). S. stercoralis (16.5%, 161) was the predominant helminth species, followed by 
hookworm (9.0%, 87), S. mansoni (5.7%, 55) and S. haematobium (2.0%, 19). Overall, TB 
patients were more frequently co-infected with any helminth species compared with controls 
(OR 1.34, 95% CI: 1.00-1.78, p=0.048; Table 9). The prevalence of helminth infection was 
lower in HIV-positive (22.7%, 45) compared with HIV-negative study participants (31.3%, 242; 
Supplementary Table 4). Similarly, helminth infection was lower among TB patients co-infected 
with HIV (22.7%, 37) compared with HIV-negative TB patients (35.3%, 153; Supplementary 
Table 5). We found that most study participants had light-intensity helminth infection. For 
example, 96.4% (54) of study participants had light-intensity hookworm infection as determined 
by the Kato-Katz method (Supplementary Table 6). The prevalence and geographic 
distribution of species-specific helminth infections in the study area is shown in Supplementary 
Figure 1.  
Table 9. Frequency distribution of helminth infections stratified by TB patients and 
household contact controls.  
Helminth Infection All TB patients Controls  Comparing TB patients and 
controls a 
 (n=972) (n=597) (n=375)    
 n (%) n (%) n (%)  OR (95% CI) p-value 
Any helminth 287 (29.5) 190 (31.8) 97 (25.9)  1.34 (1.00-1.78) 0.048 
Helminth species        
Strongyloides stercolaris 161 (16.6) 111 (18.6) 50 (13.3)  1.48 (1.03-2.13) 0.032 
Hookworm 87 (9.0) 55 (9.2) 32 (8.5)  1.09 (0.69-1.72) 0.72 
Ascaris lumbricoides 6 (0.6) 3 (0.5) 3 (0.8)  0.63 (0.13-3.12) 0.57 
Enterobius vermicularis  5 (0.5) 1 (0.2) 4 (1.1)  NA NA 
Trichuris trichiura  9 (0.9) 6 (1.0) 3 (0.8)  1.25 (0.31-5.06) 0.75 
Hymenolepis. diminuta 2 (0.2) 1 (0.2) 1 (0.3)  NA NA  
Schistosoma sppc 70 (7.2) 49 (8.2) 21 (5.6)  1.51 (0.89-2.56) 0.13 
Schistosoma mansoni 55 (5.7) 40 (6.7) 15 (4.0)  1.72 (0.94-3.17) 0.079 
Schistosoma haematobium 19 (2.0) 11 (1.8) 8 (2.1)  0.86 (0.34-2.16) 0.75 
       
Helminth infection       0.13 
None 685 (70.5) 407 (68.2) 278 (74.1)  1  
Mono-infection  237 (24.4) 158 (26.5) 79 (21.1)  1.37 (1.00-1.86)  
Infection with ≥2 species 50 (5.1) 32 (5.3) 18 (4.8)  1.21 (0.67-2.21)  
a Estimates from an unadjusted mixed-effect models with household as a random intercept 
Occupational risk for helminth infection (working in rice fields, car wash and fishing; OR, odds ratio; NA, not applicable 
 
Study participants with occupational risk for acquiring schistosomiasis, such as working in rice 
fields, sand harvesting, washing cars, and fishing had higher odds of being infected with any 
helminth species (aOR 1.42, 95% CI: 1.04-1.95, p=0.029). HIV-positive patients were less 
likely to be infected with any helminth species (aOR 0.57, 95% CI: 0.37-0.87, p=0.010; Table 
10). Study participants who did not take anthelmintic treatment in the past 12 months did not 
have significant higher odds of being co-infected with any helminth species (aOR 1.35, 95% 
CI: 0.92-1.99, p=0.12). There was no statistically significant interaction between the effects of 
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HIV infection and deworming status on TB incidence (P-value from test for interaction: 0.5). 
When analyzing the risk factors for helminth infection separately for TB patients and household 
controls without TB, we found similar results (Supplementary Table 8 and Supplementary 
Table 9).  
 
Table 10. Risk factors for any helminth infection among TB patients and household 
controls without TB. 
Characteristic Helminth infection, n (%)  Unadjusted  Adjusted 
 Yes No       
    OR (95% CI) p-value  aOR (95% CI) p-value 
Participant      0.054   0.18 
Controls  97 (33.8) 278 (40.6)  1.00   1.00  
TB patients  190 (66.2) 407 (59.4)  1.35 (1.00-1.82)   1.29 (0.88-1.87)  
Age group (years)     0.30   0.46 
18-24 50 (17.4) 144 (21.0)  1.00   1.00  
25-34 115 (40.1) 232 (33.9)  1.46 (0.96-2.23)   1.38 (0.89-2.17)  
35-44 75 (26.1) 191 (27.9)  1.13 (0.72-1.78)   1.11 (0.68-1.82)  
≥45 47 (16.4) 118 (17.2)  1.16 (0.70-1.92)   1.18 (0.69-2.03)  
Sex     0.003   0.24 
Female 93 (32.4) 294 (42.9)  1.00   1.00  
Male 194 (67.6) 391 (57.1)  1.60 (1.17-2.18)   1.23 (0.87-1.75)  
HIV status     0.022   0.010 
Negative 242 (84.3) 532 (77.7)  1.00   1.00  
Positive  45 (15.7) 153 (22.3)  0.63 (0.43-0.94)   0.57 (0.37-0.87)  
BMI category (kg/m2)     0.077   0.47 
BMI ≥18 175 (61.0) 460 (67.2)  1.00   1.00  
BMI <18 112 (39.0) 225 (32.8)  1.32 (0.97-1.79)   1.14 (0.79-1.64)  
Education level     0.28   0.50 
No/primary 243 (84.7) 563 (82.2)  1.00   1.00  
Secondary/University 44 (15.3) 122 (17.8)  0.80 (0.53-1.20)   0.86 (0.55-1.34)  
Employment status      0.13   0.42 
Unemployed  93 (32.4) 256 (37.4)  1.00   1.00  
Employed  194 (67.6) 429 (62.6)  1.28 (0.93-1.76)   1.16 (0.81-1.65)  
Number of people in the 
household 
    0.66   0.97 
≤3 218 (76.0) 69 (24.0)  1.00   1.00  
>3 513 (74.9) 172 (25.1)  0.93 (0.65-1.32)   0.99 (0.69-1.42)  
Household income per 
month (USD) 
    0.47   0.75 
≤100 229 (79.8) 534 (78.0)  1.00   1.00  
>100 58 (20.2) 151 (22.0)  0.87 (0.60-1.26)   0.94 (0.63-1.40)  
Individual deworming (in 12 
months) 
    0.043   0.12 
Yes 224 (78.0) 573 (83.6)  1.00   1.00  
No 63 (22.0) 112 (16.4)  1.48 (1.01-2.15)   1.35 (0.92-1.99)  
Occupational risk a      0.009   0.029 
No 136 (47.7) 385 (56.9)  1.00   1.00  
Yes 149 (52.3) 292 (43.1)  1.50 (1.11-2.03)   1.42 (1.04-1.95)  
a Helminth infection occupation risk (working in rice fields, car wash and fishing) 
BMI, body mass index; HIV, human immunodeficieny virus;  
Multilevel mixed-effects logistic regression model with household as a random intercept, adjusted for TB status, age-groups, sex, 
HIV status, BMI, education level, employment status, number of people living in the same household, individual deworming status, 
occupational risk and income level.  
Note: interaction between the effect of HIV and deworming status on the risk for any helminth infection: p=0.50 
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6.5.3. Helminth infection as a risk factor for TB  
Multiple logistic regression models adjusted for patient characteristics and known risk factors 
for TB showed that any helminth infection was not statistically significantly associated with TB 
(aOR 1.26, 95% CI: 0.88-1.80, p=0.22, Table 11 and Supplementary Table 10). However, 
when analyzing each helminth species separately, we found that S. mansoni infection was 
significantly associated with TB (aOR 2.15, 95% CI: 1.03-4.45, p=0.040), but there was no 
significant association between TB and S. stercoralis or hookworm infection (Supplementary 
Table 11). Other co-factors that were significantly associated with TB included: male sex, HIV 
co-infection, smoking, living in a household with ≥3 people, and a low BMI (Table 11). The 
unadjusted and adjusted ORs for any helminth infection and S. mansoni are shown in 
Supplementary Table 10. Results were more pronounced when using conditional logistic 
regression model (Supplementary Table 12).  
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Table 11. Associations of TB disease with helminth infection and other patient 
characteristics. The full table with unadjusted and adjusted odds ratios is shown in the 
Supplementary Information (S7 Table).  
Characteristics   Any helminth infection 
(n=972) 
 S. mansoni infection 
(n=972) 
 TB patients Controls  Adjusted    Adjusted  
 n (%) n (%) aOR (95% CI) p-
value 
 aOR (95% CI) p-value 
Helminth infection    0.22   0.040 
No  407 (68.2) 278 (74.1) 1.00   1.00  
Yes  190 (31.8) 97 (25.9) 1.26 (0.88-1.80)   2.15 (1.03-4.45)  
Age group (years)    0.49   0.25 
18-24 107 (17.9) 87 (23.2) 1.00   
1.00  
25-34 226 (37.9) 121 (32.3) 1.22 (0.77-1.94)   
1.24 (0.78-1.97)  
35-44 169 (28.3) 97 (25.9) 1.00 (0.60-1.67)   
1.02 (0.61-1.7)  
≥45 95 (15.9) 70 (18.7) 0.85 (0.48-1.48)   
0.88 (0.51-1.54)  
Sex    <0.001   <0.001 
Female 186 (31.2) 201 (53.6) 1.00   
1.00  
Male 411 (68.8) 174 (46.4) 3.12 (2.13-4.56)   
3.16 (2.16-4.63)  
HIV status    <0.001   <0.001 
Negative 434 (72.7) 340 (90.7) 1.00   
1.00  
Positive  163 (27.3) 35 (9.3) 6.18 (3.83-9.95)   
6.23 (3.86-10.05)  
Education level    0.55   0.57 
No/primary 500 (83.8) 306 (81.6) 1.00   1.00  
Secondary/University 97 (16.2) 69 (18.4) 1.15 (0.73-1.80)   1.14 (0.72-1.79)  
Employment status     0.63   0.66 
Unemployed  204 (34.2) 145 (38.7) 1.00   1.00  
Employed  393 (65.8) 230 (61.3) 0.91 (0.62-1.33)   0.92 (0.63-1.34)  
Smoking status     0.012   0.011 
No 489 (81.9) 342 (91.2) 1.00   1.00  
Yes  108 (18.1) 33 (8.8) 1.92 (1.15-3.21)   1.95 (1.16-3.25)  
Number of people in the 
household 
   0.018  
 0.015 
≤3 people 442 (74.0) 289 (77.1) 1.00   1.00  
>3 people  155 (26.0) 86 (22.9) 1.58 (1.08-2.30)   1.60 (1.09-2.34)  
Household income per 
month (USD) 
   0.85  
 0.95 
≤100 473 (79.2) 290 (77.3) 1.00   1.00  
>100 124 (20.8) 85 (22.7) 1.04 (0.69-1.56)   1.01 (0.68-1.52)  
BMI category (kg/m2)    <0.001   <0.001 
BMI ≥18 279 (46.7) 318 (53.3) 1.00   1.00  
BMI <18  356 (94.9) 19 (5.1) 23.20 (13.91-
38.69) 
  23.52 (14.1-
39.24)  
Occupational risk     0.24  
 0.26 
No 322 (54.2) 199 (54.1) 1.00   
1.00  
Yes 272 (45.8) 169 (45.9) 0.82 (0.59-1.15)   
0.83 (0.59-1.15)  
Individual deworming (in 
12 months) 
   0.20  
 0.21 
Yes 484 (81.1) 313 (83.5) 1.00   
1.00  
No 113 (18.9) 62 (16.5) 0.75 (0.48-1.16)   
0.76 (0.49-1.17)  
BMI, body mass index; HIV, human immunodeficieny virus; OR, odds ratio; 95% CI, 95% confidence interval 
a Helminth infection occupation risk (working in rice fields, car wash and fishing); 
Logistic regression model for TB disease status as the outcome. Model adjusted for any helminth infection/S. mansoni, age, sex, 
HIV status, BMI, education level, employment status, smoking status, number of people living in the same household, individual 
deworming status, helminth risk occupation and income level.  
49 
 
6.5.4. Effect of helminth infection on clinical presentation and disease 
severity in TB patients 
TB patients co-infected with any helminth infection were more likely than helminth un-infected 
TB patients to present with hemoptysis (74 [38.9%] vs. 123 [30.2%]), had higher median 
hemoglobin levels (11.7 g/dl, IQR: 10.1-13.0 g/dl vs. 11.3 g/dl, IQR: 9.8-12.5 g/dl) and higher 
median eosinophil counts (0.2, IQR: 0.1-0.4 cells/µl vs. 0.1, IQR: 0.05-0.2 cells/µl;  Table 12). 
TB patients co-infected with S. mansoni were more likely to have lower sputum bacterial load 
than helminth-uninfected TB patients (aOR 2.63; 95% CI: 1.38-5.26, p=0.004). Furthermore, 
we found that TB patients co-infected with S. mansoni tended to have fewer lung cavities, 
although this association lacked statistical significance (aOR 0.41, 95% CI: 0.12-1.16, p=0.088; 
Table 13). There were no statistically significant differences in radiological features between 
TB patients with and without any helminth infection as shown in Supplementary Table 13.  
 
6.5.1. Effect of helminth infection on clinical outcomes in TB patients 
Overall, 81.7% (273 TB patients) were cured at the end of TB treatment (at 6 months), 17.4% 
(58) completed treatment (AFB smear results not available at 6 months, but documented 
completion of treatment), and 0.9% (3) were treatment failures (positive AFB smear result at 6 
months). We found no significant associations between helminth infection (at time of 
recruitment) and poor gain in absolute weight (aOR 0.89, 95% CI: 0.55-1.45, p=0.63), BMI 
(aOR 0.74, 95% CI: 0.46-1.21, p=0.23), and body fat percentage (aOR 0.92, 95% CI: 0.55-
1.56, p=0.78) after 6 months on TB treatment, as shown in Supplementary Table 14. 
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Table 12. Patient characteristics of TB patients infected and not infected with helminths 
at the time of TB diagnosis.  
Characteristics Total TB and helminth TB only  
 (n=597) (n=190) (n=407) p-value 
Age, median (IQR) (years) 33 (26-40) 31 (26-39) 34 (27-40) 0.22 
Age groups (years)    0.13 
18-24 107 (17.9) 35 (18.4) 72 (17.7)  
25-34 226 (37.9) 81 (42.6) 145 (35.6)  
35-44 169 (28.3) 42 (22.1) 127 (31.2)  
≥45 95 (15.9) 32 (16.8) 63 (15.5)  
Sex     0.007 
Female  186 (31.2) 45 (23.7) 141 (34.6)  
Male 411 (68.8) 145 (76.3) 266 (65.4)  
HIV status    0.003 
Negative 434 (72.7) 153 (80.5) 281 (69.0)  
Positive 163 (27.3) 37 (19.5) 126 (31.0)  
CD4+ count, cells/mla 202 (94-273) 185 (90-259) 203 (100-273) 0.74 
Education level     0.49 
No formal education & Primary  500 (83.8) 162 (85.3) 338 (83.0)  
Secondary/University 97 (16.2) 28 (14.7) 69 (17.0)  
Occupation     0.99 
Unemployed 204 (34.2) 65 (34.2) 139 (34.2)  
Employed  393 (65.8) 125 (65.8) 268 (65.8)  
Number of people in the household    0.89 
≤3 people 442 (74.0) 140 (73.7) 302 (74.2)  
> 3 people  155 (26.0) 50 (26.3) 105 (25.8)  
Smoking status    <0.004 
No 489 (81.9) 143 (75.3) 346 (85.0)  
Yes 108 (18.1) 47 (24.7) 61 (15.0)  
Household income per month (USD)    0.45 
≤100 473 (79.2) 154 (81.1) 319 (78.4)  
>100 124 (20.8) 36 (18.9) 88 (21.6)  
Body weight (kg), median (IQR) 51 (46-57) 50.9 (46-56) 51.7 (46-57.5) 0.40 
BMI (kg/m2), median(IQR) 18.3 (16.6-20.4) 18.2 (16.5-20.2) 18.5 (16.6-20.4) 0.22  
BMI (kg/m2) groups, n (%)    0.40 
Underweight <18.5 318 (53.3) 108 (56.8) 210 (51.6)  
Normal, 18.5-24.9 256 (42.9) 78 (41.1) 178 (43.7)  
Overweight 25.0-29.9 21 (3.5) 4 (2.1) 17 (4.2)  
Obese ≥30 2 (0.3) 0 2 (0.5)  
Body fat (%) 9.5 (6.8-13.7) 9.1 (6.0-12.7) 9.8 (7.4-14.0) 0.008  
MUAC (cm), median (IQR) 23.3 (22.0-25.3) 23.7 (22.0-25.0) 23.3 (22.0-25.7) 0.99  
Waist hip ratio, median (IQR) 0.89 (0.85-0.94) 0.89 (0.85-0.94) 0.89 (0.86-0.94) 0.75  
Occupational risk     0.095 
No 322 (54.2) 93 (49.2) 229 (56.5)  
Yes 272 (45.8) 96 (50.8) 176 (43.5)  
Individual deworming (in 12 months)    0.013 
Yes 484 (81.1) 143 (75.3) 341 (83.8)  
No 113 (18.9) 47 (24.7) 66 (16.2)  
Symptoms e     
Cough 594 (99.5) 189 (99.5) 405 (99.5) 0.96 
Fever 551 (92.3) 174 (91.6) 377 (92.6) 0.65 
Weight loss 573 (96.0) 181 (95.3) 392 (96.3) 0.54 
Night sweats 566 (94.8) 184 (96.8) 382 (93.9) 0.13 
Haemoptysis  197 (33.0) 74 (38.9) 123 (30.2) 0.035 
TB score, median (IQR) 5 (4-6) 5 (4-6) 5 (4-6) 0.22  
TB score (0-5) 372 (62.3) 115 (60.5) 257 (63.1)  
TB score (6-12) 225 (37.7) 75 (39.5) 150 (36.9)  
TB treatment categories     0.40 
Retreatment 14 (2.3) 3 (1.6) 11 (2.7)  
New patients  583 (97.7) 187 (98.4) 396 (97.3)  
Blood parameters e     
Hemoglobin level  11.3 (9.9-12.7) 11.7 (10.1-13) 11.3 (9.8-12.5) 0.044  
Eosinophil, cells per µl d  0.15 (0.06-0.32) 0.2 (0.1-0.4) 0.1 (0.05-0.2) 0.003 
AFB, acid-fast bacilli; BMI, body mass index; HIV, human immunodefiency virus; IQR, interquartile range; MUAC, mid-upper arm 
circumference. Helminth infection occupation risk (working in rice fields, car wash and fishing) 
a TB patient co-infected with HIV and have CD4+ count values (n=80) 
b Fisher’s exact test 
c TB patients with an available chest X-ray film read by a radiologist (n=335)  
d TB patients with an available full blood count result (n=322) 
e “Symptoms”, and “blood parameters”: categories not mutually exclusive 
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Table 13. Effect of helminth infection on the clinical severity and clinical presentation in TB patients at the time of TB diagnosis. 
Helminth infection  Severe TB score a  High sputum bacterial 
load b 
 Lung infiltration  Lung cavitation 
aOR (95% CI) p-
value 
 aOR (95% CI) p-
value 
 aOR (95% CI) p-
value 
 aOR (95% CI) p-value 
Any helminth infection  0.55   0.12   0.42   0.82 
No 1.00   1.00   1.00   1.00  
Yes 1.12 (0.78-1.61)   0.75 (0.51-1.08)   0.82 (0.50-1.33)   0.95 (0.60-1.50)  
Strongyloides 
stercolaris c 
 0.44   0.39   0.17   0.76 
No 1.00   1.00   1.00   1.00  
Yes 1.19 (0.76-1.86)   0.82 (0.52-1.29)   1.56 (0.83-2.92)   1.09 (0.62-1.91)  
Schistosoma mansoni d  0.75   0.004   0.15   0.088 
No 1.00   1.00   1.00   1.00  
Yes 0.89 (0.45-1.78)   0.37 (0.19-0.72)   0.51 (0.21-1.27)   0.41 (0.12-1.16)  
Hookworms e   0.55   0.40   0.086   0.54 
No 1.00   1.00   1.00   1.00  
Yes 1.20 (0.67-2.15)   0.77 (0.42-1.42)   0.51 (0.23-1.10)   0.79 (0.37-1.69)  
Multiple infections  0.82   0.020   0.19   0.40 
None 1.00   1.00   1.00   1.00  
Mono 1.13 (0.77-1.67)   0.88 (0.59-1.31)   0.85 (0.51-1.43)   1.06 (0.66-1.72)  
Double or more 1.04 (0.48-2.22)   0.34 (0.16-0.73)   0.67 (0.24-1.84)   0.50 (0.17-1.44)  
 
Logistic regression model adjusted for age, sex, HIV infection and smoking status. 
a TB score (Mild [score of 1-5] and severe [score of 6-12]) 
b Sputum bacterial load (according to qualitative AFB smear microscopy grading): mild (scanty and 1+) and severe (≥+2)  
c 79 TB patients with any helminth infection other than S. stercoralis were excluded 
d 150 TB patients with helminth co-infection other than S. mansoni were excluded 
e 72 TB patients with helminth co-infection other than hookworm were excluded 
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6.6. Discussion  
We present findings on the prevalence and association of TB and helminth co-infection among 
adult TB patients and household contact controls in a highly-urbanized setting of Dar es 
Salaam, Tanzania. We found that S. mansoni infection was a risk factor for TB disease. This 
association remained significant after adjustment for other known risk factors for TB, such as 
HIV infection, smoking, and underweight (Rieder, 1999). None of the other investigated 
helminth species or the surrogate measure of “any helminth infection” were significantly 
associated with TB. Importantly, associations between any helminth co-infection and TB were 
reported in previous epidemiologic studies (Elias et al., 2006; Resende Co et al., 2006; Tristão-
Sá et al., 2002), as well as in experimental work using animal or macrophage infection models 
(Babu and Nutman, 2016; DiNardo et al., 2016; Monin et al., 2015). In line with our findings, a 
recent study with human peripheral mononuclear cells exposed to M. tuberculosis and 
S. mansoni antigens showed that S. mansoni-induced CD4+ T cells disrupt the control of 
M. tuberculosis in infected macrophages (DiNardo et al., 2016). 
 
Several studies in humans suggested that helminth infections may increase the risk for 
progression of latent M. tuberculosis infection to active TB (Elias et al., 2006; Monin et al., 
2015; Tristão-Sá et al., 2002) as well as for exacerbating the disease (Monin et al., 2015). 
However, the results of these studies are conflicting, and no differentiation at the helminth 
species level was made in these analyses. Indeed, the hypothesis of a helminth species-
specific impact on the host response is supported by a recent systematic review, which 
revealed a trend toward an association between a decrease in HIV viral loads and treatment 
for S. mansoni, but not for other helminth species (Sangaré et al., 2011). A case-control study 
from Ethiopia also found an association between TB and helminth infections, and the 
association was stronger in patients that were infected with multiple helminth species (Elias et 
al., 2006). The small number of study participants with S. mansoni infection (31 among TB 
cases, nine among controls) may have masked an association between TB and 
schistosomiasis in that study (Elias et al., 2006). In contrast, a cohort study from India showed 
no difference in TB incidence rates in helminth-infected and helminth-free individuals after 2.5 
years of follow-up (Chatterjee et al., 2014).  
 
We also found that S. mansoni, but not other helminth species, was associated with the clinical 
presentation among TB patients. Patients co-infected with S. mansoni had lower sputum 
bacterial loads at the time of TB diagnosis than S. mansoni-negative TB patients. Similarly, a 
study in Ethiopia observed lower sputum bacterial loads at TB diagnosis in TB patients co-
infected with any helminth species (Abate et al., 2015). Interestingly, our observation in TB 
patients co-infected with S. mansoni resembles the paucibacillary disease in HIV-positive 
individuals with severe immunosuppression, who frequently have negative or low bacterial 
M. tuberculosis loads in the sputum compared with HIV-negative patients (Abate et al., 2015; 
Sharma et al., 2005). Hence, the helminth-induced Th1 immunological impairment might have 
an effect on the sputum bacterial load. Moreover, TB patients with an impaired host immune 
system rarely present with lung cavitation resulting in fewer M. tuberculosis bacilli being 
expectorated in the sputum (Abate et al., 2015; Sharma et al., 2005). This is in line with our 
findings that TB patients co-infected with S. mansoni tended to present less frequently with 
lung cavitations compared with S. mansoni-negative TB patients. Any helminth co-infection did 
not appear to have an effect on clinical outcomes during follow-up. We found no evidence for 
an effect of helminth co-infection on the gain in the percentage of body fat and BMI after 6 
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months (e.g., at the time of completed TB treatment). This might be explained by the fact that 
the administration of anthelmintic treatment offered to the study participants after diagnosis 
might have reversed the Th1 immune response (Monin et al., 2015), and thus attenuated the 
effect of helminth infections on clinical outcomes. However, the effect of a reversal of the Th1 
immune response could be minimal as the anthelmintic drugs target the worms (Martin et al., 
2015), which are less immunogenic compared with deposited S. mansoni eggs (DiNardo et al., 
2016). 
 
We found that TB patients had a higher crude prevalence of helminth infections, as compared 
with household contact controls. The higher prevalence of helminth infections among TB 
patients could be the result of the pathogenic role of helminth infection in the progression from 
M. tuberculosis infection to active TB. The higher prevalence of helminth co-infection in TB 
patients has also been noted in other studies from different settings (Abate et al., 2012; 
DiNardo et al., 2016). For example, a study conducted in Ethiopia, which reported a higher 
prevalence of helminth infection among TB patients as compared with household contact 
controls (Elias et al., 2006). Overall, the prevalence of helminth infection in our study was 32% 
and lower compared with the 71% observed in the latter study (Elias et al., 2006). It is 
conceivable that the high proportion of self-reported previous use of anthelmintic drugs in our 
study (approximately 80%) could have reduced the overall prevalence of helminth infection. 
Hence, we may have underestimated the effects of helminth infection seen in our study. 
 
We also found that occupation exposing people to regular water contacts (for instance rice 
field workers, sand harvesters, car washers, and fishermen) were associated with helminth 
infections. Being exposed to freshwater bodies and being involved in water-related activities 
have previously been reported to increase the risk of helminth infections (Woodburn et al., 
2009). In the current study, HIV-positive individuals were less likely to be co-infected with 
helminths. A lower prevalence of helminth infections in HIV-positive patients has also been 
reported in a study conducted in Mwanza in northern Tanzania, which is a highly endemic area 
for helminthiases (Range et al., 2007). Of note, current clinical practice in Tanzania is to treat 
any helminth infection in HIV-positive patients at enrolment into HIV care and in case of clinical 
suspicion of helminth infection during follow-up, as specified in the HIV/AIDS management 
guideline (NACP, 2015). The use of anthelmintic drugs is safe and might be beneficial in HIV-
positive patients by possibly reducing the HIV-RNA viral load and subsequently improving 
clinical outcomes (Modjarrad and Vermund, 2010). Furthermore, cotrimoxazole preventive 
therapy (CPT), which is recommended for HIV-positive patients, has also been reported to 
have limited anthelmintic properties (Abate et al., 2012; Janssen et al., 2015). This might 
explain the lower prevalence of helminth infection among HIV-positive individuals in our study 
(NACP, 2015). 
 
Our research has several strengths and limitations that warrant consideration. An important 
strength of our study is the large sample size and the recruitment of both TB patients and 
household contact controls with similar socioeconomic profiles and exposure patterns to both 
TB and helminth infection. Our findings may well apply to other settings with a similar 
prevalence of TB, HIV, and helminth infections in sub-Saharan Africa. Furthermore, we used 
recommended TB diagnostics and a suite of standardized, quality-controlled helminth 
diagnostics, which have comparable diagnostic performance to resource-intensive molecular 
test assays (Knopp et al., 2014). 
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Study limitations include the following. First, this is an observational study which cannot 
establish a causal relationship between helminth infections and TB disease. Second, we could 
not fully verify whether or not the household contact controls were latently infected with 
M. tuberculosis, which is a prerequisite to develop TB. However, because Dar es Salaam is a 
high-burden setting for TB with considerable risk of transmission, and because living with a TB 
patient is a strong risk factor for TB (Rieder, 1999), it is reasonable to assume that the controls 
have previously been exposed and infected with M. tuberculosis. Third, we did not check the 
helminth infection status for TB patients during and after completion of TB treatment, which 
could influence the clinical outcomes. However, we do not expect a high helminth re-infection 
rate after 6 months in our study area (Tukahebwa et al., 2013). Fourth, we did not use 
molecular diagnostics such as polymerase chain reaction (PCR) which might have identified 
some more cases, but one of our previous studies revealed that also PCR approaches miss in 
particular very light intensity infections. Moreover, its performance and sensitivity vary with the 
helminth species under examination (Knopp et al., 2014). Hence, also a PCR cannot be 
considered as the diagnostic gold-standard. 
 
In conclusion, co-infection with S. mansoni, but not other helminth species, was found to be 
an independent risk factor for active TB in our study and was associated with the clinical 
presentation in TB patients. These findings suggest a role for S. mansoni, or helminth infection 
in general, in immunomodulation of human TB. Treatment of helminth infections should be 
considered in the clinical management of TB patients, and helminthiasis control/elimination 
through preventive chemotherapy might prove to be useful as an additional component of TB 
control programs. Further research is needed to establish the underlying mechanisms, and 
compare helminth-induced immune regulation by different helminth species. Prospective 
cohort studies that evaluate the effect of preventive anthelmintic chemotherapy on the 
incidence of M. tuberculosis infection and active TB could further help to understand the 
interaction between these diseases at the population level. Helminthiasis control measures, in 
combination with traditional TB control strategies, could potentially contribute to the global 
efforts to reduce TB incidence by 80% until 2030, as stipulated in WHO’s ambitious End TB 
Strategy (WHO, 2015b). 
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6.7.  Supporting information 
Supplementary Table 4. Socio-demographic and clinical characteristics of TB patients 
and household contact controls without TB, stratified by HIV infections status. 
Characteristics Total  HIV status 
 (n=972)  Positive (n=198) Negative (n=774) 
Type of study participant      
Control 375 (38.6)  35 (17.7) 340 (43.9) 
Case  597 (61.4)  163 (82.3) 434 (56.1) 
Helminth status     
Negative  685 (70.5)  153 (77.3) 532 (68.7) 
Positive  287 (29.5)  45 (22.7) 242 (31.3) 
Age, median (IQR), years 33 (26-41)  38 (33-44) 38 (25-39) 
Age groups (years)     
18-24 194 (20.0)  6 (3.0) 188 (24.3) 
25-34 347 (35.7)  64 (32.3) 283 (36.6) 
35-44 266 (27.4)  82 (41.4) 184 (23.8) 
≥45 165 (17.0)  46 (23.2) 119 (15.4) 
Sex     
Female  387 (39.8)  105 (53.0) 282 (36.4) 
Male 585 (60.2)  93 (47.0) 492 (63.6) 
Education level      
No formal education & Primary  806 (82.9)  185 (93.4) 621 (80.2) 
Secondary/University 166 (17.1)  13 (6.6) 153 (19.8) 
Occupation      
Unemployed 349 (35.9)  62 (31.3) 287 (37.1) 
Employed  623 (64.1)  136 (68.7) 487 (62.9) 
Household income (USD)     
≤100 763 (78.5)  154 (77.8) 609 (78.7) 
>100 209 (21.5)  44 (22.2) 165 (21.3) 
Weight (kg), median(IQR) 54 (48-61)  53 (47.0-59.7) 54.4 (49.0-61.0) 
BMI (kg/m2), median(IQR) 20.0 (17.6-23.4)  19.3 (17.2-22.1) 20.3 (17.8-23.9) 
BMI categories (kg/m2)     
Underweight, <18.5 337 (34.7)  81 (40.9) 256 (33.1) 
Normal, 18.5-24.9 454 (46.7)  96 (48.5) 358 (46.3) 
Overweight, 25.0-29.9 119 (12.2)  14 (7.1) 105 (13.6) 
Obese, ≥30 62 (6.4)  7 (3.5) 55 (7.1) 
Body fat percentage (%), median (IQR) 10.1 (7.7-14.7)  12.2 (8.7-15.8) 9.7 (7.2-14.4) 
MUAC (cm), median (IQR) 24.3 (22.6-26.1)  23.6 (22.0-25.7) 24.3 (22.7-26.3) 
Waist hip ratio, median (IQR) 0.89 (0.86-0.94)  0.89 (0.86-0.93) 0.89 (0.86-0.94) 
Risk occupation      
No 521 (54.2)  102 (51.5) 429 (55.4) 
Yes 441 (45.8)  96 (48.5) 345 (44.6) 
Individual deworming     
Dewormed within 12months 797 (82.0)  162 (81.8) 635 (82.0) 
Never within 12 months 175 (18.0)  36 (18.2) 139 (18.0) 
Hemoglobin level (g/dL), median (IQR) 12.0 (10.4-13.3)  10.4 (9.0-11.9) 12.3 (10.9-13.6) 
Anemia status     
Normal (Hb ≥11 g/dL) 657 (67.6)  82 (41.4) 575 (74.3) 
Anaemia (Hb <11 g/dL) 315 (32.4)  116 (58.6) 199 (25.7) 
IQR, inter-quartile range; BMI, body mass index; HIV, human immunodefiency Virus; MUAC, Mid-upper arm circumference; Tshs, 
Tanzanian Shillings; risk occupation for helminth infection (rice fields, car washing, rice harvesting and fishing)  
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Supplementary Table 5. Frequency distribution of helminth infections among TB 
patients and household controls without TB, stratified by HIV status. 
Helminth Infection All 
(n=972) 
TB patients ((n=597)  Controls (n=375) 
 
HIV-
positive 
HIV-
negative 
p-value  HIV-
positive 
HIV-
negative  
p-
valuea 
  (n=163) (n=434)   (n=35) (n=340)  
Any helminth 287 (29.5) 37 (22.7) 153 (35.3) 0.003  8 (22.9) 89 (26.2) 0.67 
     
 
   
Helminth species  
    
 
   
Strongyloides 
stercolaris 
161 (16.6) 19 (11.7) 92 (21.2) 0.008  7 (20.0) 43 (12.6) 0.22 
Hookworm 87 (9.0) 7 (4.3) 48 (11.1) 0.011  1 (2.9) 31 (9.1) 0.21 
Ascaris lumbricoides 6 (0.6) 1 (0.6) 2 (0.5) 0.62a  0 (0) 3 (0.9) 0.75  
Enterobius 
vermicularis  
5 (0.5) 0 (0) 1 (0.2) 0.73 a  1 (2.9) 3 (0.9) 0.33 
Trichuris trichiura  9 (0.9) 4 (2.5) 2 (0.5) 0.050 a  0 (0) 3 (0.9) 0.75  
Hymenolepis dimunita 2 (0.2) 0 (0) 1 (0.2) 0.73a  0 (0) 1 (0.3) 0.91  
Schistosoma spp.b 70 (7.2) 10 (6.1) 39 (9.0) 0.26  0 (0) 15 (4.4) 0.13  
Schistosoma mansoni 55 (5.7) 10 (6.1) 30 (6.9) 0.74   0 (0) 15 (4.4) 0.22  
Schistosoma 
hematobium 
19 (2.0) 1 (0.6) 10 (2.3) 0.15a  0 (0) 8 (2.4) 0.36  
     
 
   
Multiple helminth 
infection  
   
0.016  
  
1.000 
Mono-infection  237 (24.4) 33 (20.2) 125 (28.8) 
 
 7 (20) 20 (79) 
 
Double infection 44 (4.5) 3 (1.8) 24 (5.5) 
 
 1 (2.9) 2.9 (17) 
 
Triple infection  6 (0.6) 1 (0.6) 4 (0.9) 
 
 0 (0) 0 (1) 
 
aFisher’s exact; b Four patients were co-infected with both Schistosoma mansoni and Schistosoma haematobium 
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Supplementary Table 6. Frequency distribution and intensity of helminth infection in TB 
patients and household contact controls, as determined by the Kato-Katz method 
(triplicate slides).  
Helminth infection a All TB patients Controls p-value 
n (%) (n=89) (n=54) (n=35)  
     
Hookworm 56 (5.8) 35 (5.9) 21 (5.6) NA 
EPG, median (IQR) 120 (40-480) 104 (32-336) 249 (64-560) 0.16b 
Infection intensity (epg)    NA 
Light (1-1,999)  54 (96.4) 35 (100) 19 (90.5)  
Moderate (2,000-3,999) 1 (1.8) 0 1 (4.8)  
Severe (≥4,000) 1 (1.8) 0 1 (4.8)  
     
Schistosoma mansoni 25 (2.6) 14 (2.3) 11 (2.9) NA 
EPG, median (IQR) 56 (16-88) 52 (16-88) 56 (16-88) 0.83b 
Infection intensity (epg)     
Light (1-99)  20 (80.0) 11 (78.6) 9 (81.8) NA 
Moderate (100-399) 4 (16.0) 3 (21.4) 1 (9.1)  
Severe (≥400) 1 (4.0) 0 1 (9.1)  
     
Trichuris trichiura 8 (0.8) 6 (1.0) 2 (0.5) NA 
EPG, median (IQR) 24 (12-80) 24 (16-120) 24 (8-40) 0.61b 
Infection intensity (epg)     
Light (1-999)  8 (100) 6 (100) 2 (100) NA 
     
Ascaris lumbricoides 3 (0.3) 1 (0.2) 2 (0.5) NA 
EPG, median (IQR) 16 (16-80) 80 (80-80) 16 (16-16) 0.16b 
Infection intensity (epg)     
Light (1-5,000)  3 (100) 1 (100) 2 /100)  
a Four patients were co-infected by Schistosoma mansoni and Schistosoma haematobium;  
b Wilcoxon signed rank test; Helminth infection risk occupation (rice fields, car wash, rice harvest and fishing); IQR, inter-quartile 
range; EPG, Eggs per gram; NA, Not Applicable 
 
x Helminth intensity infection: Light: A. lumbricoides, 1-4,999 EPG; T. trichiura, 1-999 EPG; hookworms, 1-1,999 EPG; and S. 
mansoni, 1-99 EPG. Moderate: A. lumbricoides, 5,000-49,999 EPG; T. trichiura, 1,000-9,999 EPG; hookworms, 2,000-3,999 
EPG; and S. mansoni, 100-399 EPG. Severe: A. lumbricoides, ≥50,000 EPG; T. trichiura ≥10,000 EPG; hookworms, ≥4,000 EPG 
and S. mansoni, ≥400 EPG 
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Supplementary Table 7. Full blood count and hematological parameters in TB patients, 
stratified by helminth infection status. 
Blood parameters  Total Helminth status p-valueb 
 (n=566) a Positive (n=179) Negative (n=387)  
     
White blood cells (×109/L)  7.4 (5.7-9.6) 7.3 (5.6-9.3) 7.5 (5.7-9.8) 0.48 
Red blood cells (×109/L) 4.7 (4.1-5.29 4.7 (4.3-5.4) 4.6 (4.0-5.2) 0.11 
Haemoglobin level (g/dL) 11.2 (9.7-12-6) 11.5 (10.2-13) 11.1 (9.5-12.5) 0.014 
Haematocrit (%) 34.8 (30.5-38.9) 35.9 (31.6-39.6) 34.6 (30.0-38.3) 0.021 
MCV (fL) 75.9 (68.9-82.4) 76.0 (70.3-81.6) 75.6 (68.3-83) 0.97 
MCH (pg) 24.3 (21.6-26.7) 24.3 (22-27) 24.2 (21.5-26.7) 0.47 
MCHC (%) 32.4 (30.6-33-6) 32.5 (30.9-33.7) 32.3 (30.4-33.5) 0.20 
Platelets (×109/L) 350 (263-460) 366 (247-430) 350 (263-460) 0.29 
     
Differential blood counts (×109/L) (n=332) (n=112) (n=220)  
Neuotrophil  4.7 (3.3-6.3) 4.6 (3.1-6.1) 4.8 (3.4-6.4) 0.39 
Lymphocyte 1.5 (1.2-2.0) 1.6 (1.2-2.0) 1.5 (1.2-2.1) 0.46 
Monoctye 0.77 (0.55-1.0) 0.8 (0.5-1.1) 0.8 /0.6-1.0) 0.86 
Eosinophil  0.15 (0.06-0.32) 0.2 (0.1-0.4) 0.1 (0.05-0.2) 0.003 
Basophil  0.03 (0.02-0.05) 0.03 (0.02-0.07) 0.03 (0.02-0.05) 0.30 
MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume 
a 31 TB patients were excluded from the analysis because of the missing full blood count results; 
bWilcoxon rank-sum test; all measurements are in median (Interquartile Range, [IQR]) 
c 244 TB patients had missing differential count of white blood counts 
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Supplementary Table 8. Additional analysis: risk factors for any helminth infection 
among TB patients only. 
Characteristics  Helminth Infection    Crude    Adjusted   
n (%) Yes  No       
 n (%) (n (%) OR (95% CI) p-value  aOR (95% CI) p-value 
Age group (years)    0.13   0.095 
18-24 35 (18.4) 72 (17.7) 1.00   1.00  
25-34 81 (42.6) 145 (35.6) 1.15 (0.71-1.87)   1.25 (0.74-2.11)  
35-44 42 (22.1) 127 (31.2) 0.68 (0.40-1.16)   0.70 (0.38-1.26)  
≥45 32 (16.8) 63 (15.5) 1.04 (0.58-1.88)   1.11 (0.58-2.11)  
Sex    0.006   0.058 
Female 45 (23.7) 141 (34.6) 1.00   1.00  
Male 145 (76.3) 266 (65.4) 1.71 (1.15-2.53)   1.53 (0.99-2.37)  
HIV status    0.003   0.038 
Negative 153 (80.5) 281 (69.0) 1.00   1.00  
Positive  37 (19.5) 126 (31.0) 0.534 (0.36-0.82)   0.62 (0.39-0.97)  
Education level    0.49   0.45 
No/primary 162 (85.3) 338 (83.0) 1.00   1.00  
Secondary/University 28 (14.7) 69 (17.0) 0.85 (0.53-1.37)   0.81 (0.48-1.38)  
Employment status     0.99   0.56 
Unemployed  65 (34.2) 139 (34.2) 1.00   1.00  
Employed  125 (65.8) 268 (65.8) 1.00 (0.69-1.43)   0.89 (0.59-1.33)  
People in the household    0.89   0.49 
≤3 people 140 (73.7) 302 (74.2) 1.00   1.00  
> 3 people  50 (26.3) 105 (25.8) 1.03 (0.69-1.52)   1.16 (0.77-1.74)  
Household income (USD)    0.45   0.96 
≤100 154 (81.1) 319 (78.4) 1.00   1.00  
>100 36 (18.9) 88 (21.6) 0.85 (0.55-1.31)   1.01 (0.63-1.62)  
BMI category (kg/m2)    0.23   0.38 
BMI ≥18 82 (43.2) 197 (48.4) 1.00   1.00  
BMI < 18 108 (56.8) 210 (51.6) 1.24 (0.87-1.75)   1.17 (0.82-1.69)  
Occupational risk     0.096   0.14 
No 93 (49.2) 229 (56.5) 1.00   1.00  
Yes 96 (50.8) 176 (43.5) 1.34 (0.95-1.89)   1.32 (0.91-1.90)  
Individual deworming (in 
12 months) 
   0.015   0.022 
Yes  143 (75.3) 341 (83.8) 1.00   1.00  
No 47 (24.7) 66 (16.2) 1.70 (1.11-2.59)   1.67 (1.08-2.60)  
BMI, body mass index; HIV, human immunodeficieny virus; Helminth infection risk occupation (working in the rice fields, car wash, 
rice harvest and fishing) 
Logistic regression model was used. including the independent variables TB status, age-group, sex, HIV status, BMI, education 
level, employment status, number of people living in the same household, individual deworming status, occupational risk and 
income level in quartiles.   
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Supplementary Table 9. Additional analysis: risk factors for any helminth infection 
among household controls without TB only 
Characteristic  Helminth status  Crude    Adjusted   
 Yes No       
 n (%) (n (%)  OR (95% CI) p-value  aOR (95% CI) p-value 
Age group (years)     0.055   0.091 
18-24 15 (15.5) 72 (25.9)  1.00   1.00  
25-34 34 (35.1) 87 (31.3)  1.88 (0.95-3.71)   1.70 (0.82-3.50)  
35-44 33 (34.0) 64 (23.0)  2.47 (1.23-4.97)   2.52 (1.17-5.47)  
≥45 15 (15.5) 55 (19.8)  1.31 (0.59-2.91)   1.29 (0.55-3.02)  
Sex     0.35   0.80 
Female 48 (49.5) 153 (55.0)  1.00   1.00  
Male 49 (50.5) 125 (45.0)  1.25 (0.79-1.99)   0.93 (0.55-1.59)  
HIV status     0.67   0.35 
Negative 89 (91.8) 251 (90.3)  1.00   1.00  
Positive  8 (8.2) 27 (9.7)  0.84 (0.37-1.91)   0.66 (0.28-1.57)  
Education level     0.57   0.82 
No/primary 81 (83.5) 225 (80.9)  1.00   1.00  
Secondary/University 16 (16.5) 53 (19.1)  0.84 (0.45-1.55)   1.08 (0.54-2.18)  
Employment status      0.020   0.099 
Unemployed  28 (28.9) 117 (42.1)  1.00   1.00  
Employed  69 (71.1) 161 (57.9)  1.79 (1.09-2.95)   1.63 (0.91-2.92)  
People in the household     0.36   0.63 
≤3 people 78 (80.4) 211 (75.9)  1.00   1.00  
> 3 people  19 (19.6) 67 (24.1)  0.77 (0.43-1.36)   0.86 (0.47-1.58)  
Household income (USD)     0.99   0.37 
≤100 75 (77.3) 215 (77.3)  1.00   1.00  
>100 22 (22.7) 63 (22.7)  1.00 (0.58-1.74)   0.75 (0.39-1.42)  
BMI category (kg/m2)     0.62   0.62 
BMI ≥18 93 (95.9) 263 (94.6)  1.00   1.00  
BMI < 18 4 (4.1) 15 (5.4)  0.75 (0.24-2.33)   0.75 (0.23-2.40)  
Individual deworming (in 
12 months) 
    0.99   0.87 
Yes 81 (83.5) 232 (83.5)  1.00   1.00  
No 16 (16.5) 46 (16.5)  1.00 (0.54-1.86)   0.95 (0.49-1.83)  
Occupational risk      0.028   0.040 
No 44 (45.4) 162 (58.3)  1.00   1.00  
Yes 53 (54.6) 116 (41.7)  1.68 (1.06-2.68)   1.69 (1.02-2.78)  
BMI, body mass index; HIV, human immunodeficieny virus; Helminth infection risk occupation (working in the rice fields, car wash, 
rice harvest and fishing) 
Logistic regression model was used, including the independent variables TB status, age-group, sex, HIV status, BMI, education 
level, employment status, number of people living in the same household, individual deworming status, occupational risk and 
income level in quartiles. 
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Supplementary Table 10. Full table with unadjusted and adjusted odds ratios: Associations of TB disease with helminth infection and 
other patient characteristics comparing TB patients and household contact controls without TB. 
Characteristic   Any helminth infection (n=972)  Schistosoma mansoni infection (n=972) 
 TB patient Control            
 n (%) n (%) OR (95% CI) p-value aOR (95% CI) p-
value 
 OR (95% CI) p-value  aOR (95% CI) p-value 
Helminth infection    0.048  0.22  
 0.07 
 
 0.040 
No  407 (68.2) 278 (74.1) 1.00  1.00   
1.00  
 
1.00  
Yes  190 (31.8) 97 (25.9) 1.34 (1.00-1.79)  1.26 (0.88-1.80)   
1.72 (0.94-3.17)  
 
2.15 (1.03-4.45)  
Age group (years)    0.081  0.49  
 0.081 
 
 0.25 
18-24 107 (17.9) 87 (23.2) 1.00  1.00   
1.00  
 
1.00  
25-34 226 (37.9) 121 (32.3) 1.52 (1.06-2.17)  1.22 (0.77-1.94)   
1.52 (1.06-2.17)  
 
1.24 (0.78-1.97)  
35-44 169 (28.3) 97 (25.9) 1.42 (0.97-2.07)  1.00 (0.60-1.67)   
1.42 (0.97-2.07)  
 
1.02 (0.61-1.7)  
≥45 95 (15.9) 70 (18.7) 1.10 (0.73-1.68)  0.84 (0.48-1.48)   
1.10 (0.73-1.68)  
 
0.88 (0.51-1.54)  
Sex    <0.001  <0.001  
 <0.001 
 
 <0.001 
Female 186 (31.2) 201 (53.6) 1.00  1.00   
1.00  
 
1.00  
Male 411 (68.8) 174 (46.4) 2.55 (1.96-3.33)  3.11 (2.13-4.56)   
2.55 (1.96-3.33)  
 
3.16 (2.16-4.63)  
HIV status    <0.001  <0.001  
 <0.001 
 
 <0.001 
Negative 434 (72.7) 340 (90.7) 1.00  1.00   
1.00  
 
1.00  
Positive  163 (27.3) 35 (9.3) 3.65 (2.47-5.40)  6.18 (3.83-9.95)   
3.65 (2.47-5.4)  
 
6.23 (3.86-10.05)  
Education level    0.39  0.55  
 0.39 
 
 0.57 
No/primary 500 (83.8) 306 (81.6) 1.00  1.00   
1.00  
 
1.00  
Secondary/University 97 (16.2) 69 (18.4) 0.86 (0.61-1.21)  1.15 (0.73-1.80)   
0.86 (0.61-1.21)  
 
1.14 (0.72-1.79)  
Employment status     0.16  0.63  
 0.16 
 
 0.66 
Unemployed  204 (34.2) 145 (38.7) 1.00  1.00   
1.00  
 
1.00  
Employed  393 (65.8) 230 (61.3) 1.22 (0.93-1.59)  0.91 (0.62-1.33)   
1.22 (0.93-1.59)  
 
0.92 (0.63-1.34)  
Smoking status     <0.001  0.012  
 <0.001 
 
 0.011 
No 489 (81.9) 342 (91.2) 1.00  1.00   
1.00  
 
1.00  
Yes  108 (18.1) 33 (8.8) 2.29 (1.51-4.46)  1.92 (1.15-3.21)   
2.29 (1.51-3.46)  
 
1.95 (1.16-3.25)  
People in the household    0.29  0.018  
 0.29 
 
 0.015 
≤3 people 442 (74.0) 289 (77.1) 1.00  1.00   
1.00  
 
1.00  
>3 people  155 (26.0) 86 (22.9) 1.18 (0.87-1.60)  1.57 (1.08-2.30)   
1.18 (0.87-1.6)  
 
1.60 (1.09-2.34)  
Household income (USD)    0.48  0.85  
 0.49 
 
 0.95 
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HIV, Human Immunodeficieny Virus; BMI, body mass index; OR, Odds ratio; 95% CI, 95% Confidence Interval 
a Working in rice fields, car washing, sand harvesting and fishing.  
Logistic regression model adjusted for any helminth infection/S. mansoni, age, sex, HIV status, BMI, education level, employment status, smoking status, number of people living in the same household, 
individual deworming status, helminth risk occupation and income level. 
 
 
 
 
  
≤100 473 (79.2) 290 (77.3) 1.00  1.00   
1.00  
 
1.00  
>100 124 (20.8) 85 (22.7) 0.89 (0.65-1.22)  1.04 (0.69-1.56)   
0.89 (0.65-1.22)  
 
1.01 (0.68-1.52)  
BMI category (kg/m)    <0.001  <0.001  
 <0.001 
 
 <0.001 
BMI ≥18 279 (46.7) 318 (53.3) 1.00  1.00   1.00   1.00  
BMI <18 356 (94.9) 19 (5.1) 21.36 (13.10-
34.81) 
 23.20 (13.91-
38.69) 
  
21.36 (13.1-34.81)  
 
23.52 (14.1-39.24)  
Occupational risk     0.880  0.24  
 0.88 
 
 0.26 
No 322 (54.2) 199 (54.1) 1.00  1.00   
1.00  
 
1.00  
Yes 272 (45.8) 169 (45.9) 1.02 (0.79-1.32)  0.82 (0.59-1.15)   
1.02 (0.79-1.32)  
 
0.83 (0.59-1.15)  
Individual deworming (in 12 
months) 
   0.35  0.20  
 0.21 
 
 0.21 
Yes 484 (81.1) 313 (83.5) 1.00  1.00   
1.00  
 
1.00  
No 113 (18.9) 62 (16.5) 1.18 (0.84-1.66)  0.75 (0.48-1.16)   0.76 (0.49-1.17)   0.76 (0.49-1.17)  
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Supplementary Table 11. Full table with unadjusted and adjusted odds ratios: Associations of TB disease with Strongyloides stercolaris 
and hookworm infections comparing TB patients and household contact controls without TB. 
Characteristic   Strongyloides stercolaris (n=972)  Hookworm infection (n=972) 
 TB patient Control            
 n (%) n (%) OR (95% CI) p-value aOR (95% CI) p-
value 
 OR (95% CI) p-value  aOR (95% CI) p-value 
Helminth infection   
 0.03  0.29 
 
 0.717 
 
 0.34 
No  407 (68.2) 278 (74.1) 
1  1.00  
 
1.00  
 
1.00  
Yes  190 (31.8) 97 (25.9) 
1.49 (1.03-2.13)  1.27 (0.81-1.99)  
 
1.09 (0.69-1.72)  
 
1.31 (0.75-2.3)  
Age group (years)    0.081 
 0.25 
 
 0.081 
 
 0.25 
18-24 107 (17.9) 87 (23.2) 1.00  
1.00  
 
1.00  
 
1.00  
25-34 226 (37.9) 121 (32.3) 1.52 (1.06-2.17)  
1.23 (0.77-1.95)  
 
1.52 (1.06-2.17)  
 
1.24 (0.78-1.97)  
35-44 169 (28.3) 97 (25.9) 1.42 (0.97-2.07)  
1.00 (0.6-1.66)  
 
1.42 (0.97-2.07)  
 
1.00 (0.60-1.67)  
≥45 95 (15.9) 70 (18.7) 1.10 (0.73-1.68)  
0.84 (0.48-1.47)  
 
1.10 (0.73-1.68)  
 
0.86 (0.49-1.49)  
Sex    <0.001 
 <0.001 
 
 <0.001 
 
 <0.001 
Female 186 (31.2) 201 (53.6) 1.00  
1.00  
 
1.00  
 
1.00  
Male 411 (68.8) 174 (46.4) 2.55 (1.96-3.33)  
3.12 (2.14-4.57)  
 
2.55 (1.96-3.33)  
 
3.12 (2.13-4.56)  
HIV status    <0.001 
 <0.001 
 
 <0.001 
 
 <0.001 
Negative 434 (72.7) 340 (90.7) 1.00  
1.00  
 
1.00  
 
1.00  
Positive  163 (27.3) 35 (9.3) 3.65 (2.47-5.40)  
6.08 (3.78-9.78)  
 
3.65 (2.47-5.4)  
 
6.16 (3.82-9.91)  
Education level    0.39 
 0.59 
 
 0.39 
 
 0.55 
No/primary 500 (83.8) 306 (81.6) 1.00  
1.00  
 
1.00  
 
1.00  
Secondary/University 97 (16.2) 69 (18.4) 0.86 (0.61-1.21)  
1.13 (0.72-1.78)  
 
0.86 (0.61-1.21)  
 
1.15 (0.73-1.8)  
Employment status     0.16 
 0.59 
 
 0.16 
 
 0.68 
Unemployed  204 (34.2) 145 (38.7) 1.00  
1.00  
 
1.00  
 
1.00  
Employed  393 (65.8) 230 (61.3) 1.22 (0.93-1.59)  
0.9 (0.61-1.32)  
 
1.22 (0.93-1.59)  
 
0.92 (0.63-1.35)  
Smoking status     <0.001 
 0.013 
 
 <0.001 
 
 0.012 
No 489 (81.9) 342 (91.2) 1.00  
1.00  
 
1.00  
 
1.00  
Yes  108 (18.1) 33 (8.8) 2.29 (1.51-4.46)  
1.92 (1.15-3.2)  
 
2.29 (1.51-3.46)  
 
1.93 (1.16-3.22)  
People in the household    0.29 
 0.021 
 
 0.29 
 
 0.018 
≤3 people 442 (74.0) 289 (77.1) 1.00  
1.00  
 
1.00  
 
1.00  
>3 people  155 (26.0) 86 (22.9) 1.18 (0.87-1.60)  
1.56 (1.07-2.28)  
 
1.18 (0.87-1.6)  
 
1.58 (1.08-2.3)  
Household income (USD)    0.48 
 0.83 
 
 0.49 
 
 0.82 
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HIV, 
Human Immunodeficieny Virus; BMI, body mass index; OR, Odds ratio; 95% CI, 95% Confidence Interval 
a Working in rice fields, car washing, sand harvesting and fishing.  
Logistic regression model adjusted for any helminth infection/S. mansoni, age, sex, HIV status, BMI, education level, employment status, smoking status, number of people living in the same household, 
individual deworming status, helminth risk occupation and income level. 
 
 
 
  
≤100 473 (79.2) 290 (77.3) 1.00  
1.00  
 
1.00  
 
1.00  
>100 124 (20.8) 85 (22.7) 0.89 (0.65-1.22)  
1.05 (0.70-1.57)  
 
0.89 (0.65-1.22)  
 
1.05 (0.70-1.57)  
BMI category (kg/m)    <0.001 
 0 
 
 <0.001 
 
 <0.001 
BMI ≥18 279 (46.7) 318 (53.3) 1.00  1.00   1.00   1.00  
BMI <18 356 (94.9) 19 (5.1) 21.36 (13.10-34.81)  
23.2 (13.91-38.7)  
 
21.36 (13.1-34.81)  
 
23.53 (14.10-39.25)  
Occupational risk     0.880 
 0.28 
 
 0.88 
 
 0.25 
No 322 (54.2) 199 (54.1) 1.00  
1.00  
 
1.00  
 
1.00  
Yes 272 (45.8) 169 (45.9) 1.02 (0.79-1.32)  
0.83 (0.60-1.16)  
 
1.02 (0.79-1.32)  
 
0.82 (0.59-1.15)  
Individual deworming (in 
12 months) 
   0.35 
 0.22 
 
 0.21 
 
 0.19 
Yes 484 (81.1) 313 (83.5) 1.00  
1.00  
 
1.00  
 
1.00  
No 113 (18.9) 62 (16.5) 1.18 (0.84-1.66)  0.76 (0.49-1.18)   0.76 (0.49-1.17)   0.75 (0.48-1.16)  
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Supplementary Table 12. Additional analysis: Helminth infection and patient characteristics associated with TB among TB patients and 
household contact controls, using conditional logistic regression. 
Characteristic Any helminth infection (n=722)  Schistosoma mansoni infection (n=455) 
 TB patient Control       TB patient Control      
 n (%) n (%) OR (95% CI) p-value aOR (95% CI) p-
value 
 n (%) n (%) OR (95% CI) p-value  aOR (95% CI) p-value 
Helminth infection    0.398  0.198     0.188   0.008 
No  247 (71) 278 (74.3) 1.00  1.00   192 (90.6) 229 (94.2) 1.00   1.00  
Yes  101 (29) 96 (25.7) 1.16 (0.82-1.64)  1.45 (0.82-2.55)   20 (9.4) 14 (5.8) 1.69 (0.77-3.74)   5.29 (1.55-18.1)  
Age group (years)    0.1       0.084   0.0391 
18-24 62 (17.8) 86 (23) 1.00  1.00   32 (15.1) 59 (24.3) 1.00 0.834  1.00  
25-34 139 (39.9) 121 (32.4) 1.61 (1.07-2.44)  1.13 (0.58-2.19)   84 (39.6) 79 (32.5) 1.6 (0.96-2.66)   1.76 (0.77-4.03)  
35-44 93 (26.7) 97 (25.9) 1.33 (0.86-2.06)  0.87 (0.42-1.82)   65 (30.7) 57 (23.5) 1.64 (0.95-2.84)   2.04 (0.74-5.61)  
≥45 54 (15.5) 70 (18.7) 1.08 (0.67-1.75)  0.55 (0.25-1.2)   31 (14.6) 48 (19.8) 0.92 (0.5-1.68)   0.56 (0.2-1.51)  
Sex    0  0.001     0   0.007 
Female 115 (33) 200 (53.5) 1.00  1.00   74 (34.9) 133 (54.7) 1.00   1.00  
Male 233 (67) 174 (46.5) 2.22 (1.64-3.01)  2.37 (1.41-3.98)   138 (65.1) 110 (45.3) 2.03 (1.4-2.96)   2.44 (1.27-4.67)  
HIV status    0  0     0   0 
Negative 250 (71.8) 339 (90.6) 1.00  1.00   144 (67.9) 221 (90.9) 1.00   1.00  
Positive  98 (28.2) 35 (9.4) 4.15 (2.6-6.64)  9.83 (4.64-20.85)   68 (32.1) 22 (9.1) 4.56 (2.55-8.16)   9.36 (3.85-22.73)  
Education level    0.645  0.944     0.834   0.143 
No/primary 289 (83) 305 (81.6) 1.00  1.00   173 (81.6) 200 (82.3) 1.00   1.00  
Secondary/Universit
y 
59 (17) 69 (18.4) 0.91 (0.62-1.35)  0.98 (0.5-1.9)  
 
39 (18.4) 43 (17.7) 1.05 (0.64-1.73)   1.92 (0.8-4.6)  
Employment status     0.383  0.669     0.212   0.223 
Unemployed  125 (35.9) 145 (38.8) 1.00  1.00   69 (32.5) 101 (41.6) 1.00   1.00  
Employed  223 (64.1) 229 (61.2) 1.61 (1.07-2.44)  1.13 (0.65-1.95)   143 (67.5) 142 (58.4) 1.27 (0.87-1.86)   1.5 (0.78-2.89)  
Smoking status     0  0.008     0.008   0.176 
No 288 (82.8) 341 (91.2) 1.00  1.00   179 (84.4) 223 (91.8) 1.00   1.00  
Yes  60 (17.2) 33 (8.8) 2.28 (1.42-3.67)  2.67 (1.29-5.54)   33 (15.6) 20 (8.2) 2.34 (1.21-4.5)   2.01 (0.73-5.5)  
People in the household    0.091  0.007     0.098   0.008 
≤3 people 255 (73.3) 288 (77) 1.00  1.00   154 (72.6) 189 (77.8) 1.00   1.00  
>3 people  93 (26.7) 86 (23) 1.39 (0.95-2.05)  2.46 (1.27-4.74)   58 (27.4) 54 (22.2) 1.51 (0.92-2.48)   2.8 (1.3-6.02)  
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HIV, Human Immunodeficieny Virus; BMI, body mass index; OR, Odds ratio; 95% CI, 95% Confidence Interval 
a For comparison with Schistosoma mansoni, we excluded 232 participants with any helminth infections other than Schistosoma mansoni.b Working in rice fields, car washing, sand harvesting and fishing 
Conditional logistic regression model taking into account case-control matching, and adjusted for any helminth infection/S. mansoni, age, sex, HIV status, BMI, education level, employment status, smoking 
status, number of people living in the same household, individual deworming status, helminth risk occupation and household income level. 
Excluded TB patients due to unpaired to controls:  250 cases for any helminth infection, and 285 cases for S. mansoni infection. 
 
  
Household income 
(USD) 
   0.85  0.714 
 
   0.44   0.196 
≤100 268 (77) 289 (77.3) 1.00  1.00   163 (76.9) 183 (75.3) 1.00   1.00  
>100 80 (23) 85 (22.7) 1.04 (0.72-1.5)  1.12 (0.61-2.04)   49 (23.1) 60 (24.7) 0.84 (0.53-1.32)   0.6 (0.28-1.3)  
BMI category (kg/m)    0  0     0   0 
BMI ≥18 167 (48) 355 (94.9) 1.00  1.00   110 (51.9) 228 (93.8) 1.00   1.00  
BMI <18 
181 (52) 19 (5.1) 15.5 (8.63-27.85)  
21.01 (10.33-
42.71) 
 
 
102 (48.1) 15 (6.2) 11.48 (5.79-22.77)   19.98 (7.89-50.57)  
Occupational risk     0.321  0.015     0.807   0.061 
No 204 (58.6) 206 (55.1) 1.00  1.00   121 (57.1) 139 (57.2) 1.00   1.00  
Yes 144 (41.4) 168 (44.9) 0.85 (0.62-1.17)  0.54 (0.33-0.89)   91 (42.9) 104 (42.8) 0.95 (0.63-1.43)   0.53 (0.27-1.03)  
Individual 
deworming (in 12 
months) 
   0.552  0.18 
 
   0.298   0.278 
Yes 284 (81.6) 312 (83.4) 1.00  1.00   172 (81.1) 206 (84.8) 1.00   1.00  
No 64 (18.4) 62 (16.6) 1.13 (0.76-1.66)  0.66 (0.36-1.21)   40 (18.9) 37 (15.2) 1.31 (0.79-2.19)    0.63 (0.27-1.45)  
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Supplementary Table 13. Radiological findings of chest X-rays in TB patients at the time 
of TB diagnosis, stratified by helminth infection status. 
Radiological findings Total  TB and helminths  TB only  
 (n=335) (n=93) (n=242) p-valuea 
Infiltrations 276 (82.4) 81 (87.1) 195 (80.6) 0.16 
Unilateral 196 (71.0) 55 (67.9) 141 (72.3)  
Bilateral 80 (29.0) 26 (32.1) 54 (27.7)  
Cavitations 146 (43.6) 45 (48.4) 101 (41.7) 0.27 
Unilateral 132 (90.4) 38 (84.4) 94 (93.1)  
Bilateral 14 (9.6) 7 (15.6) 7 (6.9)  
Micronodules (< 7mm) 26 (7.8) 9 (9.7) 17 (7.0) 0.42 
Unilateral 11 (42.3) 5 (55.6) 6 (35.3)  
Bilateral 15 (57.7) 4 (44.4) 11 (64.7)  
Macronodules (≥7mm) 7 (2.1) 1 (1.1) 6 (2.5) 0.42 
Unilateral 5 (71.4) 0 (0) 5 (83.3)  
Bilateral 2 (28.6) 1 (100) 1 (16.7)  
Pleural effusion  52 (15.5) 11 (11.8) 41 (16.9) 0.25 
Unilateral 46 (88.5) 9 (81.8) 37 (90.2)  
Bilateral 6 (11.5) 2 (18.2) 4 (9.8)  
Pulmonary edema 18 (5.4) 2 (2.2) 16 (6.6) 0.11 
Unilateral 4 (22.2) 1 (50.0) 3 (18.8)  
Bilateral 14 (77.8) 1 (50.0) 13 (81.3)  
Lymph node enlargements (intrathoracic) 38 (11.3) 8 (8.6) 30 (12.4) 0.33 
Radiologist severity grading b 
   
0.76 
Mild/moderate 246 (73.4) 67 (72.0) 179 (74.0) 
 
Severe 88 (26.3) 26 (28.0) 62 (25.6) 
 
a Pearson chi-squared test; b Radiologist grading of the chest-ray severity 
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Supplementary Table 14. Association of helminth infection with poor recovery of BMI, 
poor gain of absolute weight, and percentage body fat in TB patients, between 
recruitment and after six months of completed TB treatment. 
Helminth infection  Poor BMI gain  Poor weight gain  Poor gain in percentage 
body fat 
 aOR (95% CI) p-value  aOR (95% CI) p-value  aOR (95% CI) p-value 
Any helminth  0.23   0.63   0.78 
No 1.00   1.00   1.00  
Yes 0.74 (0.46-1.21)   0.89 (0.55-1.45)   0.92 (0.55-1.56)  
Strongyloides 
stercolaris  
 0.49   0.11   0.34 
No 1.00   1.00   1.00  
Yes 0.81 (0.44-1.47)   0.62 (0.34-1.12)   0.73 (0.39-1.38)  
Schistosoma mansoni  0.35   0.77   0.62 
No 1.00   1.00   1.00  
Yes 0.68 (0.29-1.58)   0.88 (0.38-2.03)   0.80 (0.33-1.92)  
Hookworm   0.44   0.79   0.91 
No 1.00   1.00   1.00  
Yes 0.72 (0.30-1.68)   0.89 (0.37-2.12)   0.95 (0.39-2.32)  
Multiple infections  0.27   0.44   0.96 
None 1.00   1.00   1.00  
Mono 0.67 (0.40-1.13)   0.99 (0.59-1.68)   0.92 (0.52-1.62)  
Double or more 1.17 (0.44-3.11)   0.54 (0.21-1.41)   0.93 (0.35-2.53)  
Poor gain was defined defines as BMI change <2.6 kg/m2, poor weight change, as weight gain <7 kg; poor body fat gain as 
percentage body fat <0.0% 
Logistic regression model adjusted for: age, sex, HIV status, number of people in the household and income level quartiles.  
Patients with any other helminth infection were excluded: 43 TB patients for S. stercolaris; 74 TB patients for S. mansoni; 75 TB 
patients for hookworm.  
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Supplementary Figure 1. Geographical distribution of helminth infections in the study 
area. (A) The prevalence of helminth infection summarized at the ward level. (B) The 
helminth species distribution at the study area. Other helminth infections include: 
Ascaris lumbricoides, Enterobius vermicularis, Trichuris trichiura and Hymenolepis 
dimunita. 
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7.1. Abstract  
Objectives: To describe the prevalence of respiratory pathogens in tuberculosis (TB) patients 
and in their household contact controls, and to determine the clinical significance of respiratory 
pathogens in TB patients. 
 
Methods: We studied 489 smear-positive adult TB patients and 305 household contact 
controls without TB with nasopharyngeal swab samples within an ongoing prospective cohort 
study in Dar es Salaam, Tanzania, between 2013 and 2015. We used multiplex real-time PCR 
to detect 16 respiratory viruses and seven bacterial pathogens from nasopharyngeal swabs.  
 
Results: The median age of the study participants was 33 years; 61% (484/794) were men, 
and 21% (168/ 794) were HIV-positive. TB patients had a higher prevalence of HIV (28.6%; 
140/489) than controls (9.2%; 28/305). Overall prevalence of respiratory viral pathogens was 
20.4% (160/794; 95%CI 17.7-23.3%) and of bacterial pathogens 38.2% (303/794; 95%CI 34.9-
41.6%). TB patients and controls did not differ in the prevalence of respiratory viruses (Odds 
Ratio [OR] 1.00, 95%CI 0.71-1.44), but respiratory bacteria were less frequently detected in 
TB patients (OR 0.70, 95%CI 0.53-0.94). TB patients with both respiratory viruses and 
respiratory bacteria were likely to have more severe disease (adjusted OR [aOR] 1.6, 95%CI 
1.1-2.4; p 0.011). TB patients with respiratory viruses tended to have more frequent lung 
cavitations (aOR 1.6, 95%CI 0.93-2.7; p 0.089).  
 
Conclusions: Respiratory viruses are common for both TB patients and household controls. 
TB patients may present with more severe TB disease, particularly when they are co- infected 
with both bacteria and viruses.  
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7.2. Introduction  
Tuberculosis (TB) caused by the bacterium Mycobacterium tuberculosis affected an estimated 
10.4 million new cases and caused 1.7 million deaths in 2016, making TB the leading global 
cause of death from an infectious disease (WHO, 2017). Influenza pandemics have selectively 
caused higher mortality among persons with TB compared to the general population (Noymer, 
2009; Zürcher et al., 2016). For instance, the 1918 influenza pandemic brought about a sharp 
decline in TB burden, possibly because of the higher mortality among TB patients coinfected 
with influenza viruses (Noymer, 2011; Zürcher et al., 2016). 
 
In sub-Saharan Africa, HIV has been the most important risk factor driving the TB epidemic in 
recent decades (WHO, 2017). The efforts towards understanding other risk factors in TB such 
as respiratory viruses, helminths (Mhimbira et al., 2017), and bacteria (Wu et al., 2013) are 
becoming increasingly important (Marais et al., 2013). Evidence from experimental mouse 
models suggests that respiratory viruses such as influenza viruses may play a pathogenic role 
in individuals with tuberculous disease by negatively affecting immunity against M. tuberculosis 
(Redford et al., 2013). The effect of respiratory viruses on TB may mimic the development of 
bacterial pneumonia immediately after an infection with respiratory viruses (Rohde et al., 
2003). Studies of the lung microbiota (the community of microorganisms in the airways), which 
have focused on respiratory bacterial populations, suggest that there are differences in 
respiratory bacterial species populations among patients with and without TB, among new and 
recurrent TB patients, as well as among those in whom TB treatment has failed (Wu et al., 
2013). 
 
The differences in airway microorganism populations could indicate that respiratory pathogens 
can be involved in TB pathogenesis (Wood et al., 2017). However, little is known about the 
prevalence of respiratory pathogens, whether viral or bacterial, and their role in clinical 
presentation in TB. We therefore studied the prevalence of respiratory pathogens in TB 
patients and household contact controls, and assessed the associations between both 
respiratory viruses and bacterial pathogens and the clinical presentation of TB patients who 
were prospectively recruited in an area of Dar es Salaam (Tanzania) with a high TB burden. 
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7.3. Methods  
7.3.1. Study setting and study population 
This is a prospective cohort study conducted in the densely populated Temeke district of Dar 
es Salaam, Tanzania; it is a study within a previously described ongoing prospective cohort 
study of TB patients and household contact controls in Dar es Salaam (TB-DAR) (Mhimbira et 
al., 2017). Between November 2013 and October 2015, we recruited smear-positive TB 
patients diagnosed at Temeke district hospital and household contact controls who lived in the 
same household as the index TB cases (Mhimbira et al., 2017). 
 
Assuming (a) a prevalence of respiratory viruses of 25% in TB patients and of 12.5% in 
household contact controls (Bigogo et al., 2013), based on the prevalence of respiratory 
viruses in similar settings, and assuming that respiratory viruses are more frequent in TB 
patients than in controls, (b) a cluster correlation of 0.2, and (c) a nonparticipation rate of 20%, 
we estimated that 175 case-control pairs would provide 85% power to observe a statistically 
significant difference in the prevalence at the 5% level of significance.  
7.3.2. Study procedures 
At the time of recruitment of study participants, we collected a single sample of nasopharyngeal 
swabs from TB patients and controls using flexible nasopharyngeal flocked swabs (Copan 
Diagnostics, CA, USA) (“FLOQSwabsTM,” n.d.). For TB patients, the nasopharyngeal swabs 
were taken immediately after diagnosis of TB and prior to initiation of anti-TB treatment. The 
nasopharyngeal swab samples were then added to 1-mL eNAT tubes for transportation at 
temperatures between 2° and 8°C to the Ifakara Health Institute (IHI) research laboratory at 
Bagamoyo where they were stored at -80°C pending analysis. 
7.3.3. Laboratory investigations 
Detection of respiratory pathogens by multiplex PCR We used the validated multiplex real-time 
PCRs from Seegene (www.seegene.com/) for detection of a broad panel of respiratory viral 
and bacterial pathogens in accordance with the manufacturer's instructions, as previously 
published (Cho et al., 2013). The nasopharyngeal swab samples were also analysed using 
Anyplex II RV16 simultaneously which detects 16 respiratory viruses, and the Allplex 
Respiratory Panel 4 assay which detects seven respiratory bacterial pathogens 
(Supplementary Table 15). Sample processing and analysis to detect respiratory pathogens 
were all done at the IHI research laboratory in accordance with the manufacturer's instructions 
and Standard Operating Procedures (SOP). 
7.3.4. Other laboratory procedures 
TB confirmation was by positive Lowenstein-Jensen (LJ) solid media mycobacterial culture 
(done at the IHI Research laboratory in Bagamoyo). We ruled out TB in controls with both a 
negative Gene Xpert MTB/RIF result and no mycobacterial growth in LJ solid media culture. 
HIV testing for TB patients and controls was done as per Tanzania HIV testing algorithms using 
an Alere Determine HIV (Alere, USA) and a Uni-Gold HIV (Trinity Biotech; Wicklow, Ireland) 
confirmatory test rapid tests (NACP, 2015). CD4þ T cells and full blood-cell counts were 
obtained as previously described (Mhimbira et al., 2017). 
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7.3.5. Data collection and definitions 
Clinical severity of TB was graded as per published clinical TB score (Wejse et al., 2008), but 
modified to a set of 12 TB score parameters instead of 13, since tachycardia was not 
systematically measured as previously noted (Mhimbira et al., 2017). Diagnosis delay was 
defined as a cough duration of ≥3 weeks as previously published from the same cohort study 
(Said et al., 2017). 
 
Data were captured using electronic case report forms developed from the open source data 
collection software Open Data Kit (ODK, https://opendatakit.org/) on Android PC tablets, and 
data were then managed using the eManagement tool ‘odk_planner’ as published previously 
(A. Steiner et al., 2016). 
7.3.6. Statistical analysis 
We compared the baseline characteristics of TB patients and household contact controls using 
the McNemar test, paired t-test, or Wilcoxon signed rank test, as appropriate. We estimated 
the prevalence of any respiratory viruses and bacteria using logistic regression models 
adjusting for clustering at the household level. We used mixed-effects logistic regression 
models with random household intercepts to assess the risk factors associated with detection 
of respiratory pathogens in TB patients and controls. The differences in the mean Ct values of 
respiratory bacteria detected (as a relative measure of the bacterial load) between TB patients 
and controls were assessed using mixed-effect linear regression models. Logistic regression 
models adjusting for age, sex, and HIV infection were used to assess the associations between 
respiratory pathogens and clinical presentations of TB at the time of recruitment among TB 
patients, with the following outcome variables: severe TB score (score of ≥6) versus mild (score 
of 1-5), high sputum bacterial load (sputum AFB smear microscopy of ≥2+) versus low bacterial 
load, and presence versus absence of lung infiltrations and cavitations (chest x-ray findings). 
Associations were expressed as crude odds ratios (ORs) and adjusted ORs (aORs) with their 
corresponding 95% confidence intervals (95%CIs). All analyses were performed in Stata 
version 14.0 (Stata Corp, College Station, Texas, USA).  
7.3.7. Ethics approval 
The study was approved by the IHI Institutional Review Board (IHI/IRB/No: 04-2015) and the 
Medical Research Coordinating Committee of the National Institute of Medical Research 
(NIMR/HQ/R.8c/Vol.I/357) in Tanzania, as well as by the Ethics Committee of the Canton of 
Basel in Switzerland (EKNZ UBE-15/42). All study participants gave written informed consent. 
TB patients were managed as per National TB and Leprosy Programme treatment guidelines 
(NTLP, MoHSW, 2013). Treatment and care for HIV-positive individuals were as per Tanzania 
National HIV/AIDS treatment guideline (NACP, 2015). 
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7.4. Results 
7.4.1. Characteristics of study participants 
Between November 2013 and October 2015, 972 study participants were enrolled in the TB-
Dar study. A total of 794 study participants (81.6%; 794/972) had a nasopharyngeal swab 
taken, of whom 489 were TB patients and 305 were household contact controls (Figure 12). 
1). The overall median age was 33 years (interquartile range (IQR) 26.1-41.2 years), and 61% 
(484/794) were men. The overall HIV prevalence was 21.2% (168/794; 95%CI 18.4-24.1%); 
140 TB patients (28.6%; 140/489) and 28 controls (9.2%; 28/305) were HIV-positive (Table 
14).  
 
Figure 12. Flow diagram for participants enrolled in the study. 
  
77 
Table 14. Baseline characteristics of 489 tuberculosis (TB) patients and 305 household 
contact controls without TB in Dar es Salaam, Tanzania 
Characteristics 
n (%) 
All  TB patients Controls p-value 
(n=794)  (n=489) (n=305)  
Age (years), median (IQR) 33.0 (26.1-41.2)  33.0 (27.0-40.0) 32.0 (25.7-42.4) 0.7 
Age groups (years) 
 
 
  
0.096 
<25 153 (19.3)  82 (16.8) 71 (23.3)  
25-34 290 (36.5)  188 (38.4) 102 (33.4)  
35-44 205 (25.8)  132 (27) 73 (23.9)  
≥45 146 (18.4)  87 (17.8) 59 (19.3)  
Male, Sex  484 (61.0)  336 (68.7) 148 (48.5) <0.001 
HIV-positive 168 (21.2)  140 (28.6) 28 (9.2) <0.001 
Education level  
 
 
  
0.19 
No/primary  285 (35.9)  168 (34.4) 117 (38.4)  
Secondary/University 509 (64.1)  321 (65.6) 188 (61.6)  
Occupation  
 
 
  
0.25 
Employed  509 (64.1)  321 (65.6) 188 (61.6)  
Current smoker 1 
 
 
  
0.053 
Yes 104 (13.1)  73 (14.9) 31 (10.2)  
People in the household 
 
 
  
0.22 
>3 people  204 (25.7)  133 (27.2) 71 (23.3)  
Weight (kg), median (IQR) 54.0 (48.0-61.0)  51.0 (45.5-57.0) 59.0 (53.0-67.0) <0.001 
BMI (kg/m2), median (IQR) 20.1 (17.5-23.4)  18.3 (16.5-20.4) 24.0 (21.7-27.9) <0.001 
BMI categories (kg/m2) 
 
 
  
<0.001 
Normal/obese, ≥18 517 (65.1)  227 (46.4) 290 (95.1)  
Underweight, <18 277 (34.9)  262 (53.6) 15 (4.9)  
Body fat percentage (%) 9.92 (7.5-14.4)  9.41 (6.8-13.5) 11 (8.5-15.8) <0.001 
Hb level (g/dL), median (IQR) 12.1 (10.4-13.3)  11.4 (9.9-12.7) 12.8 (11.5-14.2) <0.001 
TB categories       
New 477 (97.5)  477 (97.5) NA NA 
Retreatment  12 (2.5)  12 (2.5) NA   
BMI, body mass index; IQR, interquartile range; Hb, hemoglobin; HIV, human immunodeficiency virus; NA, not 
applicable  
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7.4.2. Prevalence of respiratory viral and bacterial pathogens 
The frequency distributions of the respiratory viruses detected from study participants are 
summarized in (Table 15). The overall prevalence of any respiratory virus among TB patients 
and controls was 20.4% (161/794; 95%CI 17.7-23.3%), and the odds of detecting any virus 
was the same in TB patients and controls (OR 1.00, 95%CI 0.71-1.44; p=0.98). The most 
common respiratory species detected was human rhinovirus A/B/C (HRV), which was found in 
9.3% (74/794) of the study participants, followed by influenza A in 3.1% (25/794) and 
respiratory syncytial virus A (RSVA) in 1.9% (15/794). We detected only minor differences 
between TB patients and household contact controls in the prevalence (Table 15) and the 
semiquantitative detection (Supplementary Figure 2) of respiratory viruses. We detected 
respiratory viruses more frequently during the months of March and April, and October to 
November (Supplementary Figure 3). 
 
The prevalence of any bacterial pathogen among study participants was 38.2% (303/794; 
95%CI 34.9-41.6%, Table 2). Respiratory bacteria were less likely be detected in TB patients 
than in controls (OR 0.70, 95%CI 0.53-0.94; p 0.02). The most common bacterial species 
detected were Haemophilus influenzae, found in 26.1% of study participants (207/794), 
followed by Streptococcus pneumoniae in 21.5% (171/794). TB patients were less likely than 
household contact controls to have H. influenzae (OR 0.62, 95%CI 0.45-0.86; p=0.004). The 
mean values of cycle threshold for TB patients were slightly higher (indicating a smaller 
bacterial load) than those of household contact controls (greater bacterial load), but this did 
not reach conventional levels of statistical significance (Supplementary Figure 4). There were 
12 TB patients on a retreatment drug regimen, and in ten of them (83.3%) both respiratory 
bacteria and respiratory viruses were detected.  
 
The factors associated with detection of respiratory viruses include smoking and households 
containing three or more people. Men were the more likely to have respiratory bacteria 
(Supplementary Table 17) 
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Table 15. Frequencies of virus detection in the TB patients and household contact 
controls in Tanzania, and odds ratios of detection in TB patients compared to controls. 
Detection of viral species  All  TB 
patients 
Controls  OR (95% CI) p-value 
 
(n=794)  (n=489) (n=305)  
  
Any respiratory virus 162 (20.4)  100 (20.4) 62 (20.3)  1.00 (0.71-1.44) 0.98 
Respiratory viral species  
 
 
  
 
  
Human rhinovirus A/B/C 74 (9.3)  42 (8.6) 32 (10.5)  0.80 (0.49-1.30) 0.37 
Influenza A 25 (3.1)  15 (3.1) 10 (3.3)  0.93 (0.41-2.11) 0.87 
RSV A  15 (1.9)  12 (2.5) 3 (1.0)  2.53 (0.71-9.05) 0.15 
Adenovirus  14 (1.8)  9 (1.8) 5 (1.6)  1.13 (0.373.39) 0.83 
RSV B  12 (1.5)  9 (1.8) 3 (1.0)  1.89 (0.51-7.03) 0.34 
Parainfluenza virus 4 9 (1.1)  4 (0.8) 5 (1.6)  0.49 (0.13-1.86) 0.3 
Coronavirus OC43 9 (1.1)  5 (1.0) 4 (1.3)  0.78 (0.21-2.92) 0.71 
Coronavirus NL63 4 (0.5)  3 (0.6) 1 (0.3)  1.87 (0.19-18.12) 0.59 
Enterovirus 4 (0.5)  4 (0.8) 0 (0)  NA 
 
Bocavirus 1/2/3/4 3 (0.4)  2 (0.4) 1 (0.3)  1.24 (0.11-13.83) 0.86 
Parainfluenza virus 2 3 (0.4)  1 (0.2) 2 (0.7)  0.31 (0.03-3.44) 0.34 
Influenza B 2 (0.3)  1 (0.2) 1 (0.3)  0.62 (0.04-10.0) 0.74 
Parainfluenza virus 3 2 (0.3)  2 (0.4) 0 (0)  0.90 (0.41-1.97) 0.80 
Metapneumovirus 1 (0.1)  1 (0.2) 0 (0)  NA 
 
Coronavirus 229E 1 (0.1)  0 (0) 1 (0.3)  NA 
 
Groups of detected viruses 
 
 
  
 
  
Influenza A/B 27 (3.4)  16 (3.3) 11 (3.6)  0.90 (0.41-1.97) 0.80 
Influenza like (influenza and 
parainfluenza viruses) 
40 (5.0)  23 (4.7) 17 (5.6)  0.84 (0.44-1.60) 0.59 
Coronaviruses 14 (1.8)  8 (1.6) 6 (2.0)  0.83 (0.28-2.41) 0.73 
Parainfluenza 2/3/4 13 (1.6)  7 (1.4) 6 (2.0)  0.72 (0.24-2.17) 0.56 
RSV  25 (3.1)  19 (3.9) 6 (2.0)  2.01 (0.80-5.10) 0.14 
Groups according to the 
number of detected viral 
species 
 
 
  
 
 
0.96 
One specie  145 (18.3)  89 (18.2) 56 (18.4)  0.99 (0.69-1.44)  
≥2 species 17 (2.1)  11 (2.2) 6 (2.0)  1.15 (0.42-3.13) 
 
        
Respiratory bacterial pathogens         
Any bacterial species 303 (38.2) 
 
171 (35.0) 132 (43.3) 0.70 (0.53-0.94) 0.019 
Respiratory bacterial species  
      
Haemophilus influenzae 207 (26.1) 
 
110 (22.5) 97 (31.8) 0.62 (0.45-0.86) 0.004 
Streptococcus pneumoniae 171 (21.5) 
 
99 (20.2) 72 (23.6) 0.82 (0.58-1.16) 0.26 
Legionella pneumophila 12 (1.5) 
 
9 (1.8) 3 (1.0) 1.89 (0.51-7.03) 0.34 
Bordetella parapertussis 4 (0.5) 
 
3 (0.6) 1 (0.3) 1.88 (0.19-18.12) 0.59 
Mycoplasma pneumoniae 0 (0) 
 
0 (0) 0 (0) NA N/A 
Bordetella pertussis 5 (0.6) 
 
4 (0.8) 1 (0.3) 2.51 (0.28-22.54) 0.41 
Chlamydophila pneumoniae 0 (0) 
 
0 (0) 0 (0) NA NA 
Groups according to the number 
of detected bacterial species  
     
0.062 
One specie 209 (26.3)  119 (24.3) 90 (29.5) 0.72 (0.52-1.00)  
≥2 species  94 (11.8) 
 
52 (10.6) 42 (13.8) 0.67 (0.43-1.05) 
 
OR, odds ratio; 95% CI, 95% confidence interval; NA, not applicable 
ORs and p-value calculated from a mixed-effects logistic regression models with random household intercepts 
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7.4.3. Associations between respiratory pathogens and clinical 
presentation 
TB patients with both viral and bacterial pathogens had significantly more severe TB disease 
than TB-only patients (aOR 1.64, 95% CI 1.11-2.37; p=0.01; Table 16). Bacterial respiratory 
pathogens were not significantly associated with the clinical presentation of TB patients at TB 
diagnosis. Detection of respiratory pathogens was not associated with including diagnostic 
delay (defined as duration of symptoms of 3 weeks or more) (see Table 16). No association 
was found between detection of respiratory pathogens and chest x-ray findings among TB 
patients (Table 17). In addition, the detection of respiratory pathogens was similar for HIV-
positive and HIV-negative TB patients (Supplementary Table 16 and Supplementary Table 
17). 
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Table 16. Clinical significance of respiratory pathogens among TB patients at the time of TB diagnosis. 
Respiratory pathogens 
detected  
Severe TB score 1  High sputum bacterial 
load 2 
 Lung cavitation 3  Lung infiltrations 3  Diagnostic delay 4 
 aOR (95% CI) p-
value 
 aOR (95% CI) p-
value 
 aOR (95% CI) p-
value 
 aOR (95% CI) p-
value 
 aOR (95% CI) p-
value 
Respiratory viruses 
              
Any viral species 
 
0.072 
  
0.69 
  
0.089 
  
0.88 
  
0.46 
Yes 1.52 (0.96-2.4) 
  
1.10 (0.69-1.76) 
  
1.58 (0.93-2.68) 
  
1.04 (0.60-1.83) 
  
0.80 (0.45-1.43) 
 
Respiratory bacteria 
              
Any bacterial species  
 
0.17 
  
0.89 
  
0.65 
  
0.85 
  
0.77 
Yes 1.32 (0.89-1.94) 
  
1.03 (0.69-1.53) 
  
0.90 (0.56-1.44) 
  
0.95 (0.58-1.56) 
  
1.07 (0.67-1.71) 
 
Combined detection of 
viral and bacterial 
species 
 
0.01 
  
0.95 
  
0.7 
  
0.71 
  
0.53 
Yes 1.64 (1.11-2.37) 
  
1.00 (0.68-1.46) 
  
1.09 (0.70-1.71) 
  
0.92 (0.57-1.46) 
  
0.87 (0.55-1.37) 
 
aOR, adjusted odds ratios 
Logistic regression model adjusted for age-group, sex, and HIV infection 
1 severe TB score (6 to 12) compared to mild TB score (1 to 5)  
2 High sputum bacterial load (≥2+ according to qualitative AFB smear microscopy grading) compared to low load (scant up to 1+)  
3 As determined by chest X-ray features 
4 Diagnostic delay defined as defined symptoms duration of 3 weeks or more. 
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Table 17. Chest X-ray findings of TB patients with and without any respiratory pathogen 
(viruses and bacteria). 
Chest X-ray findings  Total  TB and respiratory 
pathogen(s) 
TB only p-value  
 
n (%)  n (%) n (%) 
 
Any respiratory 
viruses 
     
Infiltrates  236 (64)  51 (64.6) 185 (63.8) 0.90 
Cavitations 125 (33.9)  33 (41.8) 92 (31.7) 0.09 
Pleural effusion 44 (11.9)  7 (8.9) 37 (12.8) 0.34 
Lymphnodes  31 (8.4)  6 (7.6) 25 (8.6) 0.77 
Micronodules  22 (6)  5 (6.3) 17 (5.9) 0.88 
Macronodules  5 (1.4)  1 (1.3) 4 (1.4) 0.94 
Any respiratory 
bacteria  
     
Infiltrations 236 (64)  78 (63.9) 158 (64) 0.99 
Cavitations 125 (33.9)  40 (32.8) 85 (34.4) 0.76 
Pleural effusion 44 (11.9)  15 (12.3) 29 (11.7) 0.88 
Lymphnodes  31 (8.4)  11 (9) 20 (8.1) 0.77 
Micronodules  22 (6)  9 (7.4) 13 (5.3) 0.42 
Macronodules  5 (1.4)  1 (0.8) 4 (1.6) 0.53 
p-value calculated from chi-square test.  
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7.5. Discussion  
Both respiratory viruses and respiratory bacteria are commonly detected in a high-TB-
incidence setting, and the prevalence of respiratory bacteria was lower in TB patients than in 
household contact controls. Detection of respiratory viruses and respiratory bacteria in TB 
patients was associated with more severe disease. 
 
The prevalence of any respiratory viruses was the same (20%) for both TB patients and 
controls without TB. Similar prevalence of respiratory viruses in controls as compared to TB 
patients could be due to controls being more active than TB patients, hence having increased 
social contacts. The prevalence shown in our study was lower than that reported in an 
Indonesian study of influenza viruses that observed respective prevalence of around 46% and 
41% for TB patients and controls, respectively (de Paus RA et al., 2013). The difference in the 
prevalence of influenza in that study compared to ours could be due to the different study 
region (Asia versus sub-Saharan Africa) and the use of different diagnostic methods 
(immunological assay versus molecular detection). We detected respiratory viruses from 
nasopharyngeal swabs using a highly sensitive and specific molecular technique (Niang et al., 
2017)[21], whereas the study from Indonesia (de Paus RA et al., 2013) measured influenza 
virus antibody titres which also detect patients with previous exposure to influenza viruses. 
The influenza antibody titres were higher in TB patients than in controls, suggesting recent 
viral infection before the clinical manifestations of TB (de Paus RA et al., 2013). 
 
We did not find any evidence for an association between HIV infection and detection of 
respiratory pathogens. In line with our results, a household study on respiratory illness 
surveillance and HIV testing in Kenya (Judd et al., 2015) did not find any association between 
HIV and influenza viruses. However, household contacts of the HIV-infected influenza index 
cases were twice as likely to develop a secondary case of influenza-like illness (Judd et al., 
2015). 
 
We also found that the presence of both viruses and bacteria could potentially alter the clinical 
course of TB, and present with a more severe disease as measured by the previously validated 
clinical TB score (Wejse et al., 2008). Direct evidence of clinical effects of respiratory viruses 
on TB have only been demonstrated in experimental mouse models that have exhibited higher 
mycobacterial loads in the lungs and increased lung inflammation (Redford et al., 2013). The 
immunological pathway responsible for more severe clinical presentation in TB patients may 
occur either via the type I interferon-receptor dependent pathway (Redford et al., 2013) or via 
decreased MHC II expression on dendritic cells (Flórido et al., 2013), which may result in poor 
clearance of M. tuberculosis from the lungs. 
 
We found smoking and living in a household with three or more persons to be risk factors for 
respiratory viruses. Smoking has been shown, at least in animal models, to inhibit the 
pulmonary T-cell response to influenza viruses, thus increasing susceptibility to infection (Feng 
et al., 2010), and respiratory viruses were more likely to be detected in children living with a 
smoker (Nicolai et al., 2016). In addition, overcrowding which we defined as three or more 
persons in a household - is a common risk factor for most airborne pathogens such as M. 
tuberculosis (Corbett et al., 2009) and respiratory viruses (Judd et al., 2015). 
 
The prevalence of bacterial respiratory pathogens in our study was lower in TB patients than 
in household contact controls, suggesting interactions between M. tuberculosis and the 
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bacterial populations in the airways. Overall respiratory bacterial load was smaller in TB 
patients than in controls. This is similar to findings from a microbiota study which reported 
smaller bacterial loads in TB patients than in controls (Cui et al., 2012). The authors argue that 
the initial phase of M. tuberculosis invasion in the lungs may prompt an immune response that 
could also reduce the commensal flora in the lower respiratory tract (Cui et al., 2012). 
Interestingly, in a mouse model, M. tuberculosis infection in the lungs appeared also to have 
an effect on the gut microbiota, which is part of the collective human microbiota (Winglee et 
al., 2014). These findings consistently suggest interactions between M. tuberculosis and the 
communities of microorganisms, and a role for these interactions in TB pathogenesis. 
 
We believe that this is the first study to have looked systematically at a wide range of viral and 
bacterial species in TB patients and controls, and using sensitive molecular techniques and 
clinical specimens from a well-defined compartment of the airways. A particular strength of the 
study is that potentially confounding and unmeasured risk factors were minimized by studying 
patients and controls who lived in the same households. A limitation of the study is its 
undifferentiated attention to respiratory viruses because of small numbers which precluded 
assessment of the clinical effects of individual viruses. However, we presume that all 
respiratory viruses have similar levels of immunomodulation, and thus we could combine all 
respiratory viruses together. 
 
In conclusion, respiratory pathogens are common in the high-TB setting of Tanzania for both 
TB patients and household contact controls without TB. However, respiratory bacterial species 
were more frequently detected in household contact controls than in TB patients. Our findings 
suggest that TB patients co-infected with both respiratory viruses and respiratory bacteria have 
severe TB disease. Further research should focus on the pathogenic role of respiratory 
pathogens in high-TB-incidence settings and their effects on clinical and treatment outcomes.  
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7.6. Supporting information 
Supplementary Table 15. Rv16 kit Panel A/B for detection of respiratory viral 
pathogens and Allplex respiratory panel 4 for detection of bacterial respiratory 
pathogens (Seegene, South Korea). 
AnyplexII RV16 Detection  Allplex respiratory 
Panel A Panel B  Panel 4 
Adenovirus Respiratory syncytial virus A 
(RSV A) 
 Mycoplasma pneumoniae 
Influenza A virus (FluA) Respiratory syncytial virus B 
(RSV B) 
 Chlamydophila pneumoniae 
Influenza B virus (FluB) Bocavirus 1/2/3/4 (HBoV)  Legionella pneumophila  
Parainfluenza virus 1 
(PIV1) 
Metapneumovirus (MPV)  Haemophilus influenzae  
Parainfluenza virus 2 
(PIV2) 
Coronavirus 229E (CoV 229E)  Streptococcus pneumoniae  
Parainfluenza virus 3 
(PIV3) 
Coronavirus NL63 (CoV NL63)  Bordetella pertussis 
Parainfluenza virus 4 
(PIV4) 
Coronavirus OC43 (CoV OC43)  Bordetella parapertussis 
Rhinovirus A/B/C (HRV) Enterovirus (HEV)   
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Supplementary Table 16. Characteristics of TB patients at recruitment by viral 
infection status. 
Characteristics Total TB and 
viruses 
TB only p-
value 
n (%) (n=489) (n=100) (n=389) 
 
Age, median (IQR) (years) 33 (27-40) 33 (28-39) 33 (26-41) 0.99 
Age groups (years) 
   
0.60 
<25 82 (16.8) 13 (13.0) 69 (17.7) 
 
25-34 188 (38.4) 42 (42.0) 146 (37.5) 
 
35-44 132 (27) 29 (29.0) 103 (26.5) 
 
≥45 87 (17.8) 16 (16.0) 71 (18.3) 
 
Sex, Male  336 (68.7) 67 (67.0) 269 (69.2) 0.68 
HIV-positive 140 (28.6) 29 (29.0) 111 (28.5) 0.93 
CD4 cell counts, cells/µl 1 205 (91-280) 260 (160-342) 192 (90-263) 0.20 
Number of people in the household 
   
0.65 
>3 people  133 (27.2) 29 (29.0) 104 (26.7) 
 
Current smoker 
   
0.33 
Yes 73 (14.9) 18 (18) 55 (14.1) 
 
Body weight (kg), median (IQR) 51 (45.5-57) 51 (46.0-56.8) 51 (45-57) 0.66 
BMI (kg/m2), median(IQR) 18.3 (16.5-20.4) 17.5 (16.2-
20.1) 
18.4 (16.7-
20.4) 
0.11 
BMI (kg/m2) groups 
   
0.15 
Normal/Obese, ≥18 227 (46.4) 40 (40.0) 187 (48.1) 
 
Low weight, <18 262 (53.6) 60 (60.0) 202 (51.9)  
Body fat percentage (%) 9.41 (6.79-13.5) 8.71 (5.91-
13.5) 
9.58 (7.23-
13.5) 
0.15 
Symptoms 
    
Cough 486 (99.4) 99 (99.0) 387 (99.5) 0.58 
Fever 453 (92.6) 91 (91.0) 362 (93.1) 0.48 
Weight loss 474 (96.9) 99 (99.0) 375 (96.4) 0.18 
Night sweats 467 (95.5) 94 (94.0) 373 (95.9) 0.42 
Hemoptysis  133 (27.2) 32 (32.0) 101 (26.0) 0.23 
TB score categories 2 
   
0.061 
TB score (0-5) 313 (64) 56 (56.0) 257 (66.1) 
 
TB score (6-12) 176 (36) 44 (44.0) 132 (33.9) 
 
TB treatment categories  
   
0.26 
Retreatment 12 (2.5) 4 (4.0) 8 (2.1) 
 
New patients  477 (97.5) 96 (96.0) 381 (97.9) 
 
Sputum smear microscopy result 3    0.78 
Scanty and 1+ AFB 172 (35.2) 34 (34.0) 138 (35.5)  
≥2+ AFB 317 (64.8) 66 (66.0) 251 (64.5)  
Any prior antibiotic use     0.31 
Yes 436 (89.2) 92 (92) 344 (88.4)  
AFB, acid-fast bacilli; BMI, body mass index; HIV, human immunodeficiency virus; IQR, interquartile range 
1 CD4+ count is for HIV-positive patients only 
2 TB score (mild [score of 1-5] and severe [score of 6-12]) 
3 Sputum bacterial load (according to qualitative AFB smear microscopy grading): mild (scant and 1+) and severe 
(≥+2) 
p-value calculated from chi-square test.   
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Supplementary Table 17. Characteristics of TB patients by bacterial infection status 
Characteristics Total TB and 
bacteria 
TB only p-value 
  (n=489) (n=171) (n=318) 
 
Age, median (IQR) (years) 33 (27-40) 34 (29-42)    33 (26-40) 0.20 
Age groups (years) 
   
0.53 
<25 82 (16.8) 23 (13.5) 59 (18.6) 
 
25-34 188 (38.4) 70 (40.9) 118 (37.1) 
 
35-44 132 (27) 47 (27.5) 85 (26.7) 
 
≥45 87 (17.8) 31 (18.1) 56 (17.6) 
 
Sex, Male 336 (68.7) 123 (71.9) 213 (67) 0.26 
HIV-positive 140 (28.6) 50 (29.2) 90 (28.3) 0.83 
CD4 counts, cells/mL 1 205 (91-280) 234 (113-296) 198 (91-260) 0.39 
Number of people in the 
household 
   
0.75 
>3 people  133 (27.2) 45 (26.3) 88 (27.7) 
 
Current smoker 
   
0.70 
Yes 73 (14.9) 27 (15.8) 46 (14.5) 
 
Body weight (kg), median (IQR) 51 (45.5-57) 51 (45-56) 51 (46-57) 0.22 
BMI (kg/m2), median(IQR) 18.3 (16.5-20.4) 18 (16.1-20) 18.4 (16.7-20.5) 0.10 
BMI (kg/m2) groups, n (%) 
   
0.23 
Normal/Obese, ≥18 227 (46.4) 73 (42.7) 154 (48.4) 
 
Underweight, <18 262 (53.6) 98 (57.3) 164 (51.6) 
 
Body fat (%) 9.41 (6.79-13.5) 9.31 (7.13-13) 9.5 (6.49-13.9) 0.63 
Symptoms 2 
    
Cough 486 (99.4) 171 (100) 315 (99.1) 0.20 
Fever 453 (92.6) 157 (91.8) 296 (93.1) 0.61 
Weight loss 474 (96.9) 167 (97.7) 307 (96.5) 0.49 
Night sweats 467 (95.5) 166 (97.1) 301 (94.7) 0.22 
Haemoptysis  133 (27.2) 46 (26.9) 87 (27.4) 0.91 
TB score categories 3 
   
0.20 
TB score (0-5) 313 (64) 103 (60.2) 210 (66) 
 
TB score (6-12) 176 (36) 68 (39.8) 108 (34) 
 
TB treatment categories  
   
0.020 
Retreatment 12 (2.5) 8 (4.7) 4 (1.3) 
 
New patients  477 (97.5) 163 (95.3) 314 (98.7) 
 
Sputum smear microscopy 
result 4 
   0.98 
Scant and 1+ AFB 172 (35.2) 60 (35.1) 112 (35.2)  
≥2+ AFB 317 (64.8) 111 (64.9) 206 (64.8)  
Prior antibiotic use  436 (89.2) 152 (88.9) 284 (89.3) 0.89 
AFB, acid-fast bacilli; BMI, body mass index; HIV, human immunodeficiency virus; IQR, interquartile range 
1 CD4 cell count is for HIV-positive patients only 
2 categories mutually exclusive 
3 TB score (mild [score of 1-5] and severe [score of 6-12]) 
4 Sputum bacterial load (according to qualitative AFB smear microscopy grading): mild (scant and 1+) and severe 
(≥+2) 
p-value calculated from chi-square test.    
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Supplementary Figure 2. Semiquantitative detection of respiratory viruses among TB 
patients and controls. 
 
 
 
Supplementary Figure 3. Seasonal trends of the detection of respiratory viruses 
during the study period of November 2013 to June 2015.  
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Supplementary Figure 4. The Dotplot of mean Ct values of (A) Streptococcus 
pneumoniae, (B) Haemophilus influenza, and (C) Legionella pneumophila in TB 
patients and controls. Each individual dot represents a study participant.  
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8. Discussion  
8.1. General discussion  
This PhD project was done under the framework of TB-DAR study: a prospective cohort study 
of TB patients and household contact controls. The project is funded by Rudolf Geigy 
Foundation of Basel Switzerland, and is jointly implemented by IHI and Swiss TPH at Temeke 
district, Dar es Salaam Region in Tanzania. This PhD thesis has established the burden HIV, 
helminth infections and respiratory pathogens (viruses and bacteria) among TB patients and 
household contact controls. In addition, we have demonstrated TB treatment outcomes in high 
HIV setting, and the clinical significance of helminth infection and respiratory viruses among 
TB patients. To determine the burden of co-infections, we employed several quality controlled 
diagnostic tools. For helminth infection diagnosis, we used Kato-Katz, Baermann, urine 
filtration and CCA to increase overall sensitivity. We used multiplex PCR to simultaneously 
diagnosed 16 respiratory viruses and seven respiratory bacteria.  
 
A summary discussion of the main findings of this PhD thesis are discussed in the subsequent 
sections. The findings on TB mortality in high TB and HIV setting under home-based and 
facility-based DOT are discussed in section 8.1.1 The prevalence and clinical significance of 
helminth and respiratory pathogens are discussed in sections 8.1.2 and 8.1.3 respectively.  
8.1.1. TB mortality in high HIV setting 
We found that TB mortality is high among TB patients who opted for home-based DOT 
compared to facility-based DOT. The uneven burden of mortality in home-based DOT is driven 
by uneven distribution of TB mortality risk factors. The risk factors we identified included HIV, 
features of advanced HIV disease (smear-negative PTB) and old age, as also previously 
described as causes of deaths among TB patients in high TB settings (Waitt and Squire, 2011). 
TB patients preferred home-based DOT because it is more convenient to them, and not facility 
based DOT which requires TB patients to make daily visits to the health facility for TB treatment 
(Wandwalo et al., 2006, 2005). Furthermore, the patients under home-based DOT may not 
have treatment supporter who could supervise the patient, a concern raised by the health care 
workers (van den Boogaard et al., 2009). The other assumption relating to this observation is 
that, mortality risk factors assessment is not done by the health care workers during TB 
diagnosis. Presuming no risk assessment is done, then very likely no additional clinical care is 
given to high risk TB patients who have opted home-based DOT.  
 
TB deaths are essentially preventable and therefore can be avoided. TB treatment under DOT 
is effective and has good treatment success (Van Deun and Rieder, 2012). The absolute 
number of TB deaths reported in 2015 are actually higher compared to 2014, making TB a 
leading cause of deaths from an infectious disease (WHO, 2016). To reduce the TB mortality 
and contribute to the End TB Strategy, a risk assessment tools could prove beneficial as earlier 
suggested (Waitt and Squire, 2011). We think such a tool has to be robust and comprehensive 
enough to include risk factors for TB mortality in both low and high TB setting (Waitt and Squire, 
2011). We would need to consider all emerging and existing comorbidities that may negatively 
affect TB treatment outcome (Marais et al., 2013), when designing such a tool. 
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8.1.2. TB and helminth co-infection  
We found that S. mansoni infection was a risk factor for TB disease and alters clinical 
phenotypes of TB patients. TB patients infected with S. mansoni presented with lower smear 
microscopy grading and tended to have less lung cavities. Overall, TB patients had uneven 
higher burden of helminth infection compared to household contact controls. These findings in 
our study suggest that helminths, specifically S. mansoni, has a pathogenic role in TB 
pathogenesis. The findings are supported by the experimental mice models which showed 
helminth infection immunomodulate negatively the Th1 immune by inducing Th2 immune 
response (Babu and Nutman, 2016; DiNardo et al., 2016; Monin et al., 2015). Interestingly, 
certain helminth species like S. haematobium (Kjetland et al., 2006), S. mansoni (Downs et al., 
2012) and Wuchereria bancrofti (Kroidl et al., 2016) are associated with increased risk of HIV 
infection, a major risk factor TB. Thus, from our findings and other studies, helminth infection 
seems to directly increase risk of developing TB, and indirectly through increasing the risk HIV 
infection. 
 
To compare our findings on the association between TB and helminth infections, we performed 
a review of published researches reporting the association between TB and helminth as shown 
in Table 18. TB patients have higher helminth burden than either house or community controls 
(Abate et al., 2015; Elias et al., 2006; Tristão-Sá et al., 2002) or smear-negative TB patients 
(Range et al., 2007). We observed that S. mansoni is associated with TB, a finding that may 
suggest that not all helminth immunomodulation effects are equal in TB as observed with HIV 
(O’Hara and Elliott, 2016). S. mansoni eggs have soluble egg antigen (SAE) which is a potent 
immunogenic inducing a strong Th2 immune response (DiNardo et al., 2016; McKee and 
Pearce, 2004; Pearce et al., 2004). The assumption that S. mansoni is a stronger Th2 inducer, 
could be supported by our findings that TB patients infected with S. mansoni had lower sputum 
bacterial load and tended to have few lung cavities, compared to other helminth species 
identified in our study. The clinical picture of lower sputum bacterial load and less cavitary 
diseases, resembles the clinical manifestation of TB patients with severe immunosuppression 
caused HIV (Sharma et al., 2005). However, side by side comparison of helminth species on 
Th2 immune response could be more informative to assess level of immunosuppression 
caused by different helminth species.  
 
Two studies reported no difference in TB incidence among individuals with or without helminth 
infection in the general population (Chatterjee et al., 2014) or among HIV-positive individuals 
(Brown et al., 2006). The use of anthelmintic treatment offered to the study participants after 
diagnosis in both studies might have reversed the Th1 immune response (Monin et al., 2015), 
and hence have no substantial Th2 immune response in the course of follow-up period to 
cause difference in TB incidence.  
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Table 18. Previous studies on the association of TB and helminth infection 
Author-
year 
Setting TB 
burden 
Study 
design 
Study 
population 
TB 
diagnosis 
Helminth detection 
methods 
Common 
helminth 
species 
Prevalence of 
helminth 
infection 
Effect size (95%CI) Significance 
Abate, 
2015 
Ethiopia High Case-control 
study of 
smear-
positive and 
community 
controls  
TB patients 
(424)  
Community 
controls 
(306) 
 
15-60 years 
AFB Smear 
microscopy 
Direct smear 
microscopy and Kato-
Katz technique 
A. lumbricoides TB patients 
40% (121/306) 
versus 28% 
(85/306) for 
community 
controls 
Lower rate of sputum 
AFB smear positivity 
and the association 
was stronger with 
increasing smear grade 
(aOR for a smear grade 
2: 0.43 (95% CI: 0.23–
0.79), p = 0.007 
Association with 
lower smear grading 
is indicative of 
immunosuppression 
caused by helminth 
infection.  
Brown, 
2006 
Uganda High Prospective 
cohort study 
of HIV-
infected 
patients 
376 HIV 
positive 
patients  
 
17-66 years 
Mycobacterial 
culture, 
smear-
microscopy, 
clinical 
diagnosis 
Kato-Katz method or 
CAA ELISA was 
positive. Microfilaria 
were diagnosed using 
a modified Knott 
concentration method 
S. mansoni 
Hookworm 
S. stercoralis 
M. perstans 
Helminth 
prevalence was 
54% 
TB incidence with 
gastrointestinal 
nematodes (RR, 1.18; 
95% CI: 0.66–2.10) or 
M. perstans (RR, 0.42; 
CI, 0.13–1.34).  
 
A weak association 
between S. mansoni 
infection and TB was 
found (RR, 1.42; CI, 
0.86–2.34); after 
adjusting for potential 
explanatory variables 
and using more 
stringent diagnostic 
criteria (confirmed TB 
cases only, n=13), the 
association was 
strengthened (RR, 
2.31; 1.00–5.33) 
A weak association 
of increased 
incidence of TB 
among HIV-positive 
individuals.  
 
More pronounced 
association is 
observed with S. 
mansoni. Indicate 
species differences 
in inducing Th2. 
AFB, Acid fast bacilli; aOR, adjusted Odds ratio; CCA, circulating anodic antigen; ELISA, Enzyme-linked immunosorbent assay; M. perstans, Mansonella perstans, RR, rate ratio;  
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Previous studies on the association of TB and helminth infection 
Author-
year 
Setting TB 
burden 
Study 
design 
Study 
population 
TB 
diagnosis 
Helminth detection 
methods 
Common 
helminth 
species 
Prevalence 
of helminth 
infection 
Effect size (95%CI) Significance 
Chatterjee, 
2013 
India High Prospective 
cohort study 
5096 study 
participants 
 
6-65 years 
ZN, followed 
by 
fluorescence 
microscopy 
and culture. 
Direct microscopy and 
by formal-gasoline 
concentration 
techniques.  
 
W. bancrofti infection - 
measurement of CFA 
using an 
immunocromatographic 
test 
Hookworm 
W. bancrofti 
Hookworm 
(30%)  
 
W. bancrofti 
(9%) 
No difference in TB risk at 
recruitment between study 
participants with and without 
helminth (RRi 1.60; 95% CI: 
0.69, 3.71, p = 0.27),  
 
TB incidence during follow-up 
(RR 1.24; 95% CI: 0.48, 3.18, 
P = 0.66) 
No association 
between helminth 
infection and TB 
incidence.   
Elias, 2006 Ethiopia High Case-control 
study 
TB patients 
(230) and 
healthy 
household 
contacts 
(510) 
 
10-65 years 
Sputum 
microscopy 
using the 
sodium 
hypochlorite 
concentration 
techniques 
Direct microscopy and 
formol-ether 
concentration  
A. lumbricoides 
Hookworm 
S. stercoralis 
T. trichiura 
S. mansoni 
E. vermicularis 
Prevalence 
of intestinal 
helminths 
was 71% in 
patients 
and 36% in 
controls 
Conditional logistic regression 
analysis showed a strong 
association between TB and 
intestinal helminth infection 
(aOR 4.2, 95% CI 2.7–5.9, p < 
0.001).  
 
The odds of being a TB patient 
increased with the number of 
helminth species per person:  
mono-infection (aOR 4.3, 95% 
CI: 2.8–6.8);  
two species (aOR 4.7, 95% CI 
2.5–8.7) and 
three or more helminths was 
(aOR 12.2, 95% CI: 3.9–52.6).  
Increase risk TB 
which increases 
with increasing 
number of helminth 
species infecting a 
person.  
 
Dose dependent 
relationship of Th2 
induction by 
helminth species.  
aOR, adjusted Odds ratio; CFA, circulating filarial antigen; RR, rate ratio; RRi, risk ratio; ZN, Ziehl–Neelsen 
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Previous studies on the association of TB and helminth infection 
Author-
year 
Setting TB 
burden 
Study 
design 
Study 
population 
TB 
diagnosis 
Helminth detection 
methods 
Common 
helminth 
species 
Prevalence 
of helminth 
infection 
Effect size (95%CI) Significance 
Li, 2016 China High Bayesian 
geostatistical 
modeling.   
  
252,940 TB 
patients 
 
All age-
groups 
Smear 
microscopy 
and culture 
Kato-Katz technique, 
test tube filter paper 
culture, adhesive 
cellophane anal swab 
A. lumbricoides 
Hookworm 
T. trichiura 
Clonorchis 
sinensis 
Taenia spp 
Prevalence 
of helminth 
infection 
27.6% 
Active PTB (75.1% [95% CI = 
63.0–81.2%]) was spatially 
correlated to helminth 
Geographical 
overlap of TB and 
helminth infection 
distribution. 
 
High helminth 
burden corresponds 
to high TB burden. .  
Range, 
2007 
Tanzania High Cross-
sectional 
532 PTB+ 
patients and 
123 PTB- 
(clinical TB 
patients)  
 
15-85 years 
Smear 
microscopy 
and culture 
(LJ) 
Kato-katz and urine 
filtration 
Hookworm 
S. mansoni 
A. lumbricoides 
T. trichiura  
S. stercoralis 
Prevalence 
of helminth 
infection in 
PTB+ vs 
PTB- (S. 
mansoni, 
35.5% vs. 
29.3%: 
p=0.22); 
Hookworm 
19.4% vs. 
13.0%: 
p=0.11) 
Not applicable No association 
helminth infection 
and AFB smear-
positive or smear-
negative PTB.  
Resende 
Co, 2006 
Brazil High Prospective 
cohort study.  
40 TB 
patients 
 
18-53 years 
Smear 
microscopy 
and culture 
Lutz, Kato-katz and 
Baerman-Moraes 
methods 
S. stercoralis Helminth 
co-infection 
prevalence 
was in 
27·5% 
(11/40) of 
patients TB 
Severe radiological pulmonary 
disease for TB patients co-
infected with helminth (p = 
0·013) presenting as the 
number of involved lung zones 
at the end of TB treatment 
Helminth effect 
could be long lasting 
especially on the 
radiological 
findings.  
AFB, Acid fast bacilli; aOR, adjusted Odds ratio; CFA, circulating filarial antigen; PTB+, smear-positive PTB; PTB-, smear-negative PTB; RR, rate ratio; RRi, risk ratio; ZN, Ziehl–Neelsen 
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Previous studies on the association of TB and helminth infection 
Author-
year 
Setting TB 
burden 
Study 
design 
Study 
population 
TB 
diagnosis 
Helminth detection 
methods 
Common 
helminth 
species 
Prevalence 
of helminth 
infection 
Effect size (95%CI) Significance 
Tristão-
Sá, 2002 
Brazil High Matched 
case-control 
study 
57 TB 
patients and 
86 controls  
 
Adults (age 
unspecified) 
Unspecified Lutz-Hoffman method A. lumbricoides 
S. stercoralis 
T. trichiura 
Necator 
americanus 
Ancylostoma 
duodenale 
Prevalence 
of intestinal 
nematodes 
in PTB 
compared 
to a 
matched 
control 
group: 
33/57 
(57.8%) vs 
18/86 
(20.9%).  
Detection of at least one worm 
in TB patients compared to 
controls (OR=5.19; 95% CI= 
2.33-11.69; p <0.001) 
Disproportionate 
higher burden of 
helminth in TB 
patients compared 
to controls.  
aOR, adjusted Odds Ratio; OR, Odds Ratio 
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8.1.3. TB and respiratory pathogens  
Respiratory pathogens are common in our setting. We observed no difference in the 
prevalence of either respiratory viruses or bacteria in our study. We found that respiratory 
bacteria had no clinically significant effect on TB patients. However, TB patients infected with 
both respiratory and bacteria pathogens may manifest severe TB disease and cavitary 
disease. The results are consistent with increased mycobacterial growth may be because of 
decreased MHC II expression on dendritic cells (Flórido et al., 2013) or through type I interferon 
pathways (Redford et al., 2013). Though immunological pathways are from influenza infection 
models, we presume such pathways may be common for all other viruses.  
 
We also reviewed the literature of studies reporting the association between TB and respiratory 
viruses which are shown in Table 19. Only one study measured IgG levels which signified 
recent viral infection, and higher levels of IgG were associated with severe disease TB disease 
as seen from the radiological findings (de Paus RA et al., 2013).  
 
The other two studies reported higher mortality among TB patients (Archer et al., 2009; Walaza 
et al., 2015). The effect of respiratory viruses in humans from published research so far, point 
to higher TB mortality for patients who are co-infected with specifically influenza viruses. The 
influenza pandemics are good example of the selective pressure of influenza virus infection 
among TB patients and causing higher mortality (Noymer, 2011, 2009; Walaza et al., 2015; 
Zürcher et al., 2016). However, in this study we did not assess the association between 
influenza virus infection and TB mortality.  
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Table 19. Previous studies on the association of TB and respiratory viral pathogens 
Author-year Setting TB burden Study 
design 
Study 
population 
TB 
diagnosis 
Respiratory virus 
diagnosis 
Common 
respiratory 
pathogens 
Prevalence of 
respiratory 
viruses 
Clinical effect Significance  
Archer, 2009 South 
Africa 
High Prospective 
study 
12,331 
H1N1 
influenza 
virus cases  
As reported 
by the 
attending 
clinician.  
Real-time PCR 
protocol distributed by 
the United States 
Centers 
for Disease Control 
and Prevention (US 
CDC) for the detection 
and 
characterization of 
pandemic inﬂuenza A 
(H1N1) virus 
H1N1 
influenza 
virus cases 
Active 
tuberculosis 
coinfection 
was present in 
seven of 72 
(10%) 
fatal cases 
NA Influenza virus and TB co-
infection is common high TB 
burden setting.  
 
No definitive interaction 
between TB and influenza 
virus.  
de Paus, 2013 Indonesia High  Retrospective 
study 
HIV-
negative 
TB patients 
 
Community 
controls 
Smear 
microscopy 
and culture.  
IgG and IgM 
antibodies against two 
subtypes of influenza 
A virus 
H3N2 and 
H1N1 
viruses  
46% of the TB 
patients and 
41% of the 
controls had 
antibodies 
against H1N1, 
while 82% of 
the TB patients 
and 82% of the 
controls had 
antibodies 
against H3N2 
Similar 
seroprevalence 
of antibodies 
between TB 
patients and 
controls.  
 
The 
geometric 
means of the 
titers of 
antibodies 
against higher 
for TB patients 
than controls. 
 
TB patient with 
advanced 
disease have 
higher IgG 
titers.  
No correlation between 
presence of antibodies and 
manifestation of TB. 
 
 
 
 
TB patients have recent 
reinfection because of high 
titers of IgG  
 
 
 
Severity of radiological 
features may be associated 
with recent viral infection.  
CDC, Center for Disease Control and Prevention; Ig, immunoglobulin; NA, Not applicable 
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Previous studies on the association of TB and respiratory viral pathogens 
Author-year Setting TB burden Study 
design 
Study 
population 
TB 
diagnosis 
Respiratory virus 
diagnosis 
Common 
respiratory 
pathogens 
Prevalence of 
respiratory 
viruses 
Clinical effect Significance  
Walaza, 2015 South 
Africa 
High Modelling of 
surveillance 
data of 
influenza 
cases 
550,769 
deaths  
 
 
All age 
groups  
   63,596 (12%) 
were PTB 
related deaths. 
High mortality 
in PTB patients  
compared to 
HIV-infected 
non-
tuberculosis 
respiratory 
deaths (relative 
risk (RR): 5.2; 
95% CI: 4.6–
5.9) and HIV-
uninfected non-
tuberculosis  
respiratory 
deaths (RR: 
61.0; CI: 41.4–
91.0) for age 
<65 
 
PTB deaths 
were seasonal 
and increased 
each winter, 
coinciding with 
the period of 
influenza 
virus circulation 
Increased mortality in 
persons with TB co-infected 
with influenza virus.  
TB mortality follows the 
influenza epidemics 
seasonality, signifying 
possible association 
between the two diseases.  
RR, risk ratio 
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Table 20. Previous studies on the association of TB and respiratory bacterial pathogens 
Author-year Setting TB burden Study design Sample size TB diagnosis Respiratory 
pathogens 
diagnosis 
Common 
respiratory 
pathogens 
Prevalence of 
respiratory 
pathogens 
Effect size 
(95%CI) 
Significance  
Lin, 2011 Taiwan Low Cross-section PTB patients 
(182)  
 
16-93 
TST positive, 
x-ray, culture 
Gram stain and 
microbiological 
culture.   
M. pneumonia 
L. pneumonia, 
Klebsiella 
pneumoniae 
S. pneumonia 
H. influenzae 
54 (29.7%) had 
dual infections 
NA Dual infections 
are common 
and cause 
delay in TB 
diagnosis. 
 
Increased 
hospital 
morbidity and 
mortality with 
polymicrobial 
infections.  
Wu, 2013 China High Cross-section 73 TB patients 
and 20 controls 
 
13-79 
Smear 
microscopy 
PCR 
amplification of 
16S rRNA for 
microbiota 
identification by 
454 
sequencing 
Streptococcus, 
Gramulicatella 
and 
Pseudomonas 
were more 
abundant in TB 
patients.  
 
Prevotella, 
Leptotrichia, 
Treponema, 
Catonella and 
Coprococcus 
were less 
abundant in TB 
patients than in 
the healthy 
controls 
In the TB 
patient group, 
most of the 
cases were 
dominated by 
Streptococcus 
(36% in new 
TB, 50% in 
recurrent TB 
and 45% in 
treatment 
failure TB), 
followed by 
Neisseria (24% 
in new TB, 
26.7% in 
recurrent TB 
and 30% in 
treatment 
failure TB) 
NA Certain 
bacteria and 
the disorder of 
lung microbiota 
may be 
associated with 
not only onset 
of TB but also 
its recurrence 
and treatment 
failure.  
 
Differences in 
lung microbiota 
is indicative of 
pathogenic role 
of respiratory 
bacteria.  
SED = Standard error of differences of percentages. OR = Odds ratio. ARR = Adjusted risk ratio. AHR = Adjusted hazard ratio. Not clearly stated (-) 
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8.2. Novel contribution of the thesis  
Table 21. The contributions of the different chapters of this PhD thesis 
Chapter Title Innovation Finding/Validation Implication/Application 
Chapter 5 Home-based and facility-based Directly 
Observed Therapy of tuberculosis 
treatment under programmatic 
conditions in urban Tanzania 
We have evaluated 
treatment outcome of TB 
patients under routine 
care from a large dataset. 
We analyzed the 
difference in TB mortality 
between home- and 
facility-based DOT. 
More TB patients with 
risk factors for TB 
mortality opted for home-
based DOT compared to 
facility-based DOT.  
 
TB mortality was higher 
in home-based DOT 
compared to facility-
based DOT.  
 
A thorough evaluation of the TB treatment 
under DOT to quantify risk factors and 
design a mortality risk factor tool.  
 
 
Chapter 6 Prevalence and Clinical Relevance of 
Helminth Co-infections among 
Tuberculosis Patients in Urban 
Tanzania 
A first survey in Tanzania 
to use a suite diagnostic 
procedure to diagnose 
helminth infection among 
TB patients and 
household contact 
controls.  
S. mansoni infection is 
associated with TB 
disease and affect the 
clinical phenotypes of TB 
patients such as lower 
sputum smear grading 
and less formation of 
lung cavities.  
 
Diagnosis and management of helminth 
should be an integral part of routine 
management of TB patients. The 
approach will reduce morbidity and 
potential unfavorable treatment 
outcomes.  
 
To consider bidirectional screening of TB 
and helminth in patients affected by both 
diseases.   
 
Chapter 7 The clinical significance of respiratory 
viruses and bacteria among TB patients 
in Tanzania 
The use of PCR 
molecular test detects 
respiratory viruses and 
bacteria from TB 
patients. 
Respiratory viruses 
cause severe and 
cavitary TB diseases.  
Vaccination may help to reduce the 
morbidity of TB and possibly improve TB 
treatment outcome.  
 
 
DOT, directly observed therapy; PCR, Polymerase chain reaction 
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8.3. Challenges and opportunities for control of TB and HIV, 
helminth and respiratory pathogens control 
The most challenging aspects of TB control are; i) 2-3 billion people are infected with M. 
tuberculosis, and can develop TB (WHO, 2016), ii) the burden of risk factors both 
communicable and non-communicable conditions are still high especially in high TB burden 
countries (Marais et al., 2013), and iii) reduced resources for TB control which threatens 
sustaining TB control efforts (WHO, 2016). The other emerging TB control challenge, is from 
the scientific evidence that helminths which affects over a billion (Knopp et al., 2012; Pullan et 
al., 2014; Utzinger et al., 2012), could actually fuel both TB and HIV epidemics.  
 
Despite the challenges, lies the opportunities to control TB and associated co-infections. TB 
control is dependent on at least: i) reducing community exposures by reducing risk of M. 
tuberculosis infection and ii) reducing community vulnerability by controlling risk factors for 
developing TB such as HIV and helminth (Marais et al., 2013). The following sections will 
discuss opportunities to control TB for HIV (8.3.1), helminth infections (8.3.2) and respiratory 
pathogens (8.3.3) . 
8.3.1. HIV and TB control 
Tanzania has implemented the collaborative TB/HIV services since 2007, which aims at 
reducing the burden of TB and HIV for patients affected by both diseases. Highly active 
antiretroviral therapy (HAART) has reduced TB incidence (Badri et al., 2002; Houben et al., 
2012) and TB mortality (Maruza et al., 2012). The activities that target reduction of co-infection 
burden of TB and HIV are stipulated in the TB and HIV management guidelines of Tanzania 
(NACP, 2015; NTLP, MoHSW, 2013). 
 
The treatment modalities under home-based and facility-based DOT could be improved, and 
offers an opportunity to reduce TB mortality. Our findings propose the introduction of screening 
tool for TB mortality risk factors. The tools will include already defined risk factors and 
additional emerging risk factors. We postulate that such a tool will be able to reduce the TB 
mortality in both HIV-negative and HIV-positive TB patients. Thus, accelerate the progress to 
attain the End TB Strategy target of reducing TB mortality by 90% by 2035. 
 
8.3.2. Helminth infection and TB control 
Tanzanian Neglected Tropical Diseases Control Programme (NTDCP) is responsible in the 
control of schistosomiasis, STH, lymphatic filariasis and other NTDs. The National 
schistosomiasis and Soil-transmitted Helminths Control Programme (NSSCP) was established 
under the National School Health Program (NSHP) to control schistosomiasis and STH in the 
schools. NTDCP uses the MDA chemotherapy to control helminth burden in the country. The 
frequency of MDA are dependent on the burden of helminth (Prichard et al., 2012). To 
complement MDA in the control of helminth infection, environmental improvement, provision 
of clean water and safe water, and improving sanitation and hygiene are needed (Dangour et 
al., 2013; Strunz et al., 2014). These interventions will reduce the community vulnerability to 
helminth infection and subsequently reduce the potential risk of developing TB in the 
community.  
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The programmatic activities to be considered as opportunities to address TB and helminth co-
infection burden are listed below:  
i) Reciprocal screening programmes for TB and helminth infections 
ii) Combined health promotion messages and communication 
iii) Training activities for health care workers focusing on the relationship on 
the control of helminth and their effect on other pathogens such as TB, HIV 
and malaria (Salgame et al., 2013; Simon, 2016). 
8.3.3. Respiratory pathogens and TB control 
Our results show that respiratory viruses can influence the clinical phenotypes of TB patients. 
Vaccination of most common circulating viral strains may prove useful in the reducing the 
morbidity of TB that is associated co-infection with respiratory viruses. The use of respiratory 
virus vaccines, in particular influenza virus vaccine, can contributed to reduction of TB mortality 
as previously suggested in studies that reported higher mortality in TB patients infected with 
influenza virus (Archer et al., 2009; Walaza et al., 2015; Zürcher et al., 2016) 
 
8.4. Conclusions 
The following are the main conclusions of the chapters from the chapters of this PhD thesis:  
 TB patients under home-based DOT had more frequently risk factors of death such as 
older age, HIV infection and sputum smear-negative TB, and had higher mortality 
compared to patients under facility-based DOT. 
 S. mansoni is a common helminth infection even in an urban setting like Dar es Salaam 
where it was originally known to be lower. S. mansoni infection was an independent 
risk factor for active TB and altered the clinical presentation in TB patients. These 
findings suggest a role for schistosomiasis in modulating the pathogenesis of human 
TB. Treatment of helminths should be considered in clinical management of TB and TB 
control programs.  
 Both respiratory viral and bacterial pathogens are common in TB patients and controls. 
Respiratory viruses seem to cause severe disease and with a cavitary diseases in TB 
patients.  
8.5. Recommendations 
8.5.1. What can be translated into practice and policies  
a. Screening of TB mortality risk factors TB diagnosis which may provide a guide to better 
clinical care of high risk TB patients.   
b. Helminth diagnosis and treatment to be an integral part of routine management of TB 
patient during TB treatment.  
c. The control of neglected tropical diseases should be emphasized and resources be 
mobilized as complementary efforts to control TB morbidity and mortality especially in 
settings where TB and helminth burden are high.  
8.5.2. Potential research questions moving forward 
i. Quantifying the risk factors of TB mortality in high burden setting and development of 
screening tools and offer better management of TB under programmatic setting.  
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ii. The interventions studies to assess the effect of MDA of anthelminthic drugs on the 
incidence of tuberculous infection and TB.  
iii. To assess differences in immunomodulation of helminth specie and clinical significance 
of such immunomodulation.  
iv. To understand the pathogenic role of respiratory bacteria on the risk of developing TB 
from tuberculous infection.  
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